

Survival in Patients with Primary Pulmonary Hyperten

Annals of Internal Medicine

115, 343-349

DOI: [10.7326/0003-4819-115-5-343](https://doi.org/10.7326/0003-4819-115-5-343)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Myocardial protection with preconditioning.. Circulation, 1990, 82, 609-619.	1.6	446
2	Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. Journal of the American College of Cardiology, 1991, 18, 1738-1744.	1.2	63
4	The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension. New England Journal of Medicine, 1992, 327, 76-81.	13.9	1,469
5	Clinical Comments and a Pathophysiological Discussion of Scleroderma. Journal of Dermatology, 1992, 19, 509-523.	0.6	6
6	Graded balloon dilation atrial septostomy as a bridge to lung transplantation in pulmonary hypertension. American Heart Journal, 1993, 125, 1763-1766.	1.2	44
7	Echocardiographic characterization of the improvement in right ventricular function in patients with severe pulmonary hypertension after single-lung transplantation. Journal of the American College of Cardiology, 1993, 22, 1170-1174.	1.2	85
8	Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators.. Heart, 1993, 70, 461-468.	1.2	71
9	Medical Section of the American Lung Association: Lung Transplantation: Report of the ATS Workshop on Lung Transplantation. The American Review of Respiratory Disease, 1993, 147, 772-776.	2.9	62
10	The Prevalence and Significance of a Patent Foramen Ovale in Pulmonary Hypertension. Chest, 1993, 104, 1673-1675.	0.4	57
11	Primary Pulmonary Hypertension. Chest, 1993, 104, 236-250.	0.4	346
12	Right-to-left interatrial shunt in rats with progressive pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery, 1993, 106, 1072-1080.	0.4	10
13	Results of single and bilateral lung transplantation in 131 consecutive recipients. Journal of Thoracic and Cardiovascular Surgery, 1994, 107, 460-471.	0.4	201
14	Anaesthetic Management for Laparoscopic Sterilisation and Termination of Pregnancy in a Patient with Severe Primary Pulmonary Hypertension. Anaesthesia and Intensive Care, 1994, 22, 465-469.	0.2	11
15	Primary Pulmonary Hypertension. Chest, 1994, 105, 26S-28S.	0.4	13
16	Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations. Angiology, 1994, 45, 667-676.	0.8	9
17	Survival in primary pulmonary hypertension. Validation of a prognostic equation.. Circulation, 1994, 89, 1733-1744.	1.6	329
18	Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension.. Circulation, 1994, 89, 2722-2727.	1.6	222
19	Quantification of hemodynamics in primary pulmonary hypertension with magnetic resonance imaging.. American Journal of Respiratory and Critical Care Medicine, 1994, 150, 1075-1080.	2.5	53

#	ARTICLE	IF	CITATIONS
20	Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. <i>Arthritis and Rheumatism</i> , 1994, 37, 1528-1533.	6.7	94
21	New Therapies for Primary Pulmonary Hypertension. <i>Chest</i> , 1994, 105, 21S-25S.	0.4	10
22	Pulmonary Transplantation. <i>Annals of Surgery</i> , 1995, 221, 14-28.	2.1	78
23	Comparative Acute Effects of Adenosine and Prostacyclin in Primary Pulmonary Hypertension. <i>Chest</i> , 1995, 107, 54-57.	0.4	88
24	Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 152, 93-97.	2.5	230
25	Pathology and pathophysiology of primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 1995, 75, 51A-54A.	0.7	85
26	Medical treatment of primary pulmonary hypertension: A bridge to transplantation?. <i>American Journal of Cardiology</i> , 1995, 75, 63A-66A.	0.7	38
27	Role of prostacyclin in the treatment of primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 1995, 75, 67A-71A.	0.7	51
28	Medical evaluation for lung transplantation. <i>Seminars in Anesthesia</i> , 1995, 14, 110-122.	0.3	2
30	Coancestry in Apparently Sporadic Primary Pulmonary Hypertension. <i>Chest</i> , 1995, 108, 973-977.	0.4	23
31	Lung transplantation in children and young adults with cardiovascular disease. <i>Annals of Thoracic Surgery</i> , 1995, 59, 813-821.	0.7	46
32	Primary pulmonary hypertension in children: Clinical characterization and survival. <i>Journal of the American College of Cardiology</i> , 1995, 25, 466-474.	1.2	130
33	Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. <i>Journal of the American College of Cardiology</i> , 1995, 26, 1581-1585.	1.2	281
34	PULMONARY HYPERTENSION IN CHRONIC LIVER DISEASE. <i>Clinics in Chest Medicine</i> , 1996, 17, 17-33.	0.8	158
35	SYSTEMIC FAT EMBOLISM AND PULMONARY HYPERTENSION IN SICKLE CELL DISEASE. <i>Hematology/Oncology Clinics of North America</i> , 1996, 10, 1289-1303.	0.9	88
36	Transvenous procurement of pulmonary artery smooth muscle and endothelial cells using a novel endoarterial biopsy catheter in a canine model. <i>Journal of the American College of Cardiology</i> , 1996, 27, 218-224.	1.2	12
37	Intracardiac echocardiography: In vitro and in vivo validation for right ventricular volume and function. <i>American Heart Journal</i> , 1996, 131, 320-328.	1.2	21
38	A 49-year-old woman with dyspnoea, palpitations and syncope. <i>International Journal of Cardiology</i> , 1996, 55, 67-78.	0.8	8

#	ARTICLE	IF	CITATIONS
40	Lung Transplantation Overview: The Massachusetts General Hospital Experience. <i>Critical Care Nursing Clinics of North America</i> , 1996, 8, 229-238.	0.4	1
41	Coagulation and Fibrinolytic Profiles in Patients With Severe Pulmonary Hypertension. <i>Chest</i> , 1996, 110, 710-717.	0.4	146
42	Primary Pulmonary Hypertension as a Risk Factor for the Development of Obliterative Bronchiolitis in Lung Allograft Recipients. <i>Chest</i> , 1996, 110, 704-709.	0.4	47
43	Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. <i>Clinical Cardiology</i> , 1996, 19, 549-554.	0.7	49
44	Right ventricular pathology in chronic pulmonary hypertension. <i>American Journal of Cardiology</i> , 1996, 78, 584-587.	0.7	18
45	Re-examining the Clinical Safety and Roles of Calcium Antagonists in Cardiovascular Medicine. <i>American Journal of Cardiology</i> , 1996, 78, 13-18.	0.7	66
47	Primary pulmonary hypertension: immunogenetic response to high-mobility group (HMG) proteins and histone. <i>Clinical and Experimental Immunology</i> , 1996, 106, 389-395.	1.1	24
48	Reduction of pulmonary capillary blood volume in patients with severe unexplained pulmonary hypertension.. <i>Thorax</i> , 1996, 51, 855-856.	2.7	28
49	Improvement of severe pulmonary hypertension in a patient with SLE.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 561-562.	0.5	35
50	A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1996, 334, 296-301.	13.9	2,529
51	Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 153, 1299-1301.	2.5	102
52	Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin.. <i>Heart</i> , 1997, 77, 299-301.	1.2	36
53	Comparison of bronchopulmonary collaterals and collateral blood flow in patients with chronic thromboembolic and primary pulmonary hypertension.. <i>Heart</i> , 1997, 78, 171-176.	1.2	88
54	Appetite suppressants and pulmonary hypertension. <i>Thorax</i> , 1997, 52, S63-S67.	2.7	15
55	Left Main Coronary Artery Compression During Primary Pulmonary Hypertension. <i>Chest</i> , 1997, 112, 842-843.	0.4	51
56	Portopulmonary Hypertension. <i>Chest</i> , 1997, 112, 869-870.	0.4	8
57	CLINICAL TRIALS IN PULMONARY HYPERTENSION. <i>Annual Review of Medicine</i> , 1997, 48, 399-408.	5.0	12
58	Mixed connective tissue disease. <i>Arthritis and Rheumatism</i> , 1997, 10, 333-342.	6.7	15

#	ARTICLE	IF	CITATIONS
59	Successful Blade Atrial Septostomy in a Patient With Severe Primary Pulmonary Hypertension. Japanese Circulation Journal, 1997, 61, 877-881.	1.0	8
60	Primary Pulmonary Hypertension in a Patient With CD8/T-cell Large Granulocyte Leukemia*. Chest, 1997, 112, 551-553.	0.4	40
61	Long-term Continuous Intravenous Infusion of Prostacyclin for Severe Primary Pulmonary Hypertension.. Internal Medicine, 1997, 36, 794-798.	0.3	5
62	Primary Pulmonary Hypertension. New England Journal of Medicine, 1997, 336, 111-117.	13.9	1,294
63	Lung Transplantation: Selection of Patients and Analysis of Outcome. Mayo Clinic Proceedings, 1997, 72, 85-88.	1.4	9
64	PULMONARY HYPERTENSION IN SYSTEMIC AUTOIMMUNE DISEASE. Rheumatic Disease Clinics of North America, 1997, 23, 365-394.	0.8	34
65	LUNG TRANSPLANTATION. Clinics in Chest Medicine, 1997, 18, 627-644.	0.8	6
66	PATIENT SELECTION, EVALUATION, AND PREOPERATIVE MANAGEMENT FOR LUNG TRANSPLANT CANDIDATES. Clinics in Chest Medicine, 1997, 18, 183-197.	0.8	29
67	NATURAL HISTORY AND PROGNOSIS OF ADVANCED LUNG DISEASE. Clinics in Chest Medicine, 1997, 18, 435-455.	0.8	9
68	EPIDEMIOLOGY OF ADVANCED LUNG DISEASE IN THE UNITED STATES. Clinics in Chest Medicine, 1997, 18, 421-433.	0.8	12
69	Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension. Evidence-based Cardiovascular Medicine, 1997, 1, 21.	0.0	0
70	Bilateral lung transplantation for pulmonary hypertension. Transplantation Proceedings, 1997, 29, 2892-2894.	0.3	14
71	Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet, The, 1997, 349, 1365.	6.3	119
72	Hemodynamic Data and Survival in Children With Pulmonary Hypertension. Journal of the American College of Cardiology, 1997, 30, 554-560.	1.2	66
73	Primary Pulmonary Hypertension: Improved Long-Term Effects and Survival With Continuous Intravenous Epoprostenol Infusion. Journal of the American College of Cardiology, 1997, 30, 343-349.	1.2	291
74	Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31â€“32. Nature Genetics, 1997, 15, 277-280.	9.4	260
75	3 Gaucher's disease: clinical features and natural history. Best Practice and Research: Clinical Haematology, 1997, 10, 657-689.	1.1	211
76	Usefulness of Atrial Septostomy as a Treatment for Primary Pulmonary Hypertension and Guidelines for its Application. American Journal of Cardiology, 1997, 80, 369-371.	0.7	94

#	ARTICLE	IF	CITATIONS
78	Value of a Doppler-Derived Index Combining Systolic and Diastolic Time Intervals in Predicting Outcome in Primary Pulmonary Hypertension. <i>American Journal of Cardiology</i> , 1998, 81, 1157-1161.	0.7	479
79	Right ventricular diastolic performance: Compliance characteristics with focus on pulmonary hypertension, right ventricular hypertrophy, and calcium channel blockade. <i>Catheterization and Cardiovascular Diagnosis</i> , 1998, 43, 206-243.	0.7	3
81	Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. <i>Intensive Care Medicine</i> , 1998, 24, 631-634.	3.9	59
82	Primary pulmonary hypertension. <i>Lancet, The</i> , 1998, 352, 719-725.	6.3	505
83	International guidelines for the selection of lung transplant candidates. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 1998, 27, 223-229.	0.8	8
84	Lung transplantation for pulmonary hypertension: patient selection and maintenance therapy while awaiting transplantation. <i>Transplantation Reviews</i> , 1998, 12, 205-208.	1.2	0
85	Lung transplantation and repair of complex congenital heart lesions in patients with pulmonary hypertension. <i>Transplantation Reviews</i> , 1998, 12, 214-221.	1.2	0
86	The impact of bronchiolitis obliterans on late morbidity and mortality after single and bilateral lung transplantation for pulmonary hypertension. <i>Transplantation Reviews</i> , 1998, 12, 222-229.	1.2	0
87	Outcome of Pulmonary Vascular Disease in Pregnancy: A Systematic Overview From 1978 Through 1996. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1650-1657.	1.2	604
88	Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 1998, 32, 297-304.	1.2	328
89	Present use of bedside right heart catheterization in patients with cardiac disease ¹¹ This Expert Consensus Document was approved by the American College of Cardiology Board of Trustees in March 1998. ²² Address for reprints: Educational Services, American College of Cardiology, 9111 Old Georgetown Road, Bethesda, Maryland 20814-1699.. <i>Journal of the American College of Cardiology</i> , 1998, 32, 840-864.	1.2	116
90	Inhaled nitric oxide in primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 1998, 32, 1068-1073.	1.2	119
91	PULMONARY MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Clinics in Chest Medicine</i> , 1998, 19, 641-665.	0.8	140
92	Human Immunodeficiency Virus Infection and Pulmonary Hypertension: Two New Cases and a Review of 86 Reported Cases. <i>Mayo Clinic Proceedings</i> , 1998, 73, 37-45.	1.4	107
93	Pulmonary Artery Remodeling Differs in Hypoxia- and Monocrotaline-induced Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 1423-1428.	2.5	89
94	Beneficial Hemodynamic Effects of Oral Prostacyclin (PGI ₂) Analogue, Beraprost Sodium, on a Patient with Primary Pulmonary Hypertension. <i>Angiology</i> , 1998, 49, 161-164.	0.8	8
95	The donor lung: conservation of a precious resource. <i>Thorax</i> , 1998, 53, 506-513.	2.7	19
96	Rapid recurrence of pulmonary hypertension following cessation of nifedipine. <i>Postgraduate Medical Journal</i> , 1998, 74, 111-112.	0.9	0

#	ARTICLE	IF	CITATIONS
97	Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. <i>Heart</i> , 1998, 80, 151-155.	1.2	174
98	Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. <i>Heart</i> , 1998, 79, 175-179.	1.2	98
99	Biochemical Reaction Products of Nitric Oxide as Quantitative Markers of Primary Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 158, 917-923.	2.5	208
100	The Pulmonary Circulation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, S101-S108.	2.5	13
101	International Guidelines for the Selection of Lung Transplant Candidates. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 158, 335-339.	2.5	297
102	Lung Transplantation for Pulmonary Hypertension: Patient Selection and Maintenance Therapy While Awaiting Transplantation. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 1998, 10, 135-138.	0.4	7
103	The Impact of Bronchiolitis Obliterans on Late Morbidity and Mortality After Single and Bilateral Lung Transplantation for Pulmonary Hypertension. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 1998, 10, 152-159.	0.4	11
104	Lung Transplantation and Repair of Complex Congenital Heart Lesions in Patients With Pulmonary Hypertension. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 1998, 10, 144-151.	0.4	16
105	Urinary cGMP concentrations in severe primary pulmonary hypertension. <i>Thorax</i> , 1998, 53, 1059-1062.	2.7	42
106	The Short-term Effects of Digoxin in Patients With Right Ventricular Dysfunction From Pulmonary Hypertension. <i>Chest</i> , 1998, 114, 787-792.	0.4	322
107	Primary Pulmonary Hypertension. <i>Chest</i> , 1998, 114, 184S-194S.	0.4	87
108	Ethical Issues in Lung Transplantation. <i>American Journal of the Medical Sciences</i> , 1998, 315, 142-145.	0.4	3
109	Medical and Surgical Treatment Options for Pulmonary Hypertension. <i>American Journal of the Medical Sciences</i> , 1998, 315, 179-184.	0.4	7
110	Percutaneous Pulmonary Endoarterial Biopsy in an Experimental Model of Pulmonary Hypertension. <i>Chest</i> , 1998, 114, 241-250.	0.4	17
111	The Pressure-Overloaded Right Ventricle in Pulmonary Hypertension. <i>Chest</i> , 1998, 114, 101S-106S.	0.4	120
112	Circulating von Willebrand Factor Antigen as a Predictor of Short-term Prognosis in Pulmonary Hypertension. <i>Chest</i> , 1998, 114, 1276-1282.	0.4	66
113	Right and Left Ventricular Dysfunction in Patients With Severe Pulmonary Disease. <i>Chest</i> , 1998, 113, 576-583.	0.4	290
114	Long-Term Inhalation of Nitric Oxide for a Patient With Primary Pulmonary Hypertension. <i>Japanese Circulation Journal</i> , 1998, 62, 940-942.	1.0	10

#	ARTICLE	IF	CITATIONS
115	Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 276, L213-L219.	1.3	13
116	Echocardiographic Predictors of an Adverse Response to a Nifedipine Trial in Primary Pulmonary Hypertension. <i>Chest</i> , 1999, 116, 1218-1223.	0.4	25
117	Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 1500-1506.	2.5	73
118	Determination of Cardiac Output by the Fick Method, Thermodilution, and Acetylene Rebreathing in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 535-541.	2.5	208
119	Vasodilator Therapy for Primary Pulmonary Hypertension in Children. <i>Circulation</i> , 1999, 99, 1197-1208.	1.6	391
120	Rare diseases bullet 5: Primary pulmonary hypertension. <i>Thorax</i> , 1999, 54, 1107-1118.	2.7	79
121	Epoprostenol in Primary Pulmonary Hypertension. <i>Annals of Pharmacotherapy</i> , 1999, 33, 340-347.	0.9	7
122	Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. <i>Thorax</i> , 1999, 54, 372-374.	2.7	25
123	Serum Uric Acid Levels Correlate with the Severity and the Mortality of Primary Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 487-492.	2.5	250
124	Long-term effect of a new oral prostacyclin analogue, beraprost sodium, in isolated peripheral pulmonary artery stenosis in the adult. <i>Journal of Internal Medicine</i> , 1999, 246, 227-230.	2.7	2
125	Echocardiographic Evaluation of Patients with Primary Pulmonary Hypertension Before and After Atrial Septostomy. <i>Echocardiography</i> , 1999, 16, 625-634.	0.3	28
127	Pulmonary hypertension in collagen vascular disease. <i>Comprehensive Therapy</i> , 1999, 25, 133-143.	0.2	7
128	Extrinsic compression of the left main coronary artery by the pulmonary artery in patients with long-standing pulmonary hypertension. <i>American Journal of Cardiology</i> , 1999, 83, 984-986.	0.7	41
129	Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 1999, 84, 481-484.	0.7	145
130	Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. <i>American Journal of Cardiology</i> , 1999, 84, 682-686.	0.7	115
131	Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin). <i>Arthritis and Rheumatism</i> , 1999, 42, 2638-2645.	6.7	81
132	Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. <i>Lupus</i> , 1999, 8, 328-331.	0.8	18
133	Lung transplant waiting list: differential outcome of type of end-stage lung disease, one year after registration. <i>Journal of Heart and Lung Transplantation</i> , 1999, 18, 563-571.	0.3	66

#	ARTICLE	IF	CITATIONS
134	Pulmonary hypertension in pregnancy: treatment with pulmonary vasodilators. <i>Obstetrics and Gynecology</i> , 1999, 93, 494-498.	1.2	57
135	Heart-lung transplantation for primary pulmonary hypertension. <i>Annals of Thoracic Surgery</i> , 1999, 67, 937-941.	0.7	46
136	Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 1999, 34, 1188-1192.	1.2	202
137	Primary Pulmonary Hypertension and Its Life Prognosis. <i>Internal Medicine</i> , 1999, 38, 1-2.	0.3	4
138	Prediction of Life Expectancy in Patients with Primary Pulmonary Hypertension. A Retrospective Nationwide Survey from 1980-1990.. <i>Internal Medicine</i> , 1999, 38, 12-16.	0.3	53
139	Effects of Long-term Infusion of Prostacyclin on Exercise Performance in Patients With Primary Pulmonary Hypertension. <i>Chest</i> , 1999, 116, 914-920.	0.4	88
140	Do No Harm. <i>Chest</i> , 1999, 116, 1147-1148.	0.4	2
141	Development of Nonspecific Interstitial Pneumonitis Associated With Long-term Treatment of Primary Pulmonary Hypertension With Prostacyclin. <i>Chest</i> , 1999, 116, 566-569.	0.4	20
142	Pulmonary Hypertension in Pregnancy. <i>Obstetrics and Gynecology</i> , 1999, 93, 494-498.	1.2	28
143	High Prevalence of Hypothyroidism in Patients with Primary Pulmonary Hypertension. <i>American Journal of the Medical Sciences</i> , 1999, 318, 289-292.	0.4	57
144	Circulatory Failure after Anesthesia Induction in a Patient with Severe Primary Pulmonary Hypertension. <i>Anesthesiology</i> , 1999, 91, 1943-1943.	1.3	56
145	Primary Pulmonary Hypertension With Central Sleep Apnea. <i>Japanese Circulation Journal</i> , 2000, 64, 723-726.	1.0	9
146	Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. <i>Annals of Internal Medicine</i> , 2000, 132, 425.	2.0	905
147	Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial. <i>Annals of Internal Medicine</i> , 2000, 132, 435.	2.0	229
148	Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2000, 16, 276.	3.1	101
149	Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. <i>British Journal of Haematology</i> , 2000, 108, 717-723.	1.2	36
150	Fine Specificity of Anti-Fibrillin-1 Autoantibodies in Primary Pulmonary Hypertension Syndrome. <i>Scandinavian Journal of Immunology</i> , 2000, 51, 607-611.	1.3	27
151	Current management of patients with pulmonary hypertension and right ventricular insufficiency. <i>Current Cardiology Reports</i> , 2000, 2, 244-251.	1.3	2

#	ARTICLE	IF	CITATIONS
152	Approach to pulmonary hypertension. <i>Current Rheumatology Reports</i> , 2000, 2, 517-523.	2.1	1
153	Pulmonary hypertension update. <i>Comprehensive Therapy</i> , 2000, 26, 190-196.	0.2	4
154	Diagnosis and management of primary pulmonary hypertension. <i>Indian Journal of Pediatrics</i> , 2000, 67, 523-527.	0.3	4
155	Role of Nitric Oxide in the Pathogenesis of Chronic Pulmonary Hypertension. <i>Physiological Reviews</i> , 2000, 80, 1337-1372.	13.1	225
156	Effects of Iloprost Inhalation on Exercise Capacity and Ventilatory Efficiency in Patients With Primary Pulmonary Hypertension. <i>Circulation</i> , 2000, 101, 2388-2392.	1.6	126
157	Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension. <i>Circulation</i> , 2000, 102, 865-870.	1.6	768
158	Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary Hypertension. <i>Circulation</i> , 2000, 102, 411-418.	1.6	182
159	Abnormal Pulmonary Artery Pressure Response in Asymptomatic Carriers of Primary Pulmonary Hypertension Gene. <i>Circulation</i> , 2000, 102, 1145-1150.	1.6	235
160	Role of atrial septostomy in the treatment of pulmonary vascular disease. <i>Thorax</i> , 2000, 55, 95-96.	2.7	43
161	Primary Pulmonary Hypertension. <i>Circulation</i> , 2000, 102, 2781-2791.	1.6	340
162	Primary pulmonary hypertension: the pressure rises for a gene. <i>Journal of Clinical Pathology</i> , 2000, 53, 899-903.	1.0	17
163	A Physical and Transcript Map Based upon Refinement of the Critical Interval for PPH1, a Gene for Familial Primary Pulmonary Hypertension. <i>Genomics</i> , 2000, 68, 220-228.	1.3	25
164	Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. <i>American Heart Journal</i> , 2000, 139, 618-623.	1.2	43
165	Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptorâ€”II Gene. <i>American Journal of Human Genetics</i> , 2000, 67, 737-744.	2.6	1,089
166	Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 487-492.	2.5	1,012
167	Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. <i>British Journal of Rheumatology</i> , 2000, 39, 1320-1325.	2.5	95
168	Drug Treatment of Scleroderma. <i>Drugs</i> , 2001, 61, 419-427.	4.9	19
169	Current Management of Primary Pulmonary Hypertension. <i>Drugs</i> , 2001, 61, 1945-1956.	4.9	31

#	ARTICLE	IF	CITATIONS
170	Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1085-1092.	1.2	151
171	Right ventricular ischemia in patients with primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1137-1142.	1.2	218
172	MEDICAL THERAPY OF PULMONARY HYPERTENSION. <i>Clinics in Chest Medicine</i> , 2001, 22, 517-527.	0.8	65
173	Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 262-263.	0.3	71
174	Lung and heart-lung transplant practice patterns in pulmonary hypertension centers. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 1297-1304.	0.3	58
175	Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. <i>Lancet, The</i> , 2001, 358, 1119-1123.	6.3	1,421
176	PULMONARY FUNCTION TEST ABNORMALITIES IN PULMONARY VASCULAR DISEASE AND CHRONIC HEART FAILURE. <i>Clinics in Chest Medicine</i> , 2001, 22, 751-758.	0.8	18
177	ATRIAL SEPTOSTOMY FOR PULMONARY HYPERTENSION. <i>Clinics in Chest Medicine</i> , 2001, 22, 547-560.	0.8	108
178	MEDICAL THERPAY OF PULMONARY HYPERTENSION. <i>Clinics in Chest Medicine</i> , 2001, 22, 509-515.	0.8	27
179	LUNG TRANSPLANTATION FOR PRIMARY PULMONARY HYPERTENSION. <i>Clinics in Chest Medicine</i> , 2001, 22, 583-593.	0.8	38
180	THE ASSESSMENT OF PULMONARY HYPERTENSION. <i>Clinics in Chest Medicine</i> , 2001, 22, 493-508.	0.8	39
181	Trasplante pulmonar pediÁtrico. <i>Anales De PediatrÁa</i> , 2001, 54, 359-371.	0.3	4
183	Current Management of Primary Pulmonary Hypertension. <i>BioDrugs</i> , 2001, 15, 801-817.	2.2	8
184	Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension. <i>Circulation Research</i> , 2001, 88, 555-562.	2.0	256
185	Exercise Pathophysiology in Patients With Primary Pulmonary Hypertension. <i>Circulation</i> , 2001, 104, 429-435.	1.6	529
186	Stenting To Reverse Left Ventricular Ischemia Due To Left Main Coronary Artery Compression in Primary Pulmonary Hypertension. <i>Chest</i> , 2001, 120, 1412-1415.	0.4	60
187	Long-term treatment of pulmonary hypertension with aerosolized iloprost. <i>European Respiratory Journal</i> , 2001, 17, 8-13.	3.1	52
188	Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. <i>European Respiratory Journal</i> , 2001, 17, 14-19.	3.1	100

#	ARTICLE	IF	CITATIONS
189	Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. <i>European Respiratory Journal</i> , 2001, 17, 647-652.	3.1	222
190	Primary Pulmonary Hypertension In Israel. <i>Chest</i> , 2001, 119, 1801-1806.	0.4	52
192	Comparison of the Effects of Nitric Oxide, Nitroprusside, and Nifedipine on Hemodynamics and Right Ventricular Contractility in Patients With Chronic Pulmonary Hypertension. <i>Chest</i> , 2001, 119, 128-136.	0.4	64
193	Pediatric primary pulmonary hypertension. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2001, 3, 371-383.	0.4	1
194	Comment traiter une sclérodémie en 2001? <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2001, 68, 824-834.	0.0	0
195	Palliation of systemic sclerosis-associated pulmonary hypertension by atrial septostomy. <i>Arthritis and Rheumatism</i> , 2001, 44, 1660-1662.	6.7	27
196	Clinical Manifestation of HIV-Related Pulmonary Hypertension. <i>Annals of the New York Academy of Sciences</i> , 2001, 946, 223-235.	1.8	18
197	Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 2001, 88, 1060-1063.	0.7	63
198	Diagnosis and assessment of pulmonary hypertension in infants and children. <i>Progress in Pediatric Cardiology</i> , 2001, 12, 279-288.	0.2	7
199	Lung transplantation for pediatric pulmonary hypertension. <i>Progress in Pediatric Cardiology</i> , 2001, 12, 319-325.	0.2	10
200	Treating systemic sclerosis in 2001. <i>Joint Bone Spine</i> , 2001, 68, 393-402.	0.8	7
201	Characteristics and Outcomes of Patients With Sarcoidosis Listed for Lung Transplantation. <i>Chest</i> , 2001, 120, 873-880.	0.4	163
202	Nocturnal Hypoxemia Is Common in Primary Pulmonary Hypertension. <i>Chest</i> , 2001, 120, 894-899.	0.4	92
203	Clinical Correlates and Reference Intervals for Pulmonary Artery Systolic Pressure Among Echocardiographically Normal Subjects. <i>Circulation</i> , 2001, 104, 2797-2802.	1.6	592
204	Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. <i>New England Journal of Medicine</i> , 2001, 345, 325-334.	13.9	676
205	A new era in the treatment of primary pulmonary hypertension. <i>British Heart Journal</i> , 2001, 85, 251-252.	2.2	6
206	Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. <i>Thorax</i> , 2001, 56, 734-736.	2.7	21
207	Novel therapeutics for the treatment of paediatric pulmonary arterial hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 811-823.	1.9	1

#	ARTICLE	IF	CITATIONS
208	Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. <i>European Respiratory Journal</i> , 2002, 19, 664-671.	3.1	24
209	The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2002, 20, 1037-1049.	3.1	81
210	Assessment of Survival in Patients With Primary Pulmonary Hypertension. <i>Circulation</i> , 2002, 106, 319-324.	1.6	519
211	Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure. <i>European Respiratory Journal</i> , 2002, 20, 1519-1524.	3.1	169
212	Survival in Primary Pulmonary Hypertension. <i>Circulation</i> , 2002, 106, 1477-1482.	1.6	1,092
213	Hemodynamic Effects of Aerosolized Iloprost in Pulmonary Hypertension at Rest and During Exercise. <i>Chest</i> , 2002, 121, 1566-1571.	0.4	51
214	Bosentan for Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2002, 347, 292-294.	13.9	7
215	Bosentan Therapy for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2002, 346, 1258-1258.	13.9	5
216	Epoprostenol-induced pulmonary vasodilatation in patients with pulmonary hypertension measured by electrical impedance tomography. <i>Physiological Measurement</i> , 2002, 23, 237-243.	1.2	23
217	Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 341-344.	2.5	152
218	Haemodynamic evaluation of pulmonary hypertension. <i>European Respiratory Journal</i> , 2002, 20, 1314-1331.	3.1	310
219	Endothelin in Health and Disease: Endothelin Receptor Antagonists in the Management of Pulmonary Artery Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2002, 7, 9-19.	1.0	41
220	Effects and Problems of Continuous Infusion of Epoprostenol for Patients with Primary Pulmonary Hypertension.. <i>Internal Medicine</i> , 2002, 41, 784-788.	0.3	6
221	Primary Pulmonary Hypertension and Cor Pulmonale. <i>Cardiology in Review</i> , 2002, 10, 265-278.	0.6	7
222	The Prognostic Role of the ECG in Primary Pulmonary Hypertension. <i>Chest</i> , 2002, 121, 513-518.	0.4	134
223	Differential vasoactive response to endothelin receptor antagonists and prostacyclin in patients with severe pulmonary hypertension. <i>Clinical Science</i> , 2002, 103, 298S-301S.	1.8	3
224	Chapter 5: Recent advances in pulmonary hypertension therapy. <i>Annual Reports in Medicinal Chemistry</i> , 2002, 37, 41-52.	0.5	1
225	Recovery of Cardiac Function After Living-Donor Lung Transplantation in a Patient With Primary Pulmonary Hypertension.. <i>Circulation Journal</i> , 2002, 66, 294-296.	0.7	11

#	ARTICLE	IF	CITATIONS
226	Prostacyclin for pulmonary hypertension in adults. , 2002, , CD002994.		11
227	Significance of a Plasma D-dimer Test in Patients with Primary Pulmonary Hypertension. Chest, 2002, 122, 1674-1678.	0.4	43
228	Medical management of primary pulmonary hypertension. Expert Opinion on Pharmacotherapy, 2002, 3, 159-165.	0.9	14
229	Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension. Circulation, 2002, 105, 2398-2403.	1.6	586
230	Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. Journal of the American College of Cardiology, 2002, 39, 1214-1219.	1.2	729
231	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 2002, 39, 1496-1502.	1.2	584
232	Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Journal of the American College of Cardiology, 2002, 40, 780-788.	1.2	1,290
233	Current and Emerging Therapy for Primary Pulmonary Hypertension. Annals of Pharmacotherapy, 2002, 36, 1414-1423.	0.9	20
235	Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. Journal of the American Society of Echocardiography, 2002, 15, 1160-1164.	1.2	161
236	Lifelong therapy required for primary pulmonary hypertension, a rare but serious disease. Drugs and Therapy Perspectives, 2002, 18, 17-20.	0.3	0
237	Aerosolized Vasodilators in Pulmonary Hypertension. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2002, 15, 117-122.	1.2	19
238	Pulmonary hypertension and the search for the selective pulmonary vasodilator. Lancet, The, 2002, 360, 886-887.	6.3	32
239	Alternatives to lung transplantation: lung volume reduction surgery and continuous intravenous prostacyclin. Transplantation Proceedings, 2002, 34, 1283-1286.	0.3	3
240	Poor prognosis and related factors in adults with Eisenmenger syndrome. American Heart Journal, 2002, 143, 739-744.	1.2	57
241	Enfermedades vasculares del pulmÃ³n. HipertensiÃ³n pulmonar primaria. Medicina, 2002, 8, 4246-4253.	0.0	0
242	Usefulness and limits of transthoracic echocardiography in the evaluation of patients with primary and chronic thromboembolic pulmonary hypertension. Journal of the American Society of Echocardiography, 2002, 15, 1374-1380.	1.2	34
244	Right ventricular dp/dt/pmax, not dp/dtmax, noninvasively derived from tricuspid regurgitation velocity is a useful index of right ventricular contractility. Journal of the American Society of Echocardiography, 2002, 15, 136-142.	1.2	31
246	Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 800-804.	2.5	1,288

#	ARTICLE	IF	CITATIONS
247	Primary pulmonary hypertension: Current therapy. <i>Progress in Cardiovascular Diseases</i> , 2002, 45, 115-128.	1.6	54
248	Pulmonary hypertension associated with connective tissue disease. <i>Progress in Cardiovascular Diseases</i> , 2002, 45, 225-234.	1.6	90
249	Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. <i>American Journal of Cardiology</i> , 2002, 89, 34-38.	0.7	136
250	Treatment of pulmonary hypertension: A promising new age. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 57, 395-403.	0.7	1
253	Editorial: Pulmonary hypertension, (high) risk of orthotopic liver transplantation, and some lessons from "primary" pulmonary hypertension. <i>Liver Transplantation</i> , 2002, 8, 389-390.	1.3	15
255	Ventricular Arrhythmias and Autonomic Profile in Patients with Primary Pulmonary Hypertension. <i>Lung</i> , 2003, 181, 321-328.	1.4	62
256	Pulmonary Hypertension: New Perspectives. <i>Congestive Heart Failure</i> , 2003, 9, 155-162.	2.0	12
258	Pediatric lung transplantation. <i>Chest Surgery Clinics of North America</i> , 2003, 13, 485-504.	0.8	8
259	Recipient selection. <i>Chest Surgery Clinics of North America</i> , 2003, 13, 405-428.	0.8	9
260	ATS/ACCP Statement on Cardiopulmonary Exercise Testing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 211-277.	2.5	2,746
262	Pulmonary function in primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1028-1035.	1.2	166
263	Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2003, 42, 158-164.	1.2	359
264	Primary pulmonary hypertension. <i>Lancet, The</i> , 2003, 361, 1533-1544.	6.3	496
265	Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. <i>Annals of Thoracic Surgery</i> , 2003, 76, 711-718.	0.7	67
266	Primary pulmonary hypertension: survival benefits of therapy with prostacyclin analogs and transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 2117-2120.	0.3	11
267	Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function. <i>Circulation Research</i> , 2003, 93, 280-291.	2.0	464
268	Prostanoids for Pulmonary Arterial Hypertension. <i>Treatments in Respiratory Medicine</i> , 2003, 2, 123-137.	1.4	123
269	Atrial septostomy in the treatment of severe pulmonary arterial hypertension. <i>Thorax</i> , 2003, 58, 797-800.	2.7	90

#	ARTICLE	IF	CITATIONS
270	Lack of association between angiotensin converting enzyme (ACE) genotype, serum ACE activity, and haemodynamics in patients with primary pulmonary hypertension. <i>British Heart Journal</i> , 2003, 89, 445-446.	2.2	17
271	Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. <i>European Respiratory Journal</i> , 2003, 22, 330-334.	3.1	190
272	Pulmonary arterial hypertension in children. <i>European Respiratory Journal</i> , 2003, 21, 155-176.	3.1	158
273	Atrial septostomy for pulmonary arterial hypertension. <i>British Heart Journal</i> , 2003, 89, 1344-1347.	2.2	46
274	Indications, patient selection and timing of referral for lung transplantation. <i>European Respiratory Journal</i> , 2003, 22, 845-852.	3.1	96
275	Intravascular ultrasound of the elastic pulmonary arteries: a new approach for the evaluation of primary pulmonary hypertension. <i>British Heart Journal</i> , 2003, 89, 311-315.	2.2	58
276	Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension. <i>Circulation</i> , 2003, 108, 844-848.	1.6	282
277	Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 1088-1093.	0.5	631
278	Pulmonary Hypertension in Patients With End-Stage Renal Disease. <i>Chest</i> , 2003, 123, 1577-1582.	0.4	254
279	Treatment of Pulmonary Arterial Hypertension. <i>Chest</i> , 2003, 124, 2087-2092.	0.4	43
280	Outcome in 91 Consecutive Patients with Pulmonary Arterial Hypertension Receiving Epoprostenol. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 580-586.	2.5	229
281	Insights into the Genetic and Molecular Basis of Primary Pulmonary Hypertension. <i>Pediatric Research</i> , 2003, 53, 883-888.	1.1	22
282	Have we met the expectations of heart and lung transplantation in children?. <i>Pediatric Cardiac Surgery Annual</i> , 2003, 6, 164-170.	0.5	0
283	Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension. <i>Chest</i> , 2003, 124, 1294-1304.	0.4	124
284	Assessment of the vasodilator response in primary pulmonary hypertension Comparing prostacyclin and iloprost administered by either infusion or inhalation. <i>European Heart Journal</i> , 2003, 24, 356-365.	1.0	71
285	Predicting Mortality in Patients With Sarcoidosis Awaiting Lung Transplantation. <i>Chest</i> , 2003, 124, 922-928.	0.4	201
286	Primary Pulmonary Hypertension Treated with Short-Term Epoprostenol Infusion. <i>Internal Medicine</i> , 2003, 42, 824-826.	0.3	0
287	Drug Therapy for Pulmonary Arterial Hypertension. <i>Chest</i> , 2003, 124, 2045-2049.	0.4	21

#	ARTICLE	IF	CITATIONS
288	Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. <i>Blood</i> , 2003, 101, 1257-1261.	0.6	295
290	HIV-Associated Pulmonary Hypertension: Diagnosis and Treatment. , 2003, 40, 197-207.		5
291	Continuous Hemodynamic Monitoring in Pulmonary Hypertensive Patients Treated With Inhaled Iloprost. <i>Chest</i> , 2003, 124, 351-359.	0.4	40
292	Combined Spinal and Epidural Anaesthesia for Caesarean Section in a Parturient with Severe Primary Pulmonary Hypertension. <i>Anaesthesia and Intensive Care</i> , 2003, 31, 565-569.	0.2	30
293	Pulmonary arterial hypertension: a new era in management. <i>Medical Journal of Australia</i> , 2003, 178, 564-567.	0.8	16
294	Bosentan for the Treatment of Human Immunodeficiency Virus-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1212-1217.	2.5	238
295	Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2004, 350, 2521-2522.	13.9	19
296	Primary Pulmonary Hypertension in Children May Have a Different Genetic Background Than in Adults. <i>Pediatric Research</i> , 2004, 56, 571-578.	1.1	49
297	Gene Microarray Analysis of Peripheral Blood Cells in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 911-919.	2.5	150
298	End points in pulmonary arterial hypertension: the way forward. <i>European Respiratory Journal</i> , 2004, 23, 947-953.	3.1	62
299	Long term survival in primary pulmonary hypertension. <i>British Heart Journal</i> , 2004, 90, e40-e40.	2.2	5
300	Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension. <i>Circulation</i> , 2004, 110, 660-665.	1.6	223
301	Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 39-45.	2.5	230
302	Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2004, 94, 1101-1108.	2.0	97
303	Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. <i>British Journal of Rheumatology</i> , 2004, 43, 461-466.	2.5	312
304	Paradoxical Effect of Prostacyclin Infusion in a Patient with Primary Pulmonary Hypertension. <i>Angiology</i> , 2004, 55, 341-344.	0.8	1
305	Transition From Epoprostenol and Treprostinil to the Oral Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Hypertension. <i>Chest</i> , 2004, 126, 808-815.	0.4	50
306	Prognosis of Pulmonary Arterial Hypertension*. <i>Chest</i> , 2004, 126, 78S-92S.	0.4	479

#	ARTICLE	IF	CITATIONS
307	Chronic Pulmonary Embolism: Combining MR Angiography with Functional Assessment. <i>Radiology</i> , 2004, 232, 325-326.	3.6	12
308	The endothelin system in pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2004, 61, 227-237.	1.8	412
309	Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2004, 24, 1007-1010.	3.1	262
310	Bosentan: A novel agent for the treatment of pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2004, 58, 69-73.	0.8	15
311	Delayed pulmonary hypertension following splenectomy for congenital spherocytosis. <i>Internal Medicine Journal</i> , 2004, 34, 214-216.	0.5	33
312	Comparison of Impedance Cardiography to Direct Fick and Thermodilution Cardiac Output Determination in Pulmonary Arterial Hypertension. <i>Congestive Heart Failure</i> , 2004, 10, 7-10.	2.0	66
313	Usefulness of B-Type Natriuretic Peptide as a Predictor of Treatment Outcome in Pulmonary Arterial Hypertension. <i>Congestive Heart Failure</i> , 2004, 10, 221-225.	2.0	33
314	Endothelin and pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 442-453.	1.6	29
315	Prostacyclin and its analogues in the treatment of pulmonary hypertension. , 2004, 102, 139-153.		119
320	Pulmonary arterial hypertension: New management options. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 451-458.	0.4	0
321	Lower airway obstruction, bronchial hyperresponsiveness, and primary pulmonary hypertension in children. <i>Pediatric Pulmonology</i> , 2004, 37, 50-55.	1.0	32
322	Pulmonary arterial hypertension in children. <i>Pediatric Pulmonology</i> , 2004, 38, 2-22.	1.0	134
323	Drug Therapy of Primary Pulmonary Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 75-85.	1.0	14
324	The influence of VIP and epoprostenol on platelet CD62P expression and primary haemostasis in vitro. <i>Platelets</i> , 2004, 15, 55-60.	1.1	4
325	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 2243-2278.	1.0	903
326	Lung transplantation for interstitial lung disease. <i>Clinics in Chest Medicine</i> , 2004, 25, 773-782.	0.8	9
327	Echocardiography in pulmonary vascular disease. <i>Cardiology Clinics</i> , 2004, 22, 383-399.	0.9	35
328	El stent en la compresi3n del tronco coronario izquierdo en la hipertensi3n pulmonar primaria. <i>Revista Espanola De Cardiologia</i> , 2004, 57, 695-698.	0.6	7

#	ARTICLE	IF	CITATIONS
329	Pulmonary hypertension as a result of drug therapy. <i>Clinics in Chest Medicine</i> , 2004, 25, 123-131.	0.8	12
331	Classification and epidemiology of pulmonary hypertension. <i>Cardiology Clinics</i> , 2004, 22, 327-341.	0.9	15
334	Stenting in Primary Pulmonary Hypertension With Compression of the Left Main Coronary Artery. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2004, 57, 695-698.	0.4	14
335	Impact of tricuspid regurgitation on long-term survival. <i>Journal of the American College of Cardiology</i> , 2004, 43, 405-409.	1.2	1,328
336	Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, 764-770.	1.2	266
337	Clinical efficacy of sildenafil in primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1149-1153.	1.2	491
338	End points and clinical trial designs in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S48-S55.	1.2	147
339	Diagnosis and differential assessment of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S40-S47.	1.2	819
340	Prostanoid therapy for pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S56-S61.	1.2	184
341	Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2004, 351, 1425-1436.	13.9	1,627
342	Diagnosis and treatment of pulmonary arterial hypertension. <i>Cardiology Clinics</i> , 2004, 22, 441-452.	0.9	8
343	Diagnosis and evaluation of the patient with pulmonary hypertension. <i>Cardiology Clinics</i> , 2004, 22, 367-373.	0.9	9
344	Bosentan. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 175-182.	0.6	9
345	Cardiac catheterization techniques in pulmonary hypertension. <i>Cardiology Clinics</i> , 2004, 22, 401-415.	0.9	33
346	Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities. <i>International Journal of Cardiology</i> , 2004, 97, 7-10.	0.8	21
347	Surrogate end points for pulmonary arterial hypertension. <i>American Heart Journal</i> , 2004, 148, 559-565.	1.2	21
348	Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension. <i>American Journal of Medicine</i> , 2004, 116, 369-374.	0.6	120
349	Peripartum Heart Failure due to Primary Pulmonary Hypertension: Two Case Reports. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2004, 43, 151-154.	0.5	0

#	ARTICLE	IF	CITATIONS
350	Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension. <i>Chest</i> , 2004, 125, 580-586.	0.4	117
351	Anxiety and Depression in Patients With Pulmonary Hypertension. <i>Psychosomatic Medicine</i> , 2004, 66, 831-836.	1.3	196
352	Right ventricular function and failure: Methods, models, and mechanisms *. <i>Critical Care Medicine</i> , 2004, 32, 1087-1089.	0.4	32
353	Current Management of Pulmonary Hypertension. <i>Clinical Pulmonary Medicine</i> , 2004, 11, 40-53.	0.3	6
354	Evaluation of pulmonary arterial hypertension. <i>Current Opinion in Cardiology</i> , 2004, 19, 575-581.	0.8	38
355	Surgical Treatments/Interventions for Pulmonary Arterial Hypertension. <i>Chest</i> , 2004, 126, 63S-71S.	0.4	144
356	Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension. <i>Chest</i> , 2004, 126, 14S-34S.	0.4	799
357	Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2004, 126, 1452-1459.	0.4	139
358	Feasibility of Routine Pulmonary Arterial Impedance Measurements in Pulmonary Hypertension. <i>Chest</i> , 2004, 125, 2121-2128.	0.4	93
359	Epoprostenol Therapy Decreases Elevated Circulating Levels of Monocyte Chemoattractant Protein-1 in Patients With Primary Pulmonary Hypertension. <i>Circulation Journal</i> , 2004, 68, 227-231.	0.7	46
360	Novel Insertional Mutation in the Bone Morphogenetic Protein Receptor Type II Associated With Sporadic Primary Pulmonary Hypertension. <i>Circulation Journal</i> , 2004, 68, 592-594.	0.7	11
361	Pulmonary Artery Systolic Pressure is Elevated in the Elderly: Relationships between Echocardiographic and Pathological Findings. <i>Internal Medicine</i> , 2004, 43, 374-378.	0.3	4
362	Medical Therapy For Pulmonary Arterial Hypertension. <i>Chest</i> , 2004, 126, 35S-62S.	0.4	592
363	Marked Improvement with Sildenafil in a Patient with Primary Pulmonary Hypertension Unresponsive to Epoprostenol. <i>Internal Medicine</i> , 2004, 43, 945-950.	0.3	8
364	Right ventricular adaptation to pulmonary hypertension: an interspecies comparison. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 286, H1441-H1447.	1.5	125
365	Pulmonary Arterial Hypertension in Connective Tissue Disease. <i>Handbook of Systemic Autoimmune Diseases</i> , 2004, , 45-62.	0.1	1
366	Bosentan for treatment of pulmonary arterial hypertension (I). <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 843-847.	0.2	1
367	Long-term echocardiographic follow-up of a patient with primary pulmonary hypertension receiving iloprost inhalations. <i>European Journal of Echocardiography</i> , 2005, 6, 67-71.	2.3	0

#	ARTICLE	IF	CITATIONS
368	Pulmonary Endothelin-1 Clearance in Human Pulmonary Arterial Hypertension. <i>Chest</i> , 2005, 128, 622S.	0.4	8
369	Lung Transplantation. <i>Chest</i> , 2005, 127, 1006-1016.	0.4	67
370	Pro/Con Debate. <i>Chest</i> , 2005, 128, 407-415.	0.4	77
371	Characterization of Brain Natriuretic Peptide in Long-term Follow-up of Pulmonary Arterial Hypertension. <i>Chest</i> , 2005, 128, 2368-2374.	0.4	114
372	Treatment of Pulmonary Arterial Hypertension With the Endothelin Receptor Antagonist Bosentan. <i>Clinical Pulmonary Medicine</i> , 2005, 12, 121-127.	0.3	3
373	Idiopathic pulmonary arterial hypertension in children. <i>Current Opinion in Pediatrics</i> , 2005, 17, 372-380.	1.0	39
374	Clinical Challenges in Pulmonary Hypertension. <i>Chest</i> , 2005, 128, 622S-628S.	0.4	23
375	Right Atrial and Ventricular Adaptation to Chronic Right Ventricular Pressure Overload. <i>Circulation</i> , 2005, 112, 1212-8.	1.6	151
376	An Overview of Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Nursing</i> , 2005, 20, 108-116.	0.6	19
378	Oral Sildenafil Improves Primary Pulmonary Hypertension Refractory to Epoprostenol. <i>Circulation Journal</i> , 2005, 69, 461-465.	0.7	49
379	Right-sided cardiac function in healthy volunteers measured by first-pass radionuclide ventriculography and gated blood-pool SPECT: comparison with cine MRI. <i>Clinical Physiology and Functional Imaging</i> , 2005, 25, 344-349.	0.5	37
380	Current treatment strategies for pulmonary arterial hypertension. <i>Journal of Internal Medicine</i> , 2005, 258, 199-215.	2.7	56
381	New predictors of outcome in idiopathic pulmonary arterial hypertension. <i>American Journal of Cardiology</i> , 2005, 95, 199-203.	0.7	227
383	Bosentan is an alternative treatment option in a child with severe idiopathic pulmonary artery hypertension and abnormal liver enzymes. <i>Respiratory Medicine Extra</i> , 2005, 1, 140-143.	0.1	2
384	Correction of phase offset errors in main pulmonary artery flow quantification. <i>Journal of Magnetic Resonance Imaging</i> , 2005, 22, 73-79.	1.9	89
386	Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. <i>BMC Pharmacology</i> , 2005, 5, P45.	0.4	1
387	Cost-Effectiveness of Treprostinil Versus Epoprostenol in Patients with Pulmonary Arterial Hypertension: A Canadian Analysis. <i>Canadian Respiratory Journal</i> , 2005, 12, 419-425.	0.8	11
389	Classificação e avaliação diagnóstica da hipertensão pulmonar. <i>Jornal Brasileiro De Pneumologia</i> , 2005, 31, S1-S8.	0.4	14

#	ARTICLE	IF	CITATIONS
390	Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1414-1418.	1.1	194
391	Survival with first-line bosentan in patients with primary pulmonary hypertension. <i>European Respiratory Journal</i> , 2005, 25, 244-249.	3.1	565
392	Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. <i>FASEB Journal</i> , 2005, 19, 1175-1177.	0.2	158
393	Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 358-363.	2.5	62
394	Improving survival in idiopathic pulmonary arterial hypertension: revisiting the "kingdom of the near-dead". <i>Thorax</i> , 2005, 60, 981-983.	2.7	7
395	Ambrisentan for pulmonary arterial hypertension. <i>Future Cardiology</i> , 2005, 1, 425-432.	0.5	17
396	Surgical and Interventional Therapies for Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 417-428.	0.8	17
397	Pulmonary Arterial Hypertension: Evaluation of the Newly Diagnosed Patient. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 372-378.	0.8	10
398	Bosentan therapy for pulmonary arterial hypertension. <i>Future Cardiology</i> , 2005, 1, 299-309.	0.5	3
399	Changing the Prognosis of Pulmonary Arterial Hypertension: Impact of Medical Therapy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 409-416.	0.8	8
400	Endothelin Antagonism in Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 402-408.	0.8	18
401	Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. <i>European Heart Journal</i> , 2005, 26, 1993-1999.	1.0	203
402	Monocrotaline-induced pulmonary hypertension correlates with upregulation of connective tissue growth factor expression in the lung. <i>Experimental and Molecular Medicine</i> , 2005, 37, 27-35.	3.2	33
403	Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. <i>Thorax</i> , 2005, 60, 1025-1030.	2.7	180
404	Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 93-101.	3.2	16
405	Staggered Transition to Epoprostenol from Treprostinil in Pulmonary Arterial Hypertension. <i>Annals of Pharmacotherapy</i> , 2005, 39, 739-743.	0.9	9
406	Autoimmunity and pulmonary hypertension: a perspective. <i>European Respiratory Journal</i> , 2005, 26, 1110-1118.	3.1	236
407	Inhaled Iloprost in Pulmonary Arterial Hypertension. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1265-1274.	0.9	37

#	ARTICLE	IF	CITATIONS
408	Improving survival in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2005, 25, 218-220.	3.1	9
409	Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 1292-1297.	2.5	345
410	Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2005, 26, 858-863.	3.1	426
411	Bosentan Improves Exercise Tolerance and Tei Index in Patients With Pulmonary Hypertension and Prostanoid Therapy. <i>Chest</i> , 2005, 128, 709-713.	0.4	77
412	Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2005, 26, 1895-1902.	1.0	147
413	Pulmonary Arterial Hypertension. <i>Chest</i> , 2005, 127, 1836-1843.	0.4	179
414	Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2005, 46, 697-704.	1.2	245
416	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2005, 353, 2148-2157.	13.9	2,237
417	Explorations fonctionnelles dans l'hypertension artérielle pulmonaire. <i>Revue Des Maladies Respiratoires</i> , 2005, 22, 991-997.	1.7	6
418	Pulmonary Hypertension in Sickle Cell Disease: Mechanisms, Diagnosis, and Management. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 881-896.	0.9	68
420	Safety and tolerability of bosentan in adults with Eisenmenger physiology. <i>International Journal of Cardiology</i> , 2005, 98, 147-151.	0.8	97
421	Severe Left Ventricular Dysfunction Secondary to Primary Pulmonary Hypertension: Bridging Therapy With Bosentan Before Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 777-780.	0.3	9
422	Long-Term Outcome of Bosentan Treatment in Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated with the Scleroderma Spectrum of Diseases. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1626-1631.	0.3	99
423	Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. <i>Current Opinion in Pharmacology</i> , 2005, 5, 245-250.	1.7	47
425	Inhaled tolfenfrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. <i>Respiratory Research</i> , 2005, 6, 128.	1.4	34
426	Validation of a brief telephone battery for neurocognitive assessment of patients with pulmonary arterial hypertension. <i>Respiratory Research</i> , 2005, 6, 39.	1.4	21
427	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. <i>Respiratory Research</i> , 2005, 6, 76.	1.4	31
428	Health-related quality of life in patients with pulmonary arterial hypertension. <i>Respiratory Research</i> , 2005, 6, 92.	1.4	167

#	ARTICLE	IF	CITATIONS
429	Noninvasive assessment and monitoring of the pulmonary circulation. <i>European Respiratory Journal</i> , 2005, 25, 758-766.	3.1	30
430	Risk Management Strategies in the Postmarketing Period. <i>Drug Safety</i> , 2005, 28, 971-980.	1.4	51
431	Prostacyclin for pulmonary hypertension in adults. <i>The Cochrane Library</i> , 2005, , CD002994.	1.5	29
433	Impact of valve prosthesis-patient mismatch on pulmonary arterial pressure after mitral valve replacement. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1034-1040.	1.2	117
434	Diagnostic et classification des hypertensions artérielles pulmonaires. <i>EMC - Pneumologie</i> , 2005, 2, 192-203.	0.2	0
435	Medical therapeutics for pulmonary arterial hypertension: from basic science and clinical trial design to evidence-based medicine. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 347-360.	0.6	3
436	Pulmonary arterial hypertension associated to connective tissue diseases. <i>Lupus</i> , 2005, 14, 713-717.	0.8	97
437	Iloprost for idiopathic pulmonary arterial hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 215-223.	0.6	9
438	Present and Future Treatment Strategies for Pulmonary Arterial Hypertension. <i>Treatments in Respiratory Medicine</i> , 2006, 5, 271-282.	1.4	8
439	Pulmonary Arterial Hypertension. <i>Treatments in Respiratory Medicine</i> , 2006, 5, 117-127.	1.4	18
440	Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia. <i>Pharmacoeconomics</i> , 2006, 24, 903-915.	1.7	34
441	Pediatric lung transplantation. <i>Seminars in Pediatric Surgery</i> , 2006, 15, 199-207.	0.5	12
442	Pulmonary Arterial Hypertension. <i>Circulation</i> , 2006, 114, 1417-1431.	1.6	619
443	Tricuspid Annular Displacement Predicts Survival in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 1034-1041.	2.5	955
444	Right Heart Function in Scleroderma: Insights from Myocardial Doppler Tissue Imaging. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 507-514.	1.2	56
445	Pulmonary Hypertension in Children: The Twenty-First Century. <i>Pediatric Clinics of North America</i> , 2006, 53, 961-987.	0.9	103
446	Right Heart Function in Systemic Lupus Erythematosus: Insights from Myocardial Doppler Tissue Imaging. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 441-449.	1.2	28
448	Cognitive, emotional, and quality of life outcomes in patients with pulmonary arterial hypertension. <i>Respiratory Research</i> , 2006, 7, 55.	1.4	86

#	ARTICLE	IF	CITATIONS
449	Relationship of Pulmonary Arterial Capacitance and Mortality in Idiopathic Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2006, 47, 799-803.	1.2	355
450	Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1433-1437.	1.2	115
451	Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. <i>Heart</i> , 2006, 92, 969-972.	1.2	116
452	A dilated inferior vena cava is a marker of poor survival. <i>American Heart Journal</i> , 2006, 151, 730-735.	1.2	35
453	Inhibition of vascular smooth muscle cell proliferation in vitro by genetically engineered marrow stromal cells secreting calcitonin gene-related peptide. <i>Life Sciences</i> , 2006, 78, 1830-1838.	2.0	21
454	Preliminary Experience With Bosentan as Initial Therapy in Childhood Idiopathic Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 469-473.	0.3	26
455	International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update—A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 745-755.	0.3	1,080
456	Dramatic decrease in the pulmonary artery systolic pressure and disappearance of the interatrial shunt with sildenafil treatment in a patient with primary pulmonary hypertension with atrial septal aneurysm and a severe right to left shunt through the patent foramen ovale. <i>International Journal of Cardiology</i> , 2006, 110, 97-99.	0.8	7
457	The determinants of right ventricular function in patients with atrial septal defect. <i>International Journal of Cardiology</i> , 2006, 111, 127-130.	0.8	12
458	Treatments for pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2006, 100, 765-774.	1.3	13
460	Pulmonary Arterial Hypertension. , 2006, , 795-821.		0
461	Bosentan for the treatment of scleroderma. <i>Future Rheumatology</i> , 2006, 1, 549-562.	0.2	1
462	The Current Treatment of Pulmonary Arterial Hypertension. <i>Chest</i> , 2006, 130, 1198-1202.	0.4	83
463	Efficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary Hypertension. <i>Chest</i> , 2006, 129, 1636-1643.	0.4	189
464	Reversal of Idiopathic Pulmonary Arterial Hypertension and Allograft Pneumonectomy After Single Lung Transplantation. <i>Chest</i> , 2006, 130, 214-217.	0.4	27
465	Affections de l'artère pulmonaire. <i>EMC - Cardiologie</i> , 2006, 1, 1-15.	0.0	0
466	The Need for National Registries in Rare Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 228-228.	2.5	9
467	Hypertensions artérielles pulmonaires pré-capillaires. <i>EMC - Cardiologie</i> , 2006, 1, 1-13.	0.0	1

#	ARTICLE	IF	CITATIONS
468	Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2006, 129, 746-752.	0.4	741
469	Noninfectious Pulmonary Complications of HIV. <i>Clinical Pulmonary Medicine</i> , 2006, 13, 194-202.	0.3	3
470	The new lung allocation system in the United States. <i>Current Opinion in Organ Transplantation</i> , 2006, 11, 490-495.	0.8	2
471	Pulmonary Arterial Hypertension and Women. <i>Cardiology in Review</i> , 2006, 14, 312-318.	0.6	7
472	Pharmacologic treatment for pulmonary arterial hypertension. <i>Current Opinion in Cardiology</i> , 2006, 21, 561-568.	0.8	12
473	Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 353-360.	1.0	84
474	Endothelin receptor antagonists for pulmonary arterial hypertension. , 2006, , CD004434.		25
475	Evaluation of Right Ventricular Tei Index (Index of Myocardial Performance) in Healthy Dogs and Dogs with Tricuspid Regurgitation. <i>Journal of Veterinary Medical Science</i> , 2006, 68, 1307-1313.	0.3	28
476	Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. <i>Proteomics</i> , 2006, 6, 2286-2294.	1.3	52
477	Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2006, 60, 475-481.	0.8	14
478	Pulmonary arterial hypertension: New insights and new hope. <i>Respirology</i> , 2006, 11, 6-17.	1.3	56
479	Metalloproteinase-9 in circulating monocytes in pulmonary hypertension. <i>Fundamental and Clinical Pharmacology</i> , 2006, 20, 405-410.	1.0	8
480	An Abnormal Right Ventricular Apical Angle is Indicative of Global Right Ventricular Impairment. <i>Echocardiography</i> , 2006, 23, 361-368.	0.3	41
481	Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. <i>European Journal of Clinical Investigation</i> , 2006, 36, 16-24.	1.7	57
482	Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. <i>European Journal of Clinical Investigation</i> , 2006, 36, 49-53.	1.7	41
483	Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. <i>European Journal of Clinical Investigation</i> , 2006, 36, 10-15.	1.7	93
484	First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. <i>European Journal of Clinical Investigation</i> , 2006, 36, 32-38.	1.7	62
485	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 689-702.	21.5	471

#	ARTICLE	IF	CITATIONS
487	The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary Hypertension. <i>Quality of Life Research</i> , 2006, 15, 103-115.	1.5	247
488	Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 54-59.	1.0	5
490	Role of the endothelium in pulmonary arterial hypertension. <i>Vascular Pharmacology</i> , 2006, 45, 317-325.	1.0	23
491	Development of the New Lung Allocation System in the United States. <i>American Journal of Transplantation</i> , 2006, 6, 1212-1227.	2.6	658
492	P-wave amplitude and pulmonary artery pressure in scleroderma. <i>Journal of Electrocardiology</i> , 2006, 39, 385-388.	0.4	5
493	Endothelin receptor antagonists. , 2006, 110, 386-414.		154
494	Pharmacotherapy for Idiopathic Pulmonary Arterial Hypertension During the Past 25 Years. <i>Pharmacotherapy</i> , 2006, 26, 68-94.	1.2	15
496	Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. <i>Arthritis and Rheumatism</i> , 2006, 54, 3043-3050.	6.7	308
497	Mutations of the TGF- β 2 type II receptorBMP2 in pulmonary arterial hypertension. <i>Human Mutation</i> , 2006, 27, 121-132.	1.1	368
498	Pulmonary hypertension and β -thalassemia major: Report of a case, its treatment, and a review of the literature. <i>American Journal of Hematology</i> , 2006, 81, 443-447.	2.0	24
499	Efficacy of Bosentan in a Small Cohort of Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease. <i>Chest</i> , 2006, 129, 1009-1015.	0.4	49
500	“Raising the bar”™ for the treatment of pulmonary arterial hypertensionThe opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2006, 27, 510-511.	1.0	6
501	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2006, 27, 589-595.	1.0	272
502	The role of vasopressin in cardiorespiratory arrest and pulmonary hypertension. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 127-133.	0.2	37
503	Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 327-330.	1.9	2
504	Role of Prostacyclin versus Peroxisome Proliferator-Activated Receptor β 2 Receptors in Prostacyclin Sensing by Lung Fibroblasts. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006, 34, 242-246.	1.4	79
505	Genetic Association of the Serotonin Transporter in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 793-797.	2.5	88
506	Abnormal Pulmonary Function in Adults with Sickle Cell Anemia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1264-1269.	2.5	177

#	ARTICLE	IF	CITATIONS
508	The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. <i>European Journal of Cardio-thoracic Surgery</i> , 2006, 30, 499-507.	0.6	47
509	Pulmonary arterial hypertension: classification, diagnosis and contemporary management. <i>Postgraduate Medical Journal</i> , 2006, 82, 717-722.	0.9	5
510	Long-term treprostinil in pulmonary arterial hypertension: is the glass half full or half empty?. <i>European Respiratory Journal</i> , 2006, 28, 1073-1075.	3.1	1
511	Assessing right ventricular function: the role of echocardiography and complementary technologies. <i>Heart</i> , 2006, 92, i19-i26.	1.2	197
512	Measurement of quality of life in pulmonary hypertension and its significance. <i>European Respiratory Journal</i> , 2006, 28, 808-815.	3.1	126
513	Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. <i>European Respiratory Journal</i> , 2006, 28, 1195-1203.	3.1	299
514	Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better?. <i>European Respiratory Journal</i> , 2006, 28, 683-686.	3.1	11
515	Response to bosentan in children with pulmonary hypertension. <i>Heart</i> , 2006, 92, 664-670.	1.2	130
516	Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension. <i>Cerebrovascular Diseases</i> , 2006, 21, 194-200.	0.8	54
517	Approach to the Patient With Pulmonary Hypertension. , 2006, , 83-98.		5
518	Classification and Prognosis of Pulmonary Arterial Hypertension. , 2006, , 66-82.		1
519	Lung Transplantation for Pulmonary Arterial Hypertension. , 2006, , 119-131.		1
520	Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 254-257.	0.5	26
521	Emerging treatments for pulmonary arterial hypertension. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 609-619.	1.0	6
522	Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1487-1501.	0.9	24
523	Sildenafil for pulmonary arterial hypertension: when blue turns into white. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1801-1810.	0.9	4
524	Pulmonary Arterial Hypertension in France. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1023-1030.	2.5	1,736
525	Coexistence of nodular regenerative hyperplasia of the liver and pulmonary arterial hypertension in patients with connective tissue diseases: report of three cases and review of the literature. <i>Modern Rheumatology</i> , 2006, 16, 389-394.	0.9	1

#	ARTICLE	IF	CITATIONS
527	NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. <i>European Respiratory Journal</i> , 2007, 29, 737-744.	3.1	101
528	Pharmacological impact on right ventricular remodelling in pulmonary arterial hypertension. <i>Country Review Ukraine</i> , 2007, 9, H68-H74.	0.8	15
529	Contrasting Actions of Endothelin ETA and ETB Receptors in Cardiovascular Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2007, 47, 731-759.	4.2	255
530	Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. <i>Thorax</i> , 2007, 62, 617-622.	2.7	43
531	Rho Kinase Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats. <i>Circulation Research</i> , 2007, 100, 923-929.	2.0	315
532	Dual endothelin receptor antagonism: setting standards in PAH. <i>European Respiratory Review</i> , 2007, 16, 13-18.	3.0	3
533	Sitaxsentan in the management of pulmonary arterial hypertension. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 363-368.	0.5	8
534	Making a diagnosis in PAH. <i>European Respiratory Review</i> , 2007, 16, 8-12.	3.0	7
536	Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. <i>European Heart Journal</i> , 2007, 28, 1187-1189.	1.0	48
537	Unexplained Pulmonary Hypertension in Elderly Patients. <i>Chest</i> , 2007, 131, 94-100.	0.4	90
538	Right Ventricular Pressure Waveform and Wave Reflection Analysis in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 132, 37-43.	0.4	40
539	Registry and Survival Study in Chinese Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 132, 373-379.	0.4	198
540	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2007, 132, 998-1006.	0.4	223
541	Atrial Septostomy. <i>Chest</i> , 2007, 131, 947-948.	0.4	9
542	Pulmonary Hypertension and Thyroid Disease. <i>Chest</i> , 2007, 132, 793-797.	0.4	89
543	Model of chronic adaptation: right ventricular function in Eisenmenger syndrome. <i>Country Review Ukraine</i> , 2007, 9, H54-H60.	0.8	39
544	Right Ventricular Diastolic Dysfunction and the Acute Effects of Sildenafil in Pulmonary Hypertension Patients. <i>Chest</i> , 2007, 132, 11-17.	0.4	138
545	Pulmonary arterial hypertension: current therapeutic strategies. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 319-329.	3.3	54

#	ARTICLE	IF	CITATIONS
546	Primary Pulmonary Hypertension: 3D Dynamic Perfusion MRI for Quantitative Analysis of Regional Pulmonary Perfusion. <i>American Journal of Roentgenology</i> , 2007, 188, 48-56.	1.0	108
547	Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2007, 28, 1250-1257.	1.0	666
548	Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2007, 6, 608-613.	0.5	20
549	Eisenmenger syndrome and pulmonary arterial hypertension in adults with congenital heart disease. <i>Current Medical Research and Opinion</i> , 2007, 23, S19-S25.	0.9	3
550	Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. <i>British Journal of Anaesthesia</i> , 2007, 98, 657-661.	1.5	121
551	An epidemiological study of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2007, 30, 104-109.	3.1	668
552	Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. <i>Lupus</i> , 2007, 16, 279-285.	0.8	24
553	Pulmonary Arterial Hypertension: An Overview. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2007, 11, 96-103.	0.4	3
554	A USA-based registry for pulmonary arterial hypertension: 1982-2006. <i>European Respiratory Journal</i> , 2007, 30, 1103-1110.	3.1	376
555	Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2007, 11, 110-118.	0.4	7
557	Noninvasive Tools to Monitor Pulmonary Hypertension. <i>Clinical Pulmonary Medicine</i> , 2007, 14, 232-239.	0.3	0
558	Pulmonary arterial hypertension in the pediatric age. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 72-77.	0.6	22
559	Selection of candidates for lung transplantation. <i>Current Opinion in Organ Transplantation</i> , 2007, 12, 479-484.	0.8	3
560	Noninvasive Cardiac Imaging in Pulmonary Hypertension. <i>Cardiology in Review</i> , 2007, 15, 97-101.	0.6	14
561	How should we assess right ventricular function in 2008?. <i>Country Review Ukraine</i> , 2007, 9, H22-H28.	0.8	27
562	Management of acute and chronic RV dysfunction. <i>Country Review Ukraine</i> , 2007, 9, H61-H67.	0.8	3
563	Atrial Septostomy in Treatment of End-Stage Right Heart Failure in Patients With Pulmonary Hypertension. <i>Chest</i> , 2007, 131, 977-983.	0.4	144
564	Relationship of Pulmonary Arterial Capacitance and Mortality in Idiopathic Pulmonary Arterial Hypertension. <i>Yearbook of Cardiology</i> , 2007, 2007, 411-412.	0.0	0

#	ARTICLE	IF	CITATIONS
565	Pulmonary Arterial Hypertension. <i>Critical Care Nursing Quarterly</i> , 2007, 30, 20-41.	0.4	18
566	Predictors of Nocturnal Oxygen Desaturation in Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 131, 109-117.	0.4	74
567	Atrial Septostomy Decreases Sympathetic Overactivity in Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 131, 1831-1837.	0.4	75
568	Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H1120-H1128.	1.5	176
569	Right ventricular function in pulmonary hypertension: physiological concepts. <i>Country Review Ukraine</i> , 2007, 9, H5-H9.	0.8	24
570	Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 132, 764-772.	0.4	20
571	p38 MAP kinase: Essential role in hypoxia-mediated human pulmonary artery fibroblast proliferation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2007, 20, 718-725.	1.1	44
572	Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. <i>Respiratory Physiology and Neurobiology</i> , 2007, 159, 196-201.	0.7	32
573	NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2007, 101, 69-75.	1.3	65
574	Diagnosis and management of pulmonary hypertension over the past 100 years. <i>Respiratory Medicine</i> , 2007, 101, 389-398.	1.3	27
575	Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2007, 101, 1556-1562.	1.3	6
576	Pulmonary arterial pulse pressure and mortality in pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2007, 101, 2495-2501.	1.3	35
577	Selective and mixed endothelin receptor antagonism in cardiovascular disease. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 573-579.	4.0	67
578	Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. <i>American Heart Journal</i> , 2007, 153, 127-132.	1.2	243
579	Atrial septostomy improves survival in select patients with pulmonary hypertension. <i>American Heart Journal</i> , 2007, 153, 779-784.	1.2	106
580	Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: Does the beneficial effect persist?. <i>American Heart Journal</i> , 2007, 154, 776-782.	1.2	105
581	Evidence-Based Pharmacologic Management of Pulmonary Arterial Hypertension. <i>Clinical Therapeutics</i> , 2007, 29, 2134-2153.	1.1	79
582	Autologous endothelial progenitor cells transplantation for the therapy of primary pulmonary hypertension. <i>Medical Hypotheses</i> , 2007, 68, 1292-1295.	0.8	12

#	ARTICLE	IF	CITATIONS
583	Quality of Life in Pulmonary Arterial Hypertension: Improvement and Maintenance With Bosentan. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 181-187.	0.3	78
584	Assessment of Pulmonary Vascular Resistance by Doppler Echocardiography in Patients With Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 927-934.	0.3	66
585	Survival of Patients With Idiopathic Pulmonary Arterial Hypertension After Listing for Transplantation: Impact of Iloprost and Bosentan Treatment. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 898-906.	0.3	27
586	Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2007, 119, 400-402.	0.8	8
587	Place du bosentan dans le traitement de l'hypertension artérielle pulmonaire de la sclérodémie systémique. <i>Revue De Medecine Interne</i> , 2007, 28, S221-S226.	0.6	0
588	Pulmonary Vascular Disease in Adults With Congenital Heart Disease. <i>Circulation</i> , 2007, 115, 1039-1050.	1.6	344
589	Diagnosis of Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2007, 28, 59-73.	0.8	44
590	Prostanoid Therapy for Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2007, 28, 127-142.	0.8	26
591	Epoprostenol treatment in children with severe pulmonary hypertension. <i>Heart</i> , 2007, 93, 739-743.	1.2	98
592	Genetics and Mediators in Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2007, 28, 43-57.	0.8	48
593	Long-term therapeutic outcomes in pulmonary arterial hypertension. <i>Current Medical Research and Opinion</i> , 2007, 23, S11-S18.	0.9	0
594	Sitaxentan: a guide to its use in pulmonary arterial hypertension. <i>Drugs and Therapy Perspectives</i> , 2007, 23, 5-8.	0.3	0
595	Idiopathic Pulmonary Arterial Hypertension Misdiagnosed as Asthma. <i>Journal of Asthma</i> , 2007, 44, 19-22.	0.9	11
596	The French registry of pulmonary arterial hypertension in children: rationale and design. <i>Current Medical Research and Opinion</i> , 2007, 23, S27-S33.	0.9	6
597	Left ventricular dimensions in pulmonary arterial hypertension: haemodynamic and exercise correlations. <i>Current Medical Research and Opinion</i> , 2007, 23, S55-S62.	0.9	2
598	Bosentan therapy for pulmonary arterial hypertension: a case report of a 16-month-old boy. <i>Current Medical Research and Opinion</i> , 2007, 23, S103-S107.	0.9	3
599	Epidemiology of Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2007, 28, 1-22.	0.8	41
601	Combination Therapy and New Types of Agents for Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2007, 28, 169-185.	0.8	51

#	ARTICLE	IF	CITATIONS
602	Surgical Therapies for Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2007, 28, 187-202.	0.8	9
606	Psychosocial Aspects of Pulmonary Hypertension: A Review. <i>Psychosomatics</i> , 2007, 48, 467-475.	2.5	46
607	Therapeutic Applications of Sildenafil Citrate in the Management of Paediatric Pulmonary Hypertension. <i>Drugs</i> , 2007, 67, 57-73.	4.9	35
608	Sitaxentan. <i>Drugs</i> , 2007, 67, 761-770.	4.9	18
610	Treatment With Sildenafil, Bosentan, or Both in Children and Young People With Idiopathic Pulmonary Arterial Hypertension and Eisenmenger's Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2007, 60, 366-372.	0.4	11
612	Post-Heart Transplant Diastolic Dysfunction Is a Risk Factor for Mortality. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1064-1069.	1.2	47
613	Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to Therapy. <i>Clinics in Chest Medicine</i> , 2007, 28, 75-89.	0.8	45
615	Sildenafil: A recent advance in the treatment of pulmonary arterial hypertension. <i>British Journal of Cardiac Nursing</i> , 2007, 2, 61-68.	0.0	0
617	SĀNDROME DE EISENMENGER Y EMBARAZO. <i>Revista Chilena De Obstetricia Y Ginecologia</i> , 2007, 72, .	0.1	0
618	Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. <i>Core Evidence</i> , 0, .	4.7	1
620	Bosentan and sildenafil: Should the combination therapy be a valid alternative in childhood to prostacyclin infusion?. <i>Pediatric Transplantation</i> , 2007, 11, 110-112.	0.5	10
621	Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006. <i>Internal Medicine Journal</i> , 2007, 37, 38-48.	0.5	17
622	Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2007, 61, 153-156.	0.8	13
623	Pulmonary hypertension: clinical manifestations, classification and diagnosis. <i>International Journal of Clinical Practice</i> , 2007, 61, 5-14.	0.8	15
624	Imaging of the heart in pulmonary hypertension. <i>International Journal of Clinical Practice</i> , 2007, 61, 15-26.	0.8	30
625	Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2007, 61, 1756-1765.	0.8	12
626	The nurse specialist and practical issues in the care of pulmonary arterial hypertension patients. <i>International Journal of Clinical Practice</i> , 2007, 61, 10-18.	0.8	10
627	Lung transplantation for pulmonary hypertension. <i>International Journal of Clinical Practice</i> , 2007, 61, 4-9.	0.8	10

#	ARTICLE	IF	CITATIONS
628	Right Heart Function and Scleroderma: Insights from Tricuspid Annular Plane Systolic Excursion. <i>Echocardiography</i> , 2007, 24, 118-125.	0.3	61
630	Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension from Intravenous Epoprostenol to Intravenous Treprostinil. <i>American Journal of Cardiology</i> , 2007, 99, 696-698.	0.7	78
631	Classification des Âhypertensions pulmonaires. <i>Annales De Cardiologie Et D'Angeiologie</i> , 2007, 56, S106-S111.	0.3	0
633	Correlation of Tricuspid Annular Velocities With Invasive Hemodynamics in Pulmonary Hypertension. <i>Congestive Heart Failure</i> , 2007, 13, 200-204.	2.0	35
634	Pulmonary Arterial Hypertension. <i>Comprehensive Therapy</i> , 2007, 33, 231-236.	0.2	0
636	Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. <i>International Journal of Cardiovascular Imaging</i> , 2007, 23, 209-215.	0.7	23
639	Pulmonary hypertension: current diagnosis and treatment. <i>Clinical Research in Cardiology</i> , 2007, 96, 527-541.	1.5	63
642	Pulmonary Hypertension: Evaluation and Management. <i>Comprehensive Therapy</i> , 2007, 33, 150-161.	0.2	12
643	Epoprostenol treatment of acute pulmonary hypertension is associated with a Âparadoxical decrease in right ventricular contractility. <i>Intensive Care Medicine</i> , 2008, 34, 179-189.	3.9	36
645	Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 205-213.	0.7	24
646	Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes. <i>American Journal of Hematology</i> , 2008, 83, 19-25.	2.0	244
647	Pulmonary arterial hypertension and left Âsided heart disease in sickle cell disease: Clinical characteristics and association with soluble adhesion molecule expression. <i>American Journal of Hematology</i> , 2008, 83, 547-553.	2.0	58
648	Sustained Endothelial Progenitor Cell Dysfunction After Chronic Hypoxia-Induced Pulmonary Hypertension. <i>Stem Cells</i> , 2008, 26, 1017-1026.	1.4	78
649	PDE5 inhibitors and pulmonary hypertension. <i>Current Sexual Health Reports</i> , 2008, 5, 171-178.	0.4	0
650	Right heart function and haemodynamics in pulmonary hypertension. <i>International Journal of Clinical Practice</i> , 2008, 62, 11-19.	0.8	44
651	Utility of Right Ventricular Tissue Doppler Imaging: Correlation with Right Heart Catheterization. <i>Echocardiography</i> , 2008, 25, 706-711.	0.3	42
652	Effect of gender and highly active antiretroviral therapy on HIV Ârelated pulmonary arterial hypertension: results of the HIV ÂHEART Study. <i>HIV Medicine</i> , 2008, 9, 550-556.	1.0	53
653	Bosentan therapy in patients with pulmonary arterial hypertension: The relationship between improvements in 6 minute walk distance and quality of life. <i>Respirology</i> , 2008, 13, 674-682.	1.3	31

#	ARTICLE	IF	CITATIONS
654	Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: Open-label pilot study. <i>Pediatric Transplantation</i> , 2008, 12, 650-655.	0.5	124
656	The impact of the lung allocation score on short-term transplantation outcomes: A multicenter study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 135, 166-171.	0.4	136
657	Novel approach with intratracheal administration of microgelatin hydrogel microspheres incorporating basic fibroblast growth factor for rescue of rats with monocrotaline-induced pulmonary hypertension. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 1250-1256.	0.4	9
658	Sildenafil. <i>Drugs</i> , 2008, 68, 383-397.	4.9	65
659	Ambrisentan. <i>Drugs</i> , 2008, 68, 2195-2204.	4.9	36
661	Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study. <i>Respiratory Research</i> , 2008, 9, 68.	1.4	18
663	Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 51, 161-169.	1.2	178
664	Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1527-1538.	1.2	269
665	Role of Cardiac Magnetic Resonance Imaging in the Management of Patients With Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1683-1692.	1.2	178
666	Medical therapy for pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 65-81.	0.9	10
667	L'hyperpression artérielle pulmonaire: stratégies thérapeutiques actuelles. <i>Pharmacien Hospitalier</i> , 2008, 43, 35-47.	0.1	0
668	Review: Therapeutic advances in pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2008, 2, 249-265.	1.0	33
669	United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPBOR). <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 124-130.	0.3	78
670	Extracorporeal Membrane Oxygenation as a Bridge to Emergency Heart-Lung Transplantation in a Patient With Idiopathic Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 466-468.	0.3	78
671	Prognostic impact of pulmonary arterial hypertension: A population-based analysis. <i>International Journal of Cardiology</i> , 2008, 124, 183-187.	0.8	20
672	Identifying right ventricular dysfunction with tissue Doppler imaging in pulmonary hypertension. <i>International Journal of Cardiology</i> , 2008, 128, 359-363.	0.8	37
673	Quantitative evaluation of chronic pulmonary thromboemboli by multislice CT compared with pulsed Tissue Doppler Imaging and its relationship with brain natriuretic peptide. <i>International Journal of Cardiology</i> , 2008, 130, 505-512.	0.8	4
674	Venous endothelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. <i>Regulatory Peptides</i> , 2008, 151, 48-53.	1.9	17

#	ARTICLE	IF	CITATIONS
675	Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2008, 102, 1431-1438.	1.3	64
676	Ambrisentan for the management of pulmonary arterial hypertension. <i>Clinical Therapeutics</i> , 2008, 30, 825-833.	1.1	33
678	Design of the REVEAL Registry for US Patients With Pulmonary Arterial Hypertension. <i>Mayo Clinic Proceedings</i> , 2008, 83, 923-931.	1.4	74
680	Effects of selective and unselective endothelinâ€receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008, 68, 270-276.	0.6	15
681	Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 171-185.	1.0	41
682	The Role of Treprostinil in the Management of Pulmonary Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 213-217.	1.0	11
683	Diagnosis of pulmonary hypertension. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 1263-1277.	1.6	1
684	Singleâ€Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63â€2521: An Ascendingâ€Dose Study in Healthy Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 926-934.	1.0	100
685	Right Ventricular Function in Cardiovascular Disease, Part II. <i>Circulation</i> , 2008, 117, 1717-1731.	1.6	1,112
686	Immediate clinical and haemodynamic benefits of restoration of pulmonary valvar competence in patients with pulmonary hypertension. <i>Heart</i> , 2008, 95, 646-650.	1.2	26
687	Risk factors for chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2008, 33, 325-331.	3.1	336
688	Successful Treatment of Sarcoidosis-Associated Pulmonary Hypertension with Bosentan. <i>Respiration</i> , 2008, 75, 211-214.	1.2	47
689	Acute Improved Hemodynamics following Inhaled Iloprost in Chronic Thromboembolic Pulmonary Hypertension. <i>Respiration</i> , 2008, 76, 154-159.	1.2	40
690	The Emerging Role of Magnetic Resonance Imaging in the Diagnosis and Management of Pulmonary Hypertension. <i>Respiration</i> , 2008, 76, 458-470.	1.2	40
691	Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of Pharmacy Technology</i> , 2008, 24, 142-148.	0.5	0
692	Traditional and Alternative Designs for Pulmonary Arterial Hypertension Trials. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 610-616.	3.5	8
693	Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?. <i>European Heart Journal</i> , 2008, 29, 1936-1948.	1.0	87
694	Defining normal variables of right ventricular size and function in pulmonary hypertension: an echocardiographic study. <i>Postgraduate Medical Journal</i> , 2008, 84, 40-45.	0.9	89

#	ARTICLE	IF	CITATIONS
695	Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 117, 3020-3030.	1.6	208
696	Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 118, 1195-1201.	1.6	90
697	Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. <i>Thorax</i> , 2008, 63, ii1-ii41.	2.7	43
698	Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 117, 2475-2483.	1.6	116
699	Pulmonary Arterial Hypertension. , 2008, , 759-771.		0
700	Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. <i>Heart</i> , 2008, 94, i1-i41.	1.2	52
701	Upregulation of vascular calcium channels in neonatal piglets with hypoxia-induced pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2008, 295, L915-L924.	1.3	56
702	Pulmonary Hypertension, Right Ventricular Failure, and Kidney. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1232-1237.	2.2	73
703	Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. <i>European Respiratory Journal</i> , 2008, 31, 343-348.	3.1	118
704	Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2008, 295, L727-L732.	1.3	61
705	Pulmonary hypertension: basic concepts and practical management. <i>European Respiratory Journal</i> , 2008, 31, 236-237.	3.1	7
706	Biomarkers in pulmonary hypertension. <i>European Respiratory Journal</i> , 2008, 32, 503-512.	3.1	129
707	Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of <i>BMPR2</i> Mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1377-1383.	2.5	269
708	Update in Pulmonary Arterial Hypertension 2007. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 574-579.	2.5	45
709	Surrogate and Combined End Points in Pulmonary Arterial Hypertension. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 617-622.	3.5	35
710	Biological Serum Markers in the Management of Pediatric Pulmonary Arterial Hypertension. <i>Pediatric Research</i> , 2008, 63, 321-327.	1.1	86
711	<i>BMPR2</i> Mutation and Outcome in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1300-1301.	2.5	7
712	Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. <i>European Heart Journal</i> , 2008, 29, 1688-1695.	1.0	240

#	ARTICLE	IF	CITATIONS
713	Patients with Pulmonary Arterial Hypertension in Clinical Trials: Who Are They?. Proceedings of the American Thoracic Society, 2008, 5, 603-609.	3.5	12
714	Inhaled Prostanoids in the Therapy of Pulmonary Hypertension. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, 21, 1-12.	0.7	76
715	Design of the REVEAL Registry for US Patients With Pulmonary Arterial Hypertension. Mayo Clinic Proceedings, 2008, 83, 923-931.	1.4	116
716	Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 2008, 134, 229-236.	0.4	226
717	Implications of Mutations of Activin Receptor-Like Kinase 1 Gene (<i>ALK1</i>) in Addition to Bone Morphogenetic Protein Receptor II Gene (<i>BMPR2</i>) in Children With Pulmonary Arterial Hypertension. Circulation Journal, 2008, 72, 127-133.	0.7	95
718	Pulmonary Hypertension Is Associated With Reduced Patient Survival After Kidney Transplantation. Transplantation, 2008, 86, 1384-1388.	0.5	114
719	Pulmonary Arterial Hypertension. American Journal of the Medical Sciences, 2008, 335, 40-45.	0.4	16
720	Increased Mortality in African Americans with Idiopathic Pulmonary Arterial Hypertension. Journal of the National Medical Association, 2008, 100, 69-72.	0.6	32
721	Long-term Follow-up of a Fenestrated Amplatzer Atrial Septal Occluder in Pulmonary Arterial Hypertension. Chest, 2008, 133, 283-285.	0.4	47
722	Pulmonary arterial hypertension and its association with HIV infection: an overview. Aids, 2008, 22, S1-S6.	1.0	21
723	Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats. Critical Care Medicine, 2008, 36, 873-880.	0.4	59
724	Misinterpretation of a Pulmonary GI Anastomosis Stapler Line as a Retained Foreign Body. Chest, 2008, 133, 281-285.	0.4	7
725	Exercise Testing to Estimate Survival in Pulmonary Hypertension. Medicine and Science in Sports and Exercise, 2008, 40, 1725-1732.	0.2	129
726	Exercise in Patients With Pulmonary Arterial Hypertension. Journal of Cardiopulmonary Rehabilitation and Prevention, 2008, 28, 12-16.	1.2	47
727	Right Ventricular Failure in the Critically Ill Patient With Pulmonary Arterial Hypertension. Clinical Pulmonary Medicine, 2008, 15, 161-166.	0.3	0
728	Pulmonary arterial hypertension in children: a medical update. Current Opinion in Pediatrics, 2008, 20, 288-293.	1.0	28
730	Hemodynamic variables and clinical features correlated with serum uric acid in patients with pulmonary arterial hypertension. Chinese Medical Journal, 2008, 121, 2497-2503.	0.9	9
731	Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vascular Health and Risk Management, 2008, Volume 4, 1459-1466.	1.0	32

#	ARTICLE	IF	CITATIONS
732	Cavitating Lung Lesions in Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of Radiology Case Reports</i> , 2008, 2, 11-21.	0.2	11
733	Teste de vasorreatividade pulmonar. <i>Jornal Brasileiro De Pneumologia</i> , 2008, 34, 838-844.	0.4	11
734	Current Pharmacological Treatment of Pulmonary Arterial Hypertension. <i>Current Clinical Pharmacology</i> , 2008, 3, 11-19.	0.2	13
735	Addition of Sildenafil in Patients with Pulmonary Arterial Hypertension with Inadequate Response to Bosentan Monotherapy. <i>Canadian Respiratory Journal</i> , 2008, 15, 427-430.	0.8	20
736	Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPBOR) into French-Canadian and English-Canadian. <i>Canadian Respiratory Journal</i> , 2008, 15, 77-83.	0.8	26
737	Pulmonary Arterial Hypertension in Children: A Single Center Experience. <i>Korean Circulation Journal</i> , 2008, 38, 644.	0.7	5
738	The Protective Effect of Simvastatin on Monocrotaline-Induced Pulmonary Hypertension in Rats. <i>Korean Circulation Journal</i> , 2008, 38, 313.	0.7	4
739	Therapy for Pulmonary Arterial Hypertension: The More, the Merrier?. <i>Annals of Internal Medicine</i> , 2008, 149, 583.	2.0	8
740	Integrated care and optimal management of pulmonary arterial hypertension. <i>Journal of Multidisciplinary Healthcare</i> , 2009, 2, 67.	1.1	7
741	Treatment of pediatric pulmonary hypertension. <i>Vascular Health and Risk Management</i> , 2009, 5, 509.	1.0	19
743	Beneficial and Adverse Effects of Bosentan Treatment in Korean Patients With Pulmonary Artery Hypertension. <i>Korean Circulation Journal</i> , 2009, 39, 105.	0.7	6
744	Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. <i>Drug Design, Development and Therapy</i> , 2009, 3, 269.	2.0	48
745	Safety and Efficacy of Ambrisentan in the Treatment of Pulmonary Arterial Hypertension. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2675.	0.1	1
746	Hiv-Associated Pulmonary Hypertension: Case Report. <i>East African Medical Journal</i> , 2009, 85, 564-7.	0.0	0
747	Effects of Long-Acting Beraprost Sodium (TRK-100STP) in Japanese Patients With Pulmonary Arterial Hypertension. <i>International Heart Journal</i> , 2009, 50, 513-529.	0.5	35
748	Present and Prospective Pharmacotherapies in Pulmonary Arterial Hypertension. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2108.	0.1	0
749	Valida�o de um protocolo para o teste de caminhada de seis minutos em esteira para avalia�o de pacientes com hipertens�o arterial pulmonar. <i>Jornal Brasileiro De Pneumologia</i> , 2009, 35, 423-430.	0.4	29
750	Inhaled iloprost for the control of pulmonary hypertension. <i>Vascular Health and Risk Management</i> , 2009, 5, 465.	1.0	31

#	ARTICLE	IF	CITATIONS
751	Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Respiratory Journal</i> , 2009, 34, 1219-1263.	3.1	1,127
752	The saudi advisory group for pulmonary hypertension. <i>Annals of Thoracic Medicine</i> , 2009, 4, 107.	0.7	2
753	Discordance between microneurographic and heart-rate spectral indices of sympathetic activity in pulmonary arterial hypertension. <i>Heart</i> , 2009, 95, 754-758.	1.2	31
754	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. <i>Circulation</i> , 2009, 119, 2250-2294.	1.6	992
755	Conventional and targeted medical therapies. <i>Cardiology in the Young</i> , 2009, 19, 28-34.	0.4	5
756	End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?. <i>European Respiratory Journal</i> , 2009, 34, 231-242.	3.1	51
757	Inhaled iloprost for the treatment of pulmonary hypertension. <i>European Respiratory Review</i> , 2009, 18, 29-34.	3.0	34
758	Update in Pulmonary Hypertension 2008. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 650-656.	2.5	32
759	Cardiac magnetic resonance imaging for the assessment of the heart and pulmonary circulation in pulmonary hypertension. <i>European Respiratory Journal</i> , 2009, 33, 1454-1466.	3.1	90
760	A 22-Year-Old Woman With Unexplained Dyspnea. <i>Chest</i> , 2009, 136, 867-876.	0.4	1
761	The Right Ventricle in Cardiac Surgery, a Perioperative Perspective: II. Pathophysiology, Clinical Importance, and Management. <i>Anesthesia and Analgesia</i> , 2009, 108, 422-433.	1.1	212
762	Impact of the Lung Allocation Score on Lung Transplantation for Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 468-474.	2.5	151
763	Therapies for scleroderma-related pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 187-196.	1.0	27
764	Pulmonary Arterial Hypertension in Human Immunodeficiency Virus Infection. <i>Postgraduate Medicine</i> , 2009, 121, 56-67.	0.9	8
765	Recent Advances in the Management of Pulmonary Arterial Hypertension. <i>Current Respiratory Medicine Reviews</i> , 2009, 5, 41-48.	0.1	0
766	Pulmonary Arterial Hypertension Complicating Connective Tissue Diseases. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 429-439.	0.8	53
767	Usefulness of three-dimensional echocardiography in assessing right ventricular function in patients with primary pulmonary hypertension. <i>Hypertension Research</i> , 2009, 32, 419-422.	1.5	20
768	The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. <i>Hypertension Research</i> , 2009, 32, 911-915.	1.5	13

#	ARTICLE	IF	CITATIONS
769	The use of combination therapy in pulmonary arterial hypertension: new developments. <i>European Respiratory Review</i> , 2009, 18, 148-153.	3.0	33
770	Interatrial shunt for chronic pulmonary hypertension: differential impact of low-flow vs. high-flow shunting. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 296, H639-H644.	1.5	24
771	Myocardial delayed enhancement in patients with pulmonary hypertension and right ventricular failure: evaluation by cardiac MRI. <i>British Journal of Radiology</i> , 2009, 82, 821-826.	1.0	32
772	Comprehensive Invasive and Noninvasive Approach to the Right Ventricle—Pulmonary Circulation Unit. <i>Circulation</i> , 2009, 120, 992-1007.	1.6	429
773	Trends in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2009, 18, 7-12.	3.0	25
774	Early Combined Treatment with Cilostazol and Bone Marrow-Derived Endothelial Progenitor Cells Markedly Attenuates Pulmonary Arterial Hypertension in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 718-726.	1.3	59
775	Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy. <i>European Respiratory Review</i> , 2009, 18, 253-259.	3.0	18
776	Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2009, 34, 132-137.	3.1	83
777	More pressure on pulmonary hypertension. <i>European Respiratory Review</i> , 2009, 18, 1-3.	3.0	6
778	Screening for pulmonary arterial hypertension in systemic sclerosis. <i>European Respiratory Review</i> , 2009, 18, 162-169.	3.0	48
779	Value of Exercise Treadmill Testing in the Risk Stratification of Patients With Pulmonary Hypertension. <i>Circulation: Heart Failure</i> , 2009, 2, 278-286.	1.6	35
780	Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence. <i>European Respiratory Journal</i> , 2009, 34, 7-9.	3.1	3
781	Therapeutic targets in pulmonary arterial hypertension. , 2009, 121, 69-88.		80
782	Pulmonary arterial hypertension in children: Diagnostic work-up and challenges. <i>Progress in Pediatric Cardiology</i> , 2009, 27, 7-11.	0.2	47
783	Non-congenital heart disease associated pediatric pulmonary arterial hypertension. <i>Progress in Pediatric Cardiology</i> , 2009, 27, 13-23.	0.2	20
784	Medical and non-medical considerations for the outpatient management of children with pulmonary arterial hypertension. <i>Progress in Pediatric Cardiology</i> , 2009, 27, 57-61.	0.2	3
785	Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?. <i>Vascular Pharmacology</i> , 2009, 51, 90-95.	1.0	26
786	Identifying Left Ventricular Dysfunction in Pulmonary Hypertension. <i>Congestive Heart Failure</i> , 2009, 15, 218-221.	2.0	5

#	ARTICLE	IF	CITATIONS
787	Phenotyping the Right Ventricle in Patients with Pulmonary Hypertension. <i>Clinical and Translational Science</i> , 2009, 2, 294-299.	1.5	39
788	Noninvasive Estimation of Pulmonary Vascular Resistance by Doppler Echocardiography in Patients With Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2009, 103, 872-876.	0.7	59
789	Relation of Resting Heart Rate to Prognosis in Patients With Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2009, 103, 1451-1456.	0.7	44
791	A modified technique of stent fenestration of the interatrial septum improves patients with pulmonary hypertension. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 173-179.	0.7	29
792	Clinical practice: pulmonary hypertension in children. <i>European Journal of Pediatrics</i> , 2009, 168, 515-522.	1.3	17
793	Pulmonary Hypertension in Renal Failure Patients. <i>Kidney</i> , 2009, 18, 68-73.	0.1	0
796	ERG evaluation of daily, high-dose sildenafil usage. <i>Documenta Ophthalmologica</i> , 2009, 118, 225-231.	1.0	26
797	Pulmonary arterial hypertension in children: A Medical Update. <i>Indian Journal of Pediatrics</i> , 2009, 76, 77-81.	0.3	10
798	Pulmonary arterial hypertension. <i>Current Atherosclerosis Reports</i> , 2009, 11, 139-145.	2.0	5
799	Pulmonary hypertension complicating congenital heart disease. <i>Current Cardiology Reports</i> , 2009, 11, 314-320.	1.3	6
800	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. <i>Advances in Therapy</i> , 2009, 26, 813-825.	1.3	96
801	Senescent endothelial progenitor cells from dogs with pulmonary arterial hypertension: a before-after self-controlled study. <i>Journal of Physiological Sciences</i> , 2009, 59, 429-437.	0.9	17
803	Sildenafil for the Treatment of Pulmonary Hypertension in Pediatric Patients. <i>Pediatric Cardiology</i> , 2009, 30, 871-882.	0.6	51
804	Endothelin receptor antagonists in preclinical models of pulmonary hypertension. <i>European Journal of Clinical Investigation</i> , 2009, 39, 3-13.	1.7	10
805	Bleeding events in pulmonary arterial hypertension. <i>European Journal of Clinical Investigation</i> , 2009, 39, 68-73.	1.7	17
806	Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE study. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 948-955.	1.1	105
807	Noninvasive Estimation of Pulmonary Vascular Resistance in Pulmonary Hypertension. <i>Echocardiography</i> , 2009, 26, 489-494.	0.3	94
808	The evolving epidemiology of pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2009, 63, 1-3.	0.8	1

#	ARTICLE	IF	CITATIONS
809	Cardiovascular magnetic resonance imaging as applied to patients with pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2009, 63, 20-35.	0.8	14
810	Assessment of pulmonary vasculature and right heart by invasive haemodynamics and echocardiography. <i>International Journal of Clinical Practice</i> , 2009, 63, 4-19.	0.8	42
811	Long-term outcomes in pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2009, 63, 42-44.	0.8	1
812	Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. <i>Internal Medicine Journal</i> , 2009, 39, 682-691.	0.5	87
813	CONTINUOUS FLUOXETINE ADMINISTRATION PREVENTS RECURRENCE OF PULMONARY ARTERIAL HYPERTENSION AND PROLONGS SURVIVAL IN RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2009, 36, e1-5.	0.9	13
814	The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III. <i>Value in Health</i> , 2009, 12, 1100-1105.	0.1	12
815	Extrinsic Compression of Left Main Coronary Artery by the Pulmonary Trunk Secondary to Pulmonary Hypertension Documented Using 64â€ˆSlice Multidetector Computed Tomography Coronary Angiography. <i>Clinical Cardiology</i> , 2009, 32, 426-428.	0.7	23
816	Testosterone acts as an efficacious vasodilator in isolated human pulmonary arteries and veins: Evidence for a biphasic effect at physiological and supra-physiological concentrations. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 718-723.	1.8	48
817	Intratracheal Gene Transfer of Adrenomedullin Using Polyplex Nanomicelles Attenuates Monocrotaline-induced Pulmonary Hypertension in Rats. <i>Molecular Therapy</i> , 2009, 17, 1180-1186.	3.7	60
818	Molecular mechanisms of pulmonary hypertension. <i>Clinica Chimica Acta</i> , 2009, 403, 9-16.	0.5	44
819	Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. <i>Respiratory Medicine</i> , 2009, 103, 1013-1019.	1.3	39
820	Cesarean section and primary pulmonary hypertension: the role of intravenous dexmedetomidine. <i>International Journal of Obstetric Anesthesia</i> , 2009, 18, 262-267.	0.2	36
821	Pulmonary hypertension and pregnancy. <i>International Journal of Obstetric Anesthesia</i> , 2009, 18, 156-164.	0.2	250
822	Low Complication Rates With Totally Implantable Access Port Use in Epoprostenol Treatment of Pulmonary Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 273-279.	0.3	13
823	Angina Associated With Left Main Coronary Artery Compression in Pulmonary Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 527-530.	0.3	32
824	Comparison of Baseline Characteristics and Survival Between Patients With Idiopathic and Connective Tissue Diseaseâ€ˆrelated Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 621-627.	0.3	37
825	Exercise Performance in Patients With Pulmonary Hypertension Linked to Cardiac Magnetic Resonance Measures. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 899-905.	0.3	12
826	Right atrium contractility and right ventricular diastolic function assessed by pulsed Tissue Doppler Imaging can predict brain natriuretic peptide in adults with acquired pulmonary hypertension. <i>International Journal of Cardiology</i> , 2009, 135, 53-59.	0.8	31

#	ARTICLE	IF	CITATIONS
827	Treatment of right ventricular dysfunction in pulmonary arterial hypertension: Theoretical considerations. <i>Medical Hypotheses</i> , 2009, 73, 448-452.	0.8	1
828	Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: An experience-based review. <i>American Heart Journal</i> , 2009, 157, 625-635.	1.2	38
829	Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2009, 361, 1864-1871.	13.9	192
830	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , 2009, 30, 2493-2537.	1.0	3,108
831	Non-invasive investigations of the right heart: How and why?. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 219-232.	0.7	42
832	C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1211-1218.	1.2	220
833	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1573-1619.	1.2	1,797
834	End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S97-S107.	1.2	209
835	Diagnosis and Assessment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S55-S66.	1.2	984
836	Genetics and Genomics of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S32-S42.	1.2	342
837	Interventional and Surgical Modalities of Treatment in Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S67-S77.	1.2	230
838	Double-lung Transplantation in 15 Patients With Pulmonary Hypertension. <i>Archivos De Bronconeumologia</i> , 2009, 45, 366-370.	0.4	2
839	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Española De Cardiología (English Ed)</i> , 2009, 62, 1464.e1-1464.e58.	0.4	2
840	Cost-Utility of Treatments for Pulmonary Arterial Hypertension. <i>Clinical Drug Investigation</i> , 2009, 29, 635-646.	1.1	34
841	Selection of Candidates for Lung Transplantation. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 20-27.	3.5	54
842	NO-Independent, Haem-Dependent Soluble Guanylate Cyclase Stimulators. <i>Handbook of Experimental Pharmacology</i> , 2009, , 277-308.	0.9	171
843	Bosentan. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 331-350.	1.0	26
844	Doppler Echocardiography Can Provide a Comprehensive Assessment of Right Ventricular Afterload. <i>Journal of the American Society of Echocardiography</i> , 2009, 22, 1360-1367.	1.2	16

#	ARTICLE	IF	CITATIONS
845	First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. <i>European Respiratory Journal</i> , 2009, 33, 785-792.	3.1	216
846	Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1847-1858.	0.9	40
847	Oral therapies for the treatment of pulmonary arterial hypertension. <i>Applied Health Economics and Health Policy</i> , 2009, 7, 43-59.	1.0	19
848	Accuracy of Doppler Echocardiography in the Hemodynamic Assessment of Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 615-621.	2.5	863
852	Tricuspid Flow Propagation Velocity Predicts Exercise Tolerance and Readmission in Patients With Systemic Lupus Erythematosus. <i>Journal of the American Society of Echocardiography</i> , 2009, 22, 411-417.	1.2	4
853	Endothelin receptor antagonists for pulmonary arterial hypertension. , 2009, , CD004434.		12
854	The Right Ventricle Under Pressure. <i>Chest</i> , 2009, 135, 794-804.	0.4	604
855	Determinants of Right Ventricular Ejection Fraction in Pulmonary Arterial Hypertension. <i>Chest</i> , 2009, 135, 752-759.	0.4	116
856	Long-Term Epoprostenol Therapy in Pulmonary Artery Hypertension. <i>Circulation Journal</i> , 2009, 73, 523-529.	0.7	5
857	Brain Natriuretic Peptide Levels in Managing Pediatric Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2009, 135, 745-751.	0.4	103
858	Effects of the Arteriovenous Fistula on Pulmonary Artery Pressure and Cardiac Output in Patients with Chronic Renal Failure. <i>Journal of Vascular Access</i> , 2009, 10, 160-166.	0.5	89
859	The Right Ventricle: Biologic Insights and Response to Disease. <i>Current Cardiology Reviews</i> , 2009, 5, 22-28.	0.6	33
860	Exercise Testing to Estimate Survival in Pulmonary Hypertension. <i>Yearbook of Sports Medicine</i> , 2009, 2009, 232-234.	0.0	0
861	Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities. <i>Chest</i> , 2009, 135, 122-129.	0.4	167
862	Pulmonary hypertension in thoracic surgical patients. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 25-33.	0.9	29
863	Assessment of endpoints in the pediatric population: congenital heart disease and idiopathic pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, S35-S41.	1.2	22
864	Idiopathic Pulmonary Arterial Hypertension in Childhood. <i>Cardiology in Review</i> , 2010, 18, 64-66.	0.6	4
865	Pharmacotherapeutic Management of Pulmonary Arterial Hypertension. <i>Cardiology in Review</i> , 2010, 18, 148-162.	0.6	60

#	ARTICLE	IF	CITATIONS
866	Human Responses to Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Nursing</i> , 2010, 25, 420-427.	0.6	22
867	Tobacco Smoke: A Risk Factor for Pulmonary Arterial Hypertension?. <i>Chest</i> , 2010, 138, 1086-1092.	0.4	48
868	A Global Pulmonary Arterial Hypertension Registry: Is It Needed? Is It Feasible?. <i>Chest</i> , 2010, 137, 95S-101S.	0.4	17
869	New Approaches to the Treatment of Pulmonary Hypertension. <i>Cardiology in Review</i> , 2010, 18, 76-84.	0.6	10
870	Endpoints in pulmonary arterial hypertension: the role of clinical worsening. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, S1-S9.	1.2	24
871	Update on anaesthetic approach to pulmonary hypertension. <i>European Journal of Anaesthesiology</i> , 2010, 27, 317-323.	0.7	29
872	Perioperative Mortality in Patients with Pulmonary Hypertension Undergoing Major Joint Replacement. <i>Anesthesia and Analgesia</i> , 2010, 111, 1110-1116.	1.1	93
873	Pulmonary Arterial Hypertension in Connective Tissue Diseases. <i>Cardiology in Review</i> , 2010, 18, 85-88.	0.6	14
874	Pulmonary Arterial Hypertension. <i>Cardiology in Review</i> , 2010, 18, 58-63.	0.6	22
875	Pharmacologic and Pharmacokinetic Rationale for Combination Therapy in Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 56, 686-695.	0.8	3
876	Analysis of the Lung Allocation Score Estimation of Risk of Death in Patients With Pulmonary Arterial Hypertension Using Data From the REVEAL Registry. <i>Transplantation</i> , 2010, 90, 298-305.	0.5	66
877	Right ventricular adaptation to pressure overload. <i>Current Opinion in Critical Care</i> , 2010, 16, 237-243.	1.6	21
878	Diagnostic strategies for acute presentation of pulmonary hypertension in children: Particular focus on use of echocardiography, cardiac catheterization, magnetic resonance imaging, chest computed tomography, and lung biopsy. <i>Pediatric Critical Care Medicine</i> , 2010, 11, S23-S26.	0.2	13
879	Lung transplantation for pulmonary hypertension in children. <i>Pediatric Critical Care Medicine</i> , 2010, 11, S53-S56.	0.2	8
880	Sildenafil Limits Monocrotaline-Induced Pulmonary Hypertension in Rats Through Suppression of Pulmonary Vascular Remodeling. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 55, 574-584.	0.8	46
881	Cardiac complications of systemic sclerosis: recent progress in diagnosis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 696-703.	2.0	30
882	Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, S21-S26.	1.2	4
883	Does Reduced Lung Diffusing Capacity for Carbon Monoxide Predict the Presence of Pulmonary Hypertension?. <i>American Journal of the Medical Sciences</i> , 2010, 340, 54-59.	0.4	3

#	ARTICLE	IF	CITATIONS
884	Prostacyclin and milrinone by aerosolization improve pulmonary hemodynamics in newborn lambs with experimental pulmonary hypertension. <i>Journal of Applied Physiology</i> , 2010, 109, 677-684.	1.2	28
885	Pulmonary hypertension in children: A historical overview. <i>Pediatric Critical Care Medicine</i> , 2010, 11, S4-S9.	0.2	25
886	Marked Hemodynamic Improvements by High-Dose Epoprostenol Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Circulation Journal</i> , 2010, 74, 2200-2205.	0.7	59
887	Identification of New Prognostic Factors of Pulmonary Hypertension. <i>Circulation Journal</i> , 2010, 74, 1965-1971.	0.7	44
888	Dose-Dependent Reduction in Pulmonary Vascular Resistance With Epoprostenol in Pulmonary Arterial Hypertension. <i>Circulation Journal</i> , 2010, 74, 2062-2063.	0.7	8
889	Prognostic Significance of Sympathetic Nervous System Activation in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1269-1275.	2.5	182
890	Strain and strain rate echocardiography for evaluation of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. <i>Clinical Research in Cardiology</i> , 2010, 99, 491-498.	1.5	27
891	Novel Strategy for Treatment of Pulmonary Arterial Hypertension: Enhancement of Apoptosis. <i>Lung</i> , 2010, 188, 179-189.	1.4	20
892	Noninvasive Assessment of Right Ventricular Function: Will There Be Resurgence in Radionuclide Imaging Techniques?. <i>Current Cardiology Reports</i> , 2010, 12, 162-169.	1.3	23
893	Right Ventricular Failure: A Novel Era of Targeted Therapy. <i>Current Heart Failure Reports</i> , 2010, 7, 202-211.	1.3	25
894	A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. <i>International Journal of Cardiovascular Imaging</i> , 2010, 26, 509-518.	0.7	56
895	Management of Pulmonary Arterial Hypertension in Children. <i>Paediatric Respiratory Reviews</i> , 2010, 11, 240-245.	1.2	9
896	Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?. <i>BMC Cardiovascular Disorders</i> , 2010, 10, 9.	0.7	14
897	Accuracy of Noninvasively Determined Pulmonary Artery Systolic Pressure. <i>American Journal of Cardiology</i> , 2010, 105, 1192-1197.	0.7	60
898	Effectiveness of Transition from Intravenous Epoprostenol to Oral/Inhaled Targeted Pulmonary Arterial Hypertension Therapy in Pediatric Idiopathic and Familial Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2010, 105, 1485-1489.	0.7	38
899	Outcome of Pediatric Patients With Pulmonary Arterial Hypertension in the Era of New Medical Therapies. <i>American Journal of Cardiology</i> , 2010, 106, 117-124.	0.7	124
900	Usefulness of the Right Ventricular Systolic to Diastolic Duration Ratio to Predict Functional Capacity and Survival in Children With Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2010, 106, 430-436.	0.7	113
901	Long-Term Outcomes in Children With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings. <i>American Journal of Cardiology</i> , 2010, 106, 1332-1338.	0.7	101

#	ARTICLE	IF	CITATIONS
903	Left main coronary artery compression from pulmonary artery enlargement due to pulmonary hypertension: A contemporary review and argument for percutaneous revascularization. Catheterization and Cardiovascular Interventions, 2010, 76, 543-550.	0.7	55
904	Assessment of pulmonary hypertension in the pediatric catheterization laboratory: Current insights from the magic registry. Catheterization and Cardiovascular Interventions, 2010, 76, 865-873.	0.7	61
905	Computed tomography and magnetic resonance imaging of pulmonary hypertension: Pulmonary vessels and right ventricle. Journal of Magnetic Resonance Imaging, 2010, 32, 1313-1324.	1.9	26
906	Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respiratory Research, 2010, 11, 12.	1.4	69
907	Right ventricular ejection fraction is better reflected by transverse rather than longitudinal wall motion in pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 35.	1.6	176
908	Lung transplantation in children with idiopathic pulmonary arterial hypertension. Pediatric Pulmonology, 2010, 45, 263-269.	1.0	18
910	Downregulation of oxytocin receptors in right ventricle of rats with monocrotaline-induced pulmonary hypertension. Acta Physiologica, 2010, 200, 147-158.	1.8	16
911	New Annular Tissue Doppler Markers of Pulmonary Hypertension. Echocardiography, 2010, 27, 969-976.	0.3	7
912	Pulmonary arterial hypertension in adults with congenital heart disease. International Journal of Clinical Practice, 2010, 64, 13-24.	0.8	10
913	How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?. International Journal of Clinical Practice, 2010, 64, 23-32.	0.8	35
914	Registries and randomised controlled trials in pulmonary arterial hypertension: are they revealing?. International Journal of Clinical Practice, 2010, 64, 1-2.	0.8	0
915	The right ventricle. , 2010, , 163-179.		0
916	Prevalence of Acute Vasoresponsiveness in Patients With Pulmonary Hypertension: Treatment Implications. Southern Medical Journal, 2010, 103, 630-634.	0.3	3
917	Diuresis in the Setting of Right Heart Failure: A New Look at an Old Problem. Southern Medical Journal, 2010, 103, 105-106.	0.3	0
918	Pulmonary Hypertension in Cardiac Surgery. Current Cardiology Reviews, 2010, 6, 1-14.	0.6	87
919	Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy. Drug, Healthcare and Patient Safety, 2010, 2, 151.	1.0	22
920	Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Drug Design, Development and Therapy, 2010, 4, 61.	2.0	30
921	Inhaled treprostinil and pulmonary arterial hypertension. Vascular Health and Risk Management, 2010, 6, 1115.	1.0	10

#	ARTICLE	IF	CITATIONS
922	Recent Updates in Both the Diagnosis and Treatment Options that Impact the Clinical Treatment of Pulmonary Arterial Hypertension. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S4192.	0.4	0
923	Pulmonary Circulation. , 2010, , 117-141.		5
924	Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. <i>Thorax</i> , 2010, 65, 113-117.	2.7	150
925	Treatment options for paediatric pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2010, 19, 321-330.	3.0	13
926	Contemporary issues in pulmonary hypertension. <i>European Respiratory Review</i> , 2010, 19, 266-271.	3.0	12
927	Impaired Vasoconstriction and Nitric Oxide-Mediated Relaxation in Pulmonary Arteries of Hypoxia- and Monocrotaline-Induced Pulmonary Hypertensive Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 455-462.	1.3	71
928	Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. <i>European Respiratory Review</i> , 2010, 19, 314-320.	3.0	33
929	Management of severe pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2010, 19, 279-287.	3.0	17
930	Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. <i>European Respiratory Journal</i> , 2010, 35, 1079-1087.	3.1	427
931	Management of dyspnea in advanced pulmonary arterial hypertension. <i>Current Opinion in Supportive and Palliative Care</i> , 2010, 4, 76-84.	0.5	15
932	Nitrite Potently Inhibits Hypoxic and Inflammatory Pulmonary Arterial Hypertension and Smooth Muscle Proliferation via Xanthine Oxidoreductase-Dependent Nitric Oxide Generation. <i>Circulation</i> , 2010, 121, 98-109.	1.6	185
933	Pulmonary arterial hypertension and the state of limbo. <i>European Respiratory Review</i> , 2010, 19, 264-265.	3.0	0
934	A modelling study of atrial septostomy for pulmonary arterial hypertension, and its effect on the state of tissue oxygenation and systemic blood flow. <i>Cardiology in the Young</i> , 2010, 20, 25-32.	0.4	20
935	Predicting survival in pulmonary arterial hypertension: time to move forward. <i>European Respiratory Journal</i> , 2010, 35, 958-959.	3.1	4
936	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2010, 36, 549-555.	3.1	582
937	Childhood idiopathic pulmonary arterial hypertension: a national cohort study. <i>Heart</i> , 2010, 96, 1401-1406.	1.2	192
938	Predicting Survival in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2010, 122, 164-172.	1.6	1,353
939	Clinical use of sildenafil in pulmonary artery hypertension. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 13-19.	1.0	11

#	ARTICLE	IF	CITATIONS
940	Under Pressure. <i>New England Journal of Medicine</i> , 2010, 362, 449-454.	13.9	3
941	Adrenergic Receptor Blockade Reverses Right Heart Remodeling and Dysfunction in Pulmonary Hypertensive Rats. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 652-660.	2.5	257
942	Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1171-1177.	2.5	331
943	Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1161-1170.	2.5	124
944	Non-invasive assessment of pulmonary blood flow using an inert gas rebreathing device in fibrotic lung disease. <i>Thorax</i> , 2010, 65, 341-345.	2.7	12
945	Circulating biomarkers of tissue remodelling in pulmonary hypertension. <i>Biomarkers</i> , 2010, 15, 523-532.	0.9	53
946	Utility of tricuspid annular plane systolic excursion in the assessment of right ventricular function. <i>Pulmonary Vascular Research Institute (PVRI) Review</i> , 2010, 2, 17.	0.1	8
947	Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. <i>Heart</i> , 2010, 96, 2005-2009.	1.2	37
948	Pulmonary Hypertension is Prevalent in Catheter and Arterio-Venous Access Hemodialysis. <i>Nephrology Research & Reviews</i> , 2010, 2, 10-14.	0.2	0
949	Early Mortality and Cardiorespiratory Failure in Patients with Fibrodysplasia Ossificans Progressiva. <i>Journal of Bone and Joint Surgery - Series A</i> , 2010, 92, 686-691.	1.4	169
950	The role of echocardiography in the diagnosis and management of patients with pulmonary hypertension. <i>European Respiratory Review</i> , 2010, 19, 288-299.	3.0	45
951	High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. <i>Clinical Science</i> , 2010, 119, 207-213.	1.8	90
952	Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension. <i>Circulation</i> , 2010, 122, 920-927.	1.6	661
953	Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart. <i>European Respiratory Review</i> , 2010, 19, 72-82.	3.0	105
954	Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed. <i>European Respiratory Journal</i> , 2010, 36, 986-990.	3.1	34
955	Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. <i>European Respiratory Review</i> , 2010, 19, 272-278.	3.0	43
956	Pulmonary hypertension in women. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1549-1558.	0.6	41
957	Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. <i>European Heart Journal</i> , 2010, 31, 2080-2086.	1.0	157

#	ARTICLE	IF	CITATIONS
958	Pulmonary Arterial Hypertension. <i>Chest</i> , 2010, 137, 376-387.	0.4	1,018
959	Pulmonary hypertension after ventriculoatrial shunt implantation. <i>Journal of Neurosurgery</i> , 2010, 113, 1279-1283.	0.9	33
960	Pulmonary Arterial Hypertension and Lung Transplantation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 147-160.	0.8	15
961	Strategic Plan for Lung Vascular Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1554-1562.	2.5	73
962	The Right Ventricle in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 586-588.	2.5	5
963	Recomendações para a abordagem clínica do doente com hipertensão pulmonar **Recomendações aprovadas pelas Sociedades Portuguesas de Cardiologia, Cardiologia Pediátrica, Medicina Interna e Pneumologia/Recommendations approved by the Portuguese Societies of Cardiology, Paediatric Cardiology, Internal Medicine and Pulmonology. <i>Revista Portuguesa De Pneumologia</i> , 2010, 16, S7-S85.	0.7	2
964	Development of Pulmonary Arterial Hypertension in Women: Interplay of Sex Hormones and Pulmonary Vascular Disease. <i>Women's Health</i> , 2010, 6, 285-296.	0.7	41
965	Systemic Sclerosis-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1285-1293.	2.5	91
966	Out with the old, in with the new: an updated risk stratification equation for pulmonary arterial hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 739-741.	0.6	2
967	Bosentan. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1023-1034.	0.9	8
969	Right Ventricular Function in Patients With Pulmonary Embolism: Early and Late Findings Using Doppler Tissue Imaging. <i>Journal of the American Society of Echocardiography</i> , 2010, 23, 531-537.	1.2	28
970	Timing and Magnitude of Regional Right Ventricular Function: A Speckle Tracking-Derived Strain Study of Normal Subjects and Patients with Right Ventricular Dysfunction. <i>Journal of the American Society of Echocardiography</i> , 2010, 23, 823-831.	1.2	178
971	Right Ventricular Dysfunction in Patients with End-Stage Renal Disease. <i>American Journal of Nephrology</i> , 2010, 32, 432-438.	1.4	75
972	Survival in Schistosomiasis-Associated Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2010, 56, 715-720.	1.2	68
973	Imaging in Pulmonary Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2010, 3, 1287-1295.	2.3	72
974	Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 66-74.	0.7	126
975	Tadalafil. <i>Drugs</i> , 2010, 70, 479-488.	4.9	17
976	Targeted Oral Therapies in the Treatment of Pulmonary Arterial Hypertension. <i>Clinical Drug Investigation</i> , 2010, 30, 811-826.	1.1	11

#	ARTICLE	IF	CITATIONS
977	Caractéristiques et suivi prospectif sur deux ans des enfants atteints d'hypertension artérielle pulmonaire en France. Archives of Cardiovascular Diseases Supplements, 2010, 2, 137-145.	0.0	1
979	Current Therapeutic Approaches to Pulmonary Arterial Hypertension. Revista Espanola De Cardiologia (English Ed), 2010, 63, 708-724.	0.4	4
980	Analytic Review: Care of Patients With Scleroderma in the Intensive Care Setting. Journal of Intensive Care Medicine, 2010, 25, 247-258.	1.3	10
981	PRX-08066, a Novel 5-Hydroxytryptamine Receptor 2B Antagonist, Reduces Monocrotaline-Induced Pulmonary Arterial Hypertension and Right Ventricular Hypertrophy in Rats. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 364-372.	1.3	40
982	Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2010, 29, 181-187.	0.3	62
983	Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. Journal of Heart and Lung Transplantation, 2010, 29, 1150-1158.	0.3	9
984	Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2010, 140, 272-278.	0.8	301
985	Heart rate variability predicts outcome in children with pulmonary arterial hypertension. International Journal of Cardiology, 2010, 142, 159-165.	0.8	52
986	A valid and reliable belief elicitation method for Bayesian priors. Journal of Clinical Epidemiology, 2010, 63, 370-383.	2.4	66
987	Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension. Journal of Cardiac Failure, 2010, 16, 121-127.	0.7	39
988	BNP levels in patients with long-term exposure to biomass fuel and its relation to right ventricular function. Pulmonary Pharmacology and Therapeutics, 2010, 23, 420-424.	1.1	14
989	A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respiratory Medicine, 2010, 104, 9-21.	1.3	144
990	Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respiratory Medicine, 2010, 104, 731-740.	1.3	72
991	Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: A systematic review of the literature. Respiratory Medicine, 2010, 104, 1588-1607.	1.3	87
992	Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. American Heart Journal, 2010, 159, 245-257.	1.2	106
993	Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respiratory Medicine, 2010, 104, 481-496.	1.3	93
994	Clinical Efficacy of Sildenafil in Treatment of Pulmonary Arterial Hypertension in Dogs. Journal of Veterinary Internal Medicine, 2010, 24, 850-854.	0.6	70
995	REVIEW: Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension: An Overview. Cardiovascular Therapeutics, 2010, 28, e65-71.	1.1	22

#	ARTICLE	IF	CITATIONS
996	Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 150-156.	0.3	19
997	Estrategias terapéuticas actuales en la hipertensión arterial pulmonar. <i>Revista Española De Cardiología</i> , 2010, 63, 708-724.	0.6	24
998	Hipertensión pulmonar. <i>Medicine</i> , 2010, 10, 4505-4512.	0.0	0
1001	Outcomes in pulmonary hypertension: Beyond 40 metres. <i>Canadian Journal of Cardiology</i> , 2010, 26, 12B-16B.	0.8	1
1002	Gene Therapy Techniques for the Delivery of Endothelial Nitric Oxide Synthase to the Lung for Pulmonary Hypertension. <i>Methods in Molecular Biology</i> , 2010, 610, 309-321.	0.4	7
1003	Hypertension artérielle pulmonaire. <i>Revue Des Maladies Respiratoires Actualites</i> , 2010, 2, 27-37.	0.0	0
1004	Pulmonary arterial hypertension in women. <i>Revue Des Maladies Respiratoires</i> , 2010, 27, e79-e87.	1.7	18
1005	Bosentan. <i>Paediatric Drugs</i> , 2010, 12, 63-73.	1.3	15
1006	Riociguat for pulmonary hypertension. <i>Future Cardiology</i> , 2010, 6, 155-166.	0.5	30
1007	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. <i>Circulation</i> , 2010, 122, 156-163.	1.6	1,264
1008	Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. <i>Future Cardiology</i> , 2010, 6, 19-35.	0.5	22
1009	Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. <i>Current Medical Research and Opinion</i> , 2011, 27, 1827-1834.	0.9	13
1012	Facteurs pronostiques dans l'HTAP idiopathique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2011, 3, S42-S48.	0.0	1
1013	Maladies vasculaires pulmonaires. <i>Revue Des Maladies Respiratoires Actualites</i> , 2011, 3, 128-139.	0.0	0
1014	Progressive Right Ventricular Dysfunction in Patients With Pulmonary Arterial Hypertension Responding to Therapy. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2511-2519.	1.2	719
1015	Pulmonary arterial hypertension: a comparison between children and adults. <i>European Respiratory Journal</i> , 2011, 37, 665-677.	3.1	173
1016	Suppression of Histone Deacetylases Worsens Right Ventricular Dysfunction after Pulmonary Artery Banding in Rats. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1402-1410.	2.5	143
1017	Riociguat (BAY 63-2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1051-1060.	1.0	40

#	ARTICLE	IF	CITATIONS
1018	Alternatives to Lung Transplantation: Treatment of Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2011, 32, 399-410.	0.8	9
1019	Pulmonary Arterial Hypertension. <i>Critical Care Nursing Clinics of North America</i> , 2011, 23, 645-659.	0.4	1
1020	Candidate Selection, Timing of Listing, and Choice of Procedure for Lung Transplantation. <i>Clinics in Chest Medicine</i> , 2011, 32, 199-211.	0.8	23
1021	Hypertension pulmonaire (HTP). <i>Revue Des Maladies Respiratoires Actualites</i> , 2011, 3, 25-33.	0.0	0
1022	Hypertension artérielle pulmonaire et Échocardiographie. <i>Revue Des Maladies Respiratoires Actualites</i> , 2011, 3, S15-S22.	0.0	0
1023	Role of TGF- β 1 and TNF- α in IL-1 β mediated activation of proMMP-9 in pulmonary artery smooth muscle cells: Involvement of an aprotinin sensitive protease. <i>Archives of Biochemistry and Biophysics</i> , 2011, 513, 61-69.	1.4	8
1024	Current therapeutics and practical management strategies for pulmonary arterial hypertension. <i>American Heart Journal</i> , 2011, 162, 201-213.	1.2	46
1025	Treadmill testing improves survival prediction models in pulmonary arterial hypertension. <i>American Heart Journal</i> , 2011, 162, 1011-1017.	1.2	13
1026	Paigen Diet-Dependent Apolipoprotein E Knockout Mice Develop Severe Pulmonary Hypertension in an Interleukin-1 α -Dependent Manner. <i>American Journal of Pathology</i> , 2011, 179, 1693-1705.	1.9	58
1027	High-sensitive troponin T and I are related to invasive hemodynamic data and mortality in patients with left-ventricular dysfunction and precapillary pulmonary hypertension. <i>Clinica Chimica Acta</i> , 2011, 412, 1582-1588.	0.5	24
1028	Systemic Oxidative Stress and Endothelial Dysfunction is Associated With an Attenuated Acute Vascular Response to Inhaled Prostanoid in Pulmonary Artery Hypertension Patients. <i>Journal of Cardiac Failure</i> , 2011, 17, 1012-1017.	0.7	33
1029	Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 982-989.	0.3	80
1030	Lung transplantation in children with idiopathic pulmonary arterial hypertension: An 18-year experience. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1148-1152.	0.3	55
1031	A simple method to predict impaired right ventricular performance and disease severity in chronic pulmonary hypertension using strain rate imaging. <i>International Journal of Cardiology</i> , 2011, 147, 88-94.	0.8	36
1032	Lung involvement in systemic sclerosis. <i>Presse Medicale</i> , 2011, 40, e25-e39.	0.8	30
1033	Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011, 24, 169-173.	1.1	9
1034	Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011, 24, 386-393.	1.1	16
1035	Efectos a largo plazo (5 años) de bosentan en pacientes con hipertensión arterial pulmonar. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 667-673.	0.6	13

#	ARTICLE	IF	CITATIONS
1036	Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs. <i>Respiratory Medicine</i> , 2011, 105, 818-827.	1.3	52
1037	Treatment of pulmonary hypertension: bench to bedside. <i>Respiratory Medicine</i> , 2011, 105, S7-S11.	1.3	3
1039	Role of Phosphodiesterases in Adult-Onset Pulmonary Arterial Hypertension. <i>Handbook of Experimental Pharmacology</i> , 2011, , 279-305.	0.9	7
1040	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 315-328.	1.0	7
1041	Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1053-1061.	1.2	56
1042	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1585-1596.	0.9	23
1043	Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 197-205.	1.3	5
1044	Looking to the future: a new decade of pulmonary arterial hypertension therapy. <i>European Respiratory Review</i> , 2011, 20, 262-269.	3.0	55
1045	Pulmonary Hypertension and Right Ventricular Dysfunction: Physiology and Perioperative Management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2011, 25, 687-704.	0.6	67
1046	Long-Term (5 Years) Effects of Bosentan in Patients With Pulmonary Arterial Hypertension. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 667-673.	0.4	3
1047	Guidelines for the Selection of Lung Transplantation Candidates. <i>Archivos De Bronconeumologia</i> , 2011, 47, 303-309.	0.4	7
1048	Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S3-S12.	0.8	64
1049	Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S13-S19.	0.8	13
1050	Non-parenteral Therapy for Pulmonary Arterial Hypertension: A Review of Efficacy, Tolerability and Factors Related to Patient Adherence. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S2689.	0.4	0
1051	Pulmonary-atrial shunt and lung assist to treat right ventricular failure. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 2342.	3.0	10
1053	Dyspnea in Pulmonary Arterial Hypertension. , 2011, , .		0
1054	Pharmacotherapy for pulmonary arterial hypertension. <i>Journal of the Korean Medical Association</i> , 2011, 54, 1299.	0.1	1
1055	Transition from Intravenous Epoprostenol to Oral or Subcutaneous Therapy in Pulmonary Arterial Hypertension: A Retrospective Case Series and Systematic Literature Review. <i>Canadian Respiratory Journal</i> , 2011, 18, 157-162.	0.8	5

#	ARTICLE	IF	CITATIONS
1056	Long-Term Survival in Idiopathic Pulmonary Arterial Hypertension Associated with Massive Pulmonary Artery Dilation. Canadian Respiratory Journal, 2011, 18, e50-e51.	0.8	2
1057	Diagnosis and Management of Pulmonary Arterial Hypertension. Pulmonary Medicine, 2011, 2011, 1-13.	0.5	29
1058	Fractal Dimension Analysis of MDCT Images for Quantifying the Morphological Changes of the Pulmonary Artery Tree in Patients with Pulmonary Hypertension. Korean Journal of Radiology, 2011, 12, 289.	1.5	13
1059	Diseases of Pulmonary Circulation. , 2011, , 632-656.		0
1060	ACE2 Improves Right Ventricular Function in a Pressure Overload Model. PLoS ONE, 2011, 6, e20828.	1.1	60
1061	Complement C3 Deficiency Attenuates Chronic Hypoxia-Induced Pulmonary Hypertension in Mice. PLoS ONE, 2011, 6, e28578.	1.1	52
1062	Pulmonary vasodilators. , 0, , 767-782.		0
1063	Contemporary Indications and Therapeutic Implications for Digoxin Use. American Journal of Therapeutics, 2011, 18, 280-287.	0.5	6
1064	Recent progress in understanding pediatric pulmonary hypertension. Current Opinion in Pediatrics, 2011, 23, 298-304.	1.0	46
1065	Increased Right Ventricular Septomarginal Trabeculation Mass is a Novel Marker for Pulmonary Hypertension. Investigative Radiology, 2011, 46, 567-575.	3.5	31
1066	Clinically Significant Change in Stroke Volume in Pulmonary Hypertension. Chest, 2011, 139, 1003-1009.	0.4	100
1067	Integration of Clinical and Hemodynamic Parameters in the Prediction of Long-term Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2011, 139, 1285-1293.	0.4	124
1068	Delay in Recognition of Pulmonary Arterial Hypertension. Chest, 2011, 140, 19-26.	0.4	228
1069	Pulmonary Vascular Stiffness: Measurement, Modeling, and Implications in Normal and Hypertensive Pulmonary Circulations. , 2011, 1, 1413-1435.		43
1070	A Phase III, Multicenter, Collaborative, Open-Label Clinical Trial of Sildenafil in Japanese Patients With Pulmonary Arterial Hypertension. Circulation Journal, 2011, 75, 677-682.	0.7	20
1071	The bosentan patient registry: long-term survival in pulmonary arterial hypertension. Internal Medicine Journal, 2011, 41, 227-234.	0.5	24
1072	Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Internal Medicine Journal, 2011, 41, 235-244.	0.5	29
1073	Non-invasive stroke volume measurement by cardiac magnetic resonance imaging and inert gas rebreathing in pulmonary hypertension. Clinical Physiology and Functional Imaging, 2011, 31, 221-226.	0.5	18

#	ARTICLE	IF	CITATIONS
1074	Pulmonary vascular disease associated with parasitic infection—the role of schistosomiasis. <i>Clinical Microbiology and Infection</i> , 2011, 17, 15-24.	2.8	33
1075	The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients. <i>International Journal of Clinical Practice</i> , 2011, 65, 6-14.	0.8	50
1076	Transforming growth factor signalling: a common pathway in pulmonary arterial hypertension and systemic sclerosis. <i>International Journal of Clinical Practice</i> , 2011, 65, 35-43.	0.8	10
1077	Correlation of pulmonary function variables with hemodynamic measurements in patients with pulmonary arterial hypertension. <i>Clinical Respiratory Journal</i> , 2011, 5, 35-43.	0.6	9
1078	Two cases of stem cell therapy for pulmonary hypertension: A clinical report. <i>Respiratory Medicine CME</i> , 2011, 4, 70-74.	0.1	2
1079	Pulmonary Hypertension in Systemic Sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 19-37.	1.6	39
1080	Acute pressure overload of the right ventricle. Comparison of two models of right-left shunt. Pulmonary artery to left atrium and right atrium to left atrium: experimental study. <i>Journal of Cardiothoracic Surgery</i> , 2011, 6, 143.	0.4	4
1081	Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension. <i>Clinical Therapeutics</i> , 2011, 33, 993-1004.	1.1	34
1082	Pulmonary Arterial Hypertension. <i>Current Problems in Cardiology</i> , 2011, 36, 461-517.	1.1	42
1083	Normativa para la selección de pacientes candidatos a trasplante pulmonar. <i>Archivos De Bronconeumologia</i> , 2011, 47, 303-309.	0.4	23
1085	Right Ventricular Systolic Pressure Assessed by Echocardiography: A Predictive Factor of Mortality in Patients With Scleroderma. <i>Clinical Cardiology</i> , 2011, 34, 488-493.	0.7	14
1086	The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2011, 5, 195-206.	1.0	20
1087	Combination therapy in pulmonary arterial hypertension: do we have the right strategy?. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 191-205.	1.0	6
1088	Genetic counselling for pulmonary arterial hypertension: a matter of variable variability. <i>Netherlands Heart Journal</i> , 2011, 19, 89-92.	0.3	7
1089	Pulmonary arterial hypertension and lung transplantation. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 441-454.	1.0	30
1090	Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 173-179.	1.0	80
1091	Pediatric Lung Transplantation. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011, 13, 68-78.	0.4	18
1092	Scleroderma Lung Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 104-116.	2.9	41

#	ARTICLE	IF	CITATIONS
1093	Treatment for pulmonary hypertension including lung transplantation. <i>General Thoracic and Cardiovascular Surgery</i> , 2011, 59, 538-546.	0.4	2
1094	Pulmonale Hypertension. <i>Wiener Klinische Wochenschrift Education</i> , 2011, 6, 78-93.	0.0	0
1095	Novel computed tomographic chest metrics to detect pulmonary hypertension. <i>BMC Medical Imaging</i> , 2011, 11, 7.	1.4	85
1096	Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. <i>BMC Pulmonary Medicine</i> , 2011, 11, 56.	0.8	16
1097	Treatment of pediatric pulmonary hypertension with simvastatin: An observational study. <i>Pediatric Pulmonology</i> , 2011, 46, 261-265.	1.0	11
1098	Right ventricular volumes and ejection fraction by MR imaging and stereology: Comparison with standard image analysis method. <i>Clinical Anatomy</i> , 2011, 24, 868-873.	1.5	5
1099	Pediatric pulmonary arterial hypertension: current and emerging therapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1845-1864.	0.9	7
1100	Advances in the Management of Pediatric Pulmonary Hypertension. <i>Respiratory Care</i> , 2011, 56, 1314-1340.	0.8	39
1101	Two Cases of Pulmonary Hypertension Associated with Type III Glycogen Storage Disease. <i>JIMD Reports</i> , 2011, 1, 79-82.	0.7	11
1102	Effect of Warfarin on Survival in Scleroderma-associated Pulmonary Arterial Hypertension (SSc-PAH) and Idiopathic PAH. Belief Elicitation for Bayesian Priors. <i>Journal of Rheumatology</i> , 2011, 38, 462-469.	1.0	30
1103	Treatment of Pulmonary Arterial Hypertension: Great Expectations!. <i>Journal of Rheumatology</i> , 2011, 38, 403-405.	1.0	1
1104	VEGF Receptor Inhibition As a Model of Pulmonary Hypertension in Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1103-1105.	2.5	5
1105	Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 1-15.	1.4	199
1106	Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 253-263.	0.7	5
1107	Update on Pulmonary Vascular Diseases 2010. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 26-31.	2.5	3
1108	Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2583-2593.	0.9	11
1109	Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension. , 2011, 1, 1929-1941.		13
1110	Treatment of pulmonary arterial hypertension with targeted therapies. <i>Nature Reviews Cardiology</i> , 2011, 8, 526-538.	6.1	125

#	ARTICLE	IF	CITATIONS
1111	Symptom Experience of Pulmonary Arterial Hypertension Patients. <i>Clinical Nursing Research</i> , 2011, 20, 120-134.	0.7	41
1112	Extracorporeal membrane oxygenation as a bridge to lung transplantation in a patient with persistent severe porto-pulmonary arterial hypertension following liver transplantation. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, 777-778.	0.6	7
1113	Right Ventricle in Pulmonary Hypertension. , 2011, 1, 525-40.		38
1114	Right Ventricular Strain for Prediction of Survival in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 139, 1299-1309.	0.4	298
1115	A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. <i>European Respiratory Journal</i> , 2011, 37, 1096-1103.	3.1	86
1116	Pulmonary Vascular Wall Stiffness: An Important Contributor to the Increased Right Ventricular Afterload with Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2011, 1, 212-223.	0.8	172
1117	Role of Lipoxygenase Metabolites of Arachidonic Acid in Enhanced Pulmonary Artery Contractions of Female Rabbits. <i>Hypertension</i> , 2011, 57, 825-832.	1.3	15
1118	Platelet Serotonin Content and Transpulmonary Platelet Serotonin Gradient in Patients with Pulmonary Hypertension. <i>Respiration</i> , 2011, 81, 211-216.	1.2	19
1119	Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 257-265.	1.6	253
1120	Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2011, 38, 1343-1348.	3.1	121
1121	Bosentan for the treatment of adult pulmonary hypertension. <i>Future Cardiology</i> , 2011, 7, 19-37.	0.5	14
1122	Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension. <i>Critical Care Nurse</i> , 2011, 31, e1-e10.	0.5	8
1123	Living with pulmonary hypertension: quality not just quantity. <i>European Respiratory Journal</i> , 2011, 38, 512-513.	3.1	4
1124	Longitudinal Shortening Accounts for the Majority of Right Ventricular Contraction and Improves After Pulmonary Vasodilator Therapy in Normal Subjects and Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 140, 27-33.	0.4	157
1125	Inaccuracy of Doppler Echocardiographic Estimates of Pulmonary Artery Pressures in Patients With Pulmonary Hypertension. <i>Chest</i> , 2011, 139, 988-993.	0.4	328
1126	Survival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era. <i>Chest</i> , 2011, 140, 301-309.	0.4	161
1127	Predicting Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 139, 1263-1264.	0.4	9
1128	Does the Outcome Justify an Oral-First Treatment Strategy for Management of Pulmonary Arterial Hypertension?. <i>Chest</i> , 2011, 140, 697-705.	0.4	4

#	ARTICLE	IF	CITATIONS
1129	Pulmonary Arterial Hypertension in China. <i>Chest</i> , 2011, 140, 276-278.	0.4	0
1130	Tricuspid Annular Plane Systolic Excursion Is a Robust Outcome Measure in Systemic Sclerosis-associated Pulmonary Arterial Hypertension. <i>Journal of Rheumatology</i> , 2011, 38, 2410-2418.	1.0	102
1131	Bone Morphogenetic Protein Receptor II Is a Novel Mediator of Endothelial Nitric-oxide Synthase Activation. <i>Journal of Biological Chemistry</i> , 2011, 286, 33134-33140.	1.6	79
1132	Response to Letter Regarding Article, "Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension". <i>Circulation</i> , 2011, 123, .	1.6	1
1133	PET Imaging May Provide a Novel Biomarker and Understanding of Right Ventricular Dysfunction in Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 641-647.	1.3	89
1134	Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease. <i>European Respiratory Review</i> , 2011, 20, 236-242.	3.0	67
1135	Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 153-161.	1.0	6
1136	Pharmacokinetic evaluation of ambrisentan. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 371-380.	1.5	15
1137	The role of the right ventricle in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2011, 20, 243-253.	3.0	210
1138	Hemodynamic monitoring in pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 173-178.	1.0	7
1139	Atrial septostomy in patients with pulmonary hypertension: should it be recommended?. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 363-376.	1.0	20
1140	The value of tools to assess pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2011, 20, 222-235.	3.0	27
1141	Pediatric Pulmonary Hypertension in the Netherlands. <i>Circulation</i> , 2011, 124, 1755-1764.	1.6	272
1142	Implications of Exercise-Induced Pulmonary Arterial Hypertension. <i>Medicine and Science in Sports and Exercise</i> , 2011, 43, 983-989.	0.2	24
1143	Intensive Care Unit Management of Patients with Severe Pulmonary Hypertension and Right Heart Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1114-1124.	2.5	259
1144	Vasoreactivity to Inhaled Nitric Oxide with Oxygen Predicts Long-Term Survival in Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2011, 1, 250-258.	0.8	49
1145	A Critical Role for the Protein Apoptosis Repressor With Caspase Recruitment Domain in Hypoxia-Induced Pulmonary Hypertension. <i>Circulation</i> , 2011, 124, 2533-2542.	1.6	34
1146	Apelin and Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2011, 1, 334-346.	0.8	72

#	ARTICLE	IF	CITATIONS
1147	Survival in Pulmonary Arterial Hypertension: A Brief Review of Registry Data. <i>Pulmonary Circulation</i> , 2011, 1, 430-431.	0.8	18
1148	Overview of Current Therapeutic Approaches for Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2011, 1, 138-159.	0.8	44
1149	Lung Transplantation for Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2011, 1, 182-191.	0.8	50
1150	Right Ventricular Dysfunction and Failure in Chronic Pressure Overload. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-7.	0.5	46
1151	Optimal management of severe pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2011, 20, 254-261.	3.0	18
1152	Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. <i>Heart</i> , 2011, 97, 1054-1060.	1.2	154
1153	Treatment of pulmonary arterial hypertension with circulating angiogenic cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2011, 301, L12-L19.	1.3	19
1154	Surgical Treatment of Pulmonary Hypertension: Lung Transplantation. <i>Pulmonary Circulation</i> , 2011, 1, 327-333.	0.8	29
1155	Imaging in pulmonary hypertension, part 1: clinical perspectives, classification, imaging techniques and imaging algorithm. <i>Postgraduate Medical Journal</i> , 2012, 88, 271-279.	0.9	27
1156	Pulmonary arterial hypertension: an imaging review comparing MR pulmonary angiography and perfusion with multidetector CT angiography. <i>British Journal of Radiology</i> , 2012, 85, 1446-1456.	1.0	16
1157	Three-dimensional Analysis of Right Ventricular Shape and Function in Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2012, 2, 34-40.	0.8	46
1158	Pediatric Lung Transplantation. , 2012, , 671-681.		1
1159	Etiopathogenetic Mechanisms of Pulmonary Hypertension in Sleep-Related Breathing Disorders. <i>Pulmonary Medicine</i> , 2012, 2012, 1-10.	0.5	27
1160	Cardiac arrhythmia mechanisms in rats with heart failure induced by pulmonary hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H2381-H2395.	1.5	73
1161	Cardiac-specific genetic inhibition of nuclear factor- κ B prevents right ventricular hypertrophy induced by monocrotaline. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H1655-H1666.	1.5	40
1162	Wall Shear Stress is Decreased in the Pulmonary Arteries of Patients with Pulmonary Arterial Hypertension: An Image-Based, Computational Fluid Dynamics Study. <i>Pulmonary Circulation</i> , 2012, 2, 470-476.	0.8	109
1163	Imaging in pulmonary hypertension, part 3: small vessel diseases. <i>Postgraduate Medical Journal</i> , 2012, 88, 397-406.	0.9	3
1164	The Impact of Pulmonary Arterial Hypertension-Targeted Therapy on Survival in Chinese Patients with Idiopathic Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2012, 2, 373-378.	0.8	13

#	ARTICLE	IF	CITATIONS
1165	A critical analysis of survival in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2012, 21, 218-222.	3.0	39
1166	Ambrisentan and Tadalafil Synergistically Relax Endothelin-Induced Contraction of Rat Pulmonary Arteries. <i>Hypertension</i> , 2012, 59, 705-711.	1.3	29
1167	The challenge of breathlessness in the detection of pulmonary hypertension. <i>European Respiratory Review</i> , 2012, 21, 1-3.	3.0	4
1168	Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism. <i>Circulation Research</i> , 2012, 110, 739-748.	2.0	152
1169	The fifth world symposium on pulmonary hypertension will REVEAL the impact of registries. <i>European Respiratory Review</i> , 2012, 21, 4-5.	3.0	5
1170	Prognostic Value of Right Ventricular Longitudinal Peak Systolic Strain in Patients With Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 628-636.	1.3	204
1171	A new approach to kinematic feature extraction from the human right ventricle for classification of hypertension: a feasibility study. <i>Physics in Medicine and Biology</i> , 2012, 57, 7905-7922.	1.6	15
1172	Right Ventricular Plasticity and Functional Imaging. <i>Pulmonary Circulation</i> , 2012, 2, 309-326.	0.8	27
1173	Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 960-971.	0.8	55
1174	Testosterone Negatively Regulates Right Ventricular Load Stress Responses in Mice. <i>Pulmonary Circulation</i> , 2012, 2, 352-358.	0.8	64
1175	Pulmonary hypertension and lung transplantation: <i>Thorax</i> publication activity review 2008â€“2010. <i>Thorax</i> , 2012, 67, 828-831.	2.7	0
1176	Reverse right ventricular structural and extracellular matrix remodeling by estrogen in severe pulmonary hypertension. <i>Journal of Applied Physiology</i> , 2012, 113, 149-158.	1.2	50
1177	Warfarin in Systemic Sclerosis-associated and Idiopathic Pulmonary Arterial Hypertension. A Bayesian Approach to Evaluating Treatment for Uncommon Disease. <i>Journal of Rheumatology</i> , 2012, 39, 276-285.	1.0	75
1178	Modern Age Pathology of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 261-272.	2.5	501
1179	Left Ventricular Dysfunction Induced by Nonsevere Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 181-189.	2.5	74
1180	Inhaled treprostinil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2012, 6, 255-265.	1.0	11
1181	Pulmonary Complications of Sickle Cell Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1154-1165.	2.5	143
1182	Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressureâ€“loaded right ventricle. <i>European Journal of Heart Failure</i> , 2012, 14, 1067-1074.	2.9	62

#	ARTICLE	IF	CITATIONS
1183	Impact of Sildenafil on Survival of Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1357-1364.	1.0	11
1184	Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 1003-1011.	1.0	19
1185	Chronic hypoxia induces right heart failure in caveolin-1 ^{-/-} mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H2518-H2527.	1.5	49
1186	Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. <i>Current Medical Research and Opinion</i> , 2012, 28, 1069-1076.	0.9	8
1187	Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries. <i>Progress in Respiratory Research</i> , 2012, , 85-93.	0.1	11
1188	Survival in Childhood Pulmonary Arterial Hypertension. <i>Circulation</i> , 2012, 125, 113-122.	1.6	321
1189	ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. <i>European Respiratory Journal</i> , 2012, 39, 945-955.	3.1	356
1190	Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden. <i>Scandinavian Journal of Public Health</i> , 2012, 40, 777-783.	1.2	14
1191	Survival in pulmonary hypertension in Spain: insights from the Spanish registry. <i>European Respiratory Journal</i> , 2012, 40, 596-603.	3.1	342
1192	The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012, 39, 589-596.	3.1	297
1193	Sildenafil Prevents and Reverses Transverse-Tubule Remodeling and Ca ²⁺ Handling Dysfunction in Right Ventricle Failure Induced by Pulmonary Artery Hypertension. <i>Hypertension</i> , 2012, 59, 355-362.	1.3	84
1194	How to detect disease progression in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2012, 21, 40-47.	3.0	30
1195	Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading. <i>Circulation</i> , 2012, 125, 289-297.	1.6	369
1196	Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 790-796.	2.5	483
1197	Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2012, 6, CCRPM.S8678.	0.5	5
1198	Exercise Intolerance in Pulmonary Arterial Hypertension. <i>Pulmonary Medicine</i> , 2012, 2012, 1-10.	0.5	38
1199	Pulmonary Hypertension in Parenchymal Lung Disease. <i>Pulmonary Medicine</i> , 2012, 2012, 1-14.	0.5	4
1200	Comparison of ¹⁸ F-FDG uptake by Right Ventricular Myocardium in Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. <i>Pulmonary Circulation</i> , 2012, 2, 365-372.	0.8	55

#	ARTICLE	IF	CITATIONS
1201	Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. <i>Cardiovascular Research</i> , 2012, 93, 682-693.	1.8	78
1202	Differences in Hemodynamic Parameters and Exercise Capacity Between Patients With Pulmonary Arterial Hypertension and Chronic Heart Failure. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2012, 32, 379-385.	1.2	14
1203	Prolonged QRS Duration. <i>Chest</i> , 2012, 141, 374-380.	0.4	53
1204	Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. <i>Heart</i> , 2012, 98, 1805-1811.	1.2	237
1205	Pulmonary hypertension: a guide for GPs. <i>British Journal of General Practice</i> , 2012, 62, e795-e797.	0.7	6
1207	Chronic Thromboembolic Pulmonary Hypertension. <i>Progress in Respiratory Research</i> , 2012, , 226-236.	0.1	1
1208	Validation of the Pulmonary Hypertension Connection Equation for Survival Prediction in Pulmonary Arterial Hypertension. <i>Chest</i> , 2012, 141, 642-650.	0.4	62
1209	Non-invasive algorithms for the diagnosis of pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1037-1041.	1.8	8
1210	The Role of Collagen Synthesis in Ventricular and Vascular Adaptation to Hypoxic Pulmonary Hypertension. , 2012, , .		0
1211	How Long Can We Leave Patients With Pulmonary Arterial Hypertension on Oral Drug Monotreatment?. <i>Circulation Journal</i> , 2012, 76, 1089-1090.	0.7	1
1212	Progressive Changes in Right Ventricular Geometric Shortening and Long-term Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2012, 141, 935-943.	0.4	121
1213	Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. <i>Chest</i> , 2012, 142, 1150-1157.	0.4	104
1214	Prevalence and Prognostic Value of Left Ventricular Diastolic Dysfunction in Idiopathic and Heritable Pulmonary Arterial Hypertension. <i>Chest</i> , 2012, 141, 1457-1465.	0.4	66
1215	Emerging therapies for pulmonary arterial hypertension: a review of recently completed and ongoing clinical trials. <i>Clinical Investigation</i> , 2012, 2, 491-501.	0.0	0
1216	Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension. <i>Circulation Journal</i> , 2012, 76, 1245-1252.	0.7	17
1217	Platelet Level as a New Prognostic Factor for Idiopathic Pulmonary Arterial Hypertension in the Era of Combination Therapy. <i>Circulation Journal</i> , 2012, 76, 1494-1500.	0.7	23
1218	Missense Mutations of the <i>BMPR1B</i> (<i>ALK6) Gene in Childhood Idiopathic Pulmonary Arterial Hypertension. <i>Circulation Journal</i> , 2012, 76, 1501-1508.	0.7	89
1219	Is Magnetic Resonance Imaging of Right Ventricular Volume Useful Clinically for Evaluation of Pulmonary Arterial Hypertension?. <i>Circulation Journal</i> , 2012, 76, 1595-1596.	0.7	0

#	ARTICLE	IF	CITATIONS
1220	Safety and Efficacy of Epoprostenol Therapy in Pulmonary Veno-Occlusive Disease and Pulmonary Capillary Hemangiomatosis. <i>Circulation Journal</i> , 2012, 76, 1729-1736.	0.7	38
1221	Significance of Electrocardiographic Right Ventricular Hypertrophy in Patients with Pulmonary Hypertension with or without Right Ventricular Systolic Dysfunction. <i>Internal Medicine</i> , 2012, 51, 2277-2283.	0.3	11
1222	Prognostic Value of Cardiac Magnetic Resonance Imaging for Idiopathic Pulmonary Arterial Hypertension Before Initiating Intravenous Prostacyclin Therapy. <i>Circulation Journal</i> , 2012, 76, 1737-1743.	0.7	43
1223	Clinical features of paediatric pulmonary hypertension: a registry study. <i>Lancet, The</i> , 2012, 379, 537-546.	6.3	441
1224	Anesthesia and Pulmonary Hypertension. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 199-217.	1.6	63
1225	Imatinib mesylate for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 119-134.	1.9	58
1226	Immune and inflammatory mechanisms in pulmonary arterial hypertension. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 218-228.	1.6	94
1227	Clinical implications of haemoptysis in patients with pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2012, 66, 5-12.	0.8	18
1228	Pharmacotherapy for Pulmonary Hypertension. <i>Pediatric Clinics of North America</i> , 2012, 59, 1129-1146.	0.9	19
1229	The Pharmacological Treatment of Pulmonary Arterial Hypertension. <i>Pharmacological Reviews</i> , 2012, 64, 583-620.	7.1	105
1230	Metabolism of the right ventricle and the response to hypertrophy and failure. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 229-233.	1.6	19
1231	Contraception, Pregnancy and Rare Respiratory Diseases. <i>Archivos De Bronconeumologia</i> , 2012, 48, 372-378.	0.4	3
1232	Pulmonary Arterial Hypertension in the Elderly-Clinical Characteristics and Long-Term Survival. <i>Lung</i> , 2012, 190, 645-649.	1.4	22
1233	Anticoncepci3n, embarazo y enfermedades respiratorias minoritarias. <i>Archivos De Bronconeumologia</i> , 2012, 48, 372-378.	0.4	7
1234	Potts Shunt in Children With Idiopathic Pulmonary Arterial Hypertension: Long-Term Results. <i>Annals of Thoracic Surgery</i> , 2012, 94, 817-824.	0.7	116
1235	Pulmonary hypertensionâ€”â€œstate of the artâ€•management in 2012. <i>Indian Heart Journal</i> , 2012, 64, 60-73.	0.2	2
1236	Pharmacotherapy for Pulmonary Arterial Hypertension. <i>Heart Failure Clinics</i> , 2012, 8, 385-402.	1.0	1
1237	Right Ventricular Longitudinal Peak Systolic Strain Measurements from the Subcostal View in Patients with Suspected Pulmonary Hypertension: A Feasibility Study. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 674-681.	1.2	21

#	ARTICLE	IF	CITATIONS
1238	Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): A pilot study. <i>Annales D'Endocrinologie</i> , 2012, 73, 20-25.	0.6	51
1240	Right Ventricular Adaptation and Maladaptation in Chronic Pulmonary Arterial Hypertension. <i>Cardiology Clinics</i> , 2012, 30, 257-269.	0.9	44
1241	Risk stratification of serious adverse events after gastric bypass in the Bariatric Outcomes Longitudinal Database. <i>Surgery for Obesity and Related Diseases</i> , 2012, 8, 671-677.	1.0	75
1242	Factors Limiting Exercise Tolerance in Chronic Lung Diseases. , 2012, 2, 1779-817.		63
1243	Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension. <i>Applied Health Economics and Health Policy</i> , 2012, 10, 175-188.	1.0	17
1244	The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 249-252.	0.5	63
1245	Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. <i>Respiratory Medicine</i> , 2012, 106, 730-739.	1.3	26
1246	Novel peptide for attenuation of hypoxia-induced pulmonary hypertension via modulation of nitric oxide release and phosphodiesterase -5 activity. <i>Peptides</i> , 2012, 35, 78-85.	1.2	4
1247	Serum High-Density Lipoprotein Cholesterol Levels as a Prognostic Indicator in Patients With Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2012, 110, 433-439.	0.7	32
1248	Outcomes of Childhood Pulmonary Arterial Hypertension in BMPR2 and ALK1 Mutation Carriers. <i>American Journal of Cardiology</i> , 2012, 110, 586-593.	0.7	72
1249	Introduction: Devising a Prognostic Score for Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2012, 110, S1-S2.	0.7	2
1250	Characterizing the Right Ventricle: Advancing Our Knowledge. <i>American Journal of Cardiology</i> , 2012, 110, S3-S8.	0.7	26
1251	Hemodynamics in Pulmonary Arterial Hypertension: Current and Future Perspectives. <i>American Journal of Cardiology</i> , 2012, 110, S9-S15.	0.7	44
1252	Cardiac Magnetic Resonance Imaging: What Can It Add to Our Knowledge of the Right Ventricle in Pulmonary Arterial Hypertension?. <i>American Journal of Cardiology</i> , 2012, 110, S25-S31.	0.7	61
1253	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 150-158.	0.3	91
1254	Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 364-372.	0.3	50
1255	Systemic endothelial dysfunction in children with idiopathic pulmonary arterial hypertension correlates with disease severity. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 642-647.	0.3	25
1256	Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 735-743.	0.3	44

#	ARTICLE	IF	CITATIONS
1257	Current pathophysiological concepts and management of pulmonary hypertension. International Journal of Cardiology, 2012, 155, 350-361.	0.8	48
1258	Serial phase-contrast MRI for prediction of pulmonary hemodynamic changes in patients with pulmonary arterial hypertension. International Journal of Cardiology, 2012, 157, 140-142.	0.8	11
1259	Development and validation of a fully automated online human dried blood spot analysis of bosentan and its metabolites using the Sample Card And Prep DBS System. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 885-886, 50-60.	1.2	47
1260	Evolving Epidemiology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 707-709.	2.5	49
1261	Practical Considerations for the Pharmacotherapy of Pulmonary Arterial Hypertension. Pharmacotherapy, 2012, 32, 838-855.	1.2	11
1262	Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 14.	1.6	187
1263	Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 31.	1.6	114
1264	Cardiovascular magnetic resonance in pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 10.	1.6	56
1265	An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry. Chest, 2012, 142, 448-456.	0.4	926
1266	Pulmonary Arterial Hypertension in Connective Tissue Diseases. Heart Failure Clinics, 2012, 8, 413-425.	1.0	58
1267	Ventricular Function in Patients with End-stage Renal Disease Starting Dialysis Therapy: A Tissue Doppler Imaging Study. Echocardiography, 2012, 29, 1054-1059.	0.3	22
1268	Pulmonary hypertension associated with rheumatic diseases: baseline characteristics from the Korean registry. International Journal of Rheumatic Diseases, 2012, 15, e80-9.	0.9	25
1269	Treatment of Pulmonary Arterial Hypertension in Connective Tissue Disease. Drugs, 2012, 72, 1039-1056.	4.9	2
1270	Vortex Formation in the Heart. , 2012, , 45-79.		13
1271	Treatment of Pulmonary Hypertension. , 2012, , 437-445.		0
1272	Assessment of Pulmonary Endothelial Function During Invasive Testing in Children and Adolescents With Idiopathic Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2012, 60, 157-164.	1.2	29
1273	Effectiveness and Safety of Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Children. American Journal of Cardiology, 2012, 110, 1704-1709.	0.7	62
1274	Validation of the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) pulmonary hypertension prediction model in a unique population and utility in the prediction of long-term survival. Journal of Heart and Lung Transplantation, 2012, 31, 1165-1170.	0.3	29

#	ARTICLE	IF	CITATIONS
1275	Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: Results from a cross-sectional patient survey. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 1102-1108.	0.3	64
1276	Ablation of Typical Right Atrial Flutter in Patients with Pulmonary Hypertension. <i>Heart Lung and Circulation</i> , 2012, 21, 695-699.	0.2	26
1277	Why all pulmonary hypertensive patients need a heart catheter study?. <i>Progress in Pediatric Cardiology</i> , 2012, 34, 123-127.	0.2	0
1278	Imaging of Pulmonary Hypertension. , 2012, , 139-160.		0
1279	Novel Methods for Assessment of Right Heart Structure and Function in Pulmonary Hypertension. <i>Clinics in Perinatology</i> , 2012, 39, 685-701.	0.8	12
1280	Predicting survival in pulmonary arterial hypertension in the UK. <i>European Respiratory Journal</i> , 2012, 40, 604-611.	3.1	108
1281	The study of risk in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2012, 21, 234-238.	3.0	15
1282	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 747-755.	0.9	16
1283	Exhaled breath condensate in pulmonary arterial hypertension. <i>Journal of Breath Research</i> , 2012, 6, 036006.	1.5	9
1284	Nanoparticle-Mediated Treatment of Pulmonary Arterial Hypertension. <i>Methods in Enzymology</i> , 2012, 508, 325-354.	0.4	25
1285	Diagnostic Dilemmas in Pulmonary Hypertension. <i>Heart Failure Clinics</i> , 2012, 8, 331-352.	1.0	1
1286	Prognostication in Pulmonary Arterial Hypertension. <i>Heart Failure Clinics</i> , 2012, 8, 373-383.	1.0	8
1287	Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2012, 12, 75.	0.8	22
1288	Right Ventricular Performance in Congenital Heart Disease: A Physiologic and Pathophysiologic Perspective. <i>Cardiology Clinics</i> , 2012, 30, 205-218.	0.9	14
1289	Clinical Impact of Atrial Fibrillation in Patients with Pulmonary Hypertension. <i>PLoS ONE</i> , 2012, 7, e33902.	1.1	68
1290	The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats. <i>PLoS ONE</i> , 2012, 7, e43433.	1.1	100
1291	Nicorandil Prevents Right Ventricular Remodeling by Inhibiting Apoptosis and Lowering Pressure Overload in Rats with Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2012, 7, e44485.	1.1	25
1292	Thermodilution and Fick Cardiac Outputs Differ: Impact on Pulmonary Hypertension Evaluation. <i>Canadian Respiratory Journal</i> , 2012, 19, 261-266.	0.8	41

#	ARTICLE	IF	CITATIONS
1293	PGC-1 α Induction in Pulmonary Arterial Hypertension. <i>Oxidative Medicine and Cellular Longevity</i> , 2012, 2012, 1-8.	1.9	24
1294	Vascular Compromise and Hemodynamics in Pulmonary Arterial Hypertension: Model Predictions. <i>Canadian Respiratory Journal</i> , 2012, 19, 209-215.	0.8	1
1295	Hypoxia-Induced Oxidative Stress in Health Disorders. <i>Oxidative Medicine and Cellular Longevity</i> , 2012, 2012, 1-2.	1.9	21
1296	Atrial Septostomy. <i>Progress in Respiratory Research</i> , 2012, , 254-261.	0.1	0
1298	Macrophage Migration Inhibitory Factor Mediates Hypoxia-Induced Pulmonary Hypertension. <i>Molecular Medicine</i> , 2012, 18, 215-223.	1.9	63
1299	Vascular Compromise and Hemodynamics in Pulmonary Arterial Hypertension: Model Predictions. <i>Canadian Respiratory Journal</i> , 2012, 19, e15-e17.	0.8	2
1300	Childhood Pulmonary Arterial Hypertension. , 2012, , 1003-1018.		0
1301	A Pathophysiological Approach to Understanding Pulmonary Hypertension in Cardiac Surgery. , 2012, , .		0
1302	Inhaled treprostinil: a therapeutic review. <i>Drug Design, Development and Therapy</i> , 2012, 6, 19.	2.0	43
1303	Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1049-1060.	1.8	14
1304	Erythroid-Specific Transcriptional Changes in PBMCs from Pulmonary Hypertension Patients. <i>PLoS ONE</i> , 2012, 7, e34951.	1.1	63
1305	New Insights into the Pathological Features of Asthma/COPD and Pulmonary Arterial Hypertension. <i>Air & Water Borne Diseases</i> , 2012, 01, .	0.3	0
1306	Invasive Rest and Exercise Hemodynamics in the Modern Management of Pulmonary Vascular Disease: An Expanding Role in the Future. <i>Progress in Respiratory Research</i> , 2012, , 23-36.	0.1	0
1307	Pulmonary Arterial Hypertension Complicating Connective Tissue Disorders. <i>Progress in Respiratory Research</i> , 2012, , 94-104.	0.1	0
1308	Exercise Testing in Pulmonary Arterial Hypertension. <i>Progress in Respiratory Research</i> , 2012, , 37-47.	0.1	3
1309	Perfil hemodinâmico de gravidade ao teste de vasorreatividade pulmonar em esquistossomóticos. <i>Arquivos Brasileiros De Cardiologia</i> , 2012, 99, 789-796.	0.3	12
1310	Effect of Small Hairpin RNA Targeting Endothelin-Converting Enzyme-1 in Monocrotaline-Induced Pulmonary Hypertensive Rats. <i>Journal of Korean Medical Science</i> , 2012, 27, 1507.	1.1	2
1311	Echocardiographic assessment of Right Ventricular (RV) Function. <i>Cardiovascular Journal</i> , 2012, 5, 92-99.	0.0	0

#	ARTICLE	IF	CITATIONS
1312	Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension. Cellular and Molecular Life Sciences, 2012, 69, 2805-2831.	2.4	18
1313	Cardiac sympathetic activation in patients with pulmonary arterial hypertension. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 302, R1153-R1157.	0.9	50
1314	Inhaled Low-Dose Iloprost for Pulmonary Hypertension: A Prospective, Multicenter, Open-Label Study. Clinical Cardiology, 2012, 35, 365-370.	0.7	10
1315	The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension. Chest, 2012, 141, 354-362.	0.4	448
1316	Current status of lung transplantation. Chronic Respiratory Disease, 2012, 9, 131-145.	1.0	16
1317	Pulmonary Hypertension: How the Radiologist Can Help. Radiographics, 2012, 32, 9-32.	1.4	124
1319	Redefining the Role of Cardiovascular Imaging in Patients with Pulmonary Arterial Hypertension. Current Cardiology Reports, 2012, 14, 366-373.	1.3	8
1320	Leflunomide-Induced Pulmonary Hypertension in a Young Woman with Rheumatoid Arthritis: A Case Report. Cardiovascular Toxicology, 2012, 12, 180-183.	1.1	16
1321	Black blood MRI has diagnostic and prognostic value in the assessment of patients with pulmonary hypertension. European Radiology, 2012, 22, 695-702.	2.3	37
1322	Atrial Electrical and Structural Remodeling Associated with Longstanding Pulmonary Hypertension and Right Ventricular Hypertrophy in Humans. Journal of Cardiovascular Electrophysiology, 2012, 23, 614-620.	0.8	72
1323	Morphologic and Functional Remodeling of the Right Ventricle in Pulmonary Hypertension by Real Time Three Dimensional Echocardiography. American Journal of Cardiology, 2012, 109, 906-913.	0.7	47
1324	Comparison of Baseline Predictors of Prognosis in Pulmonary Arterial Hypertension in Patients Surviving 2 Years and Those Surviving 5 Years After Baseline Right-Sided Cardiac Catheterization. American Journal of Cardiology, 2012, 109, 1514-1520.	0.7	26
1325	Usefulness of Beta-Blocker Therapy and Outcomes in Patients With Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 109, 1504-1509.	0.7	70
1326	Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb® Pro: Formulation aspects and nanoparticle stability to nebulization. International Journal of Pharmaceutics, 2012, 422, 398-408.	2.6	62
1327	Catheter Ablation of Typical Atrial Flutter in Severe Pulmonary Hypertension. Journal of Cardiovascular Electrophysiology, 2012, 23, 1185-1190.	0.8	24
1328	Diagnosis and mortality prediction in pulmonary hypertension: the value of the electrocardiogram-derived ventricular gradient. Journal of Electrocardiology, 2012, 45, 312-318.	0.4	19
1329	Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension. European Journal of Clinical Investigation, 2012, 42, 933-942.	1.7	33
1330	Feasibility and efficacy of bypassing the right ventricle and pulmonary circulation to treat right ventricular failure: an experimental study. Journal of Cardiothoracic Surgery, 2012, 7, 15.	0.4	8

#	ARTICLE	IF	CITATIONS
1331	Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 31.	1.0	32
1332	A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 91.	0.7	26
1333	A Novel Channelopathy in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 351-361.	13.9	412
1334	Managing an acutely ill patient with pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 77-83.	1.0	2
1335	Dispersion Durations of P-wave and QT Interval in Children With Congenital Heart Disease and Pulmonary Arterial Hypertension. <i>Pediatric Cardiology</i> , 2013, 34, 591-596.	0.6	18
1336	QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. <i>International Journal of Cardiology</i> , 2013, 167, 669-676.	0.8	77
1337	Heritable and Idiopathic Forms of Pulmonary Arterial Hypertension. , 2013, , 1-20.		0
1339	Cardiac magnetic resonance-derived right ventricular outflow tract systolic flow acceleration: a novel index of right ventricular function and prognosis in patients with pulmonary arterial hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2013, 29, 1759-1767.	0.7	9
1340	Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. <i>Basic Research in Cardiology</i> , 2013, 108, 325.	2.5	65
1342	Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. <i>Current Pediatrics Reports</i> , 2013, 1, 92-101.	1.7	2
1343	Role of Rho-kinase and its inhibitors in pulmonary hypertension. , 2013, 137, 352-364.		63
1344	Novel Medical Therapies for Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2013, 34, 867-880.	0.8	9
1345	Ghrelin protects human pulmonary artery endothelial cells against hypoxia-induced injury via PI3-kinase/Akt. <i>Peptides</i> , 2013, 42, 112-117.	1.2	34
1346	Parenteral and Inhaled Prostanoid Therapy in the Treatment of Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2013, 34, 825-840.	0.8	36
1347	Lung Transplantation and Atrial Septostomy in Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2013, 34, 857-865.	0.8	10
1348	Disease targeting therapies in patients with Eisenmenger syndrome: Response to treatment and long-term efficiency. <i>International Journal of Cardiology</i> , 2013, 167, 840-847.	0.8	68
1349	Survival and Prognostic Factors in Systemic Sclerosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2412-2423.	6.7	205
1350	Contributions of pulmonary hypertension to HIV-related cardiac dysfunction. <i>Indian Heart Journal</i> , 2013, 65, 644-649.	0.2	4

#	ARTICLE	IF	CITATIONS
1351	Geometry of the right heart and tricuspid regurgitation to exclude elevated pulmonary artery pressure: New insights. <i>International Journal of Cardiology</i> , 2013, 168, 3866-3871.	0.8	12
1352	Simple exercise echocardiography using a Master's two-step test for early detection of pulmonary arterial hypertension. <i>Journal of Cardiology</i> , 2013, 62, 176-182.	0.8	17
1353	Right Heart Adaptation to Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D22-D33.	1.2	770
1355	Causes and Circumstances of Death in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 365-369.	2.5	186
1356	Pulmonary arterial hypertension in SLE: what do we know?. <i>Lupus</i> , 2013, 22, 1274-1285.	0.8	25
1357	Transplantation for Idiopathic Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 2503-2513.	1.6	64
1358	Impaired Left Ventricular Mechanics in Pulmonary Arterial Hypertension. <i>Circulation: Heart Failure</i> , 2013, 6, 748-755.	1.6	106
1359	Pulmonary hypertension in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 425-434.	1.4	17
1360	Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. <i>Atherosclerosis Supplements</i> , 2013, 14, 203-211.	1.2	36
1361	HIV and the heart: the impact of antiretroviral therapy: a global perspective. <i>European Heart Journal</i> , 2013, 34, 3538-3546.	1.0	100
1362	Pediatric Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D117-D126.	1.2	451
1363	Management of Right Ventricular Failure in Pulmonary Hypertension (and After LVAD Implantation). <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 533-543.	0.4	4
1364	Health-Related Quality of Life in a National Cohort of Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension. <i>Archivos De Bronconeumologia</i> , 2013, 49, 181-188.	0.4	17
1366	An Update on Medical Therapy for Pulmonary Arterial Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 614-622.	1.5	19
1367	Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, .	1.0	3
1368	Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 97.	1.2	226
1369	Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension. <i>Respiratory Research</i> , 2013, 14, 130.	1.4	35
1370	Epidemiology of Pulmonary Arterial Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 638-649.	1.5	17

#	ARTICLE	IF	CITATIONS
1371	Ventricular Remodeling in Heart Failure with Preserved Ejection Fraction. <i>Current Heart Failure Reports</i> , 2013, 10, 341-349.	1.3	48
1372	The Diagnostic Accuracy of Doppler Echocardiography in Assessment of Pulmonary Artery Systolic Pressure: A Meta-Analysis. <i>Echocardiography</i> , 2013, 30, 258-265.	0.3	90
1373	Novel Therapeutic Approaches to Preserve the Right Ventricle. <i>Current Heart Failure Reports</i> , 2013, 10, 12-17.	1.3	14
1374	Atrial Septostomy in Patients with End-Stage Pulmonary Hypertension. No More Needles but Wires, Energy and Close Anatomical Definition. <i>Journal of Interventional Cardiology</i> , 2013, 26, 62-68.	0.5	15
1375	Impact of Acute Pulmonary Embolization on Arterial Stiffening and Right Ventricular Function in Dogs. <i>Annals of Biomedical Engineering</i> , 2013, 41, 195-204.	1.3	29
1376	Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 1128-1138.	1.6	482
1377	Evaluation of right ventricular volume and ejection fraction by gated 18F-FDG PET in patients with pulmonary hypertension: Comparison with cardiac MRI and CT. <i>Journal of Nuclear Cardiology</i> , 2013, 20, 242-252.	1.4	28
1378	Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 1114-1122.	0.3	86
1379	Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2013, 168, 1370-1377.	0.8	35
1380	Epidemiology of Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2013, 34, 619-637.	0.8	54
1381	Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D51-D59.	1.2	432
1382	Marked changes in right ventricular contractile pattern after cardiothoracic surgery: Implications for post-surgical assessment of right ventricular function. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 777-783.	0.3	152
1383	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. <i>International Journal of Cardiology</i> , 2013, 168, 871-880.	0.8	357
1384	Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. <i>International Journal of Cardiology</i> , 2013, 167, 220-224.	0.8	12
1385	Treatment Goals of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D73-D81.	1.2	250
1386	An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: Emerging role of CT-proET-1. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 1214-1221.	0.3	30
1387	Diagnosis of Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2013, 34, 665-681.	0.8	21
1388	Postoperative Right Ventricular Failure After Left Ventricular Assist Device Placement is Predicted by Preoperative Echocardiographic Structural, Hemodynamic, and Functional Parameters. <i>Journal of Cardiac Failure</i> , 2013, 19, 16-24.	0.7	127

#	ARTICLE	IF	CITATIONS
1389	Right atrial volume and phasic function in pulmonary hypertension. <i>International Journal of Cardiology</i> , 2013, 168, 420-426.	0.8	45
1390	Is Patient-Prosthesis Mismatch a Perioperative Predictor of Long-Term Mortality After Aortic Valve Replacement?. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013, 27, 647-653.	0.6	19
1391	Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. <i>Clinics in Chest Medicine</i> , 2013, 34, 707-717.	0.8	10
1392	Marked reduction in the ratio of main right ventricular chamber to outflow tract function in patients with proximal bilateral acute pulmonary embolism. <i>International Journal of Cardiology</i> , 2013, 168, 592-593.	0.8	3
1393	Managing Pulmonary Arterial Hypertension and Optimizing Treatment Options: Prognosis of Pulmonary Artery Hypertension. <i>American Journal of Cardiology</i> , 2013, 111, 10C-15C.	0.7	17
1394	Children with pulmonary arterial hypertension and prostanoid therapy: Long-term hemodynamics. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 546-552.	0.3	62
1395	Standard Nonspecific Therapies in the Management of Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2013, 34, 799-810.	0.8	13
1396	Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: Initial clinical experience. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 381-387.	0.3	114
1397	Longitudinal strain curves in the RV free wall differ in morphology in patients with pulmonary hypertension compared to controls. <i>International Journal of Cardiology</i> , 2013, 167, 2753-2756.	0.8	14
1398	Pulmonary Arterial Hypertension: New Insights Into the Optimal Role of Current and Emerging Prostacyclin Therapies. <i>American Journal of Cardiology</i> , 2013, 111, 1A-16A.	0.7	62
1399	Calidad de vida relacionada con la salud en una cohorte nacional de pacientes con hipertensi3n arterial pulmonar o hipertensi3n pulmonar tromboemb3lica cr3nica. <i>Archivos De Bronconeumologia</i> , 2013, 49, 181-188.	0.4	38
1400	Association of Cardiac Troponin I With Disease Severity and Outcomes in Patients With Pulmonary Hypertension. <i>American Journal of Cardiology</i> , 2013, 111, 1812-1817.	0.7	29
1401	Right Ventricular Function Predicts Clinical Response to Specific Vasodilator Therapy in Patients with Pulmonary Hypertension. <i>Echocardiography</i> , 2013, 30, 17-26.	0.3	25
1403	Pulmonary hypertension in bronchopulmonary dysplasia. <i>Seminars in Perinatology</i> , 2013, 37, 124-131.	1.1	143
1404	Pulmonary hypertension: diagnosis and management. <i>BMJ, The</i> , 2013, 346, f2028-f2028.	3.0	119
1405	Methods for Measuring Right Ventricular Function and Hemodynamic Coupling with the Pulmonary Vasculature. <i>Annals of Biomedical Engineering</i> , 2013, 41, 1384-1398.	1.3	69
1406	Sildenafil improves long-term effect of endothelial progenitor cell-based treatment for monocrotaline-induced rat pulmonary arterial hypertension. <i>Cytotherapy</i> , 2013, 15, 209-223.	0.3	25
1407	Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. <i>Future Cardiology</i> , 2013, 9, 335-349.	0.5	34

#	ARTICLE	IF	CITATIONS
1408	Pulmonary Hypertension in Patients Undergoing Cardiac Surgery: Pathophysiology, Perioperative Management, and Outcomes. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013, 27, 551-572.	0.6	37
1409	Benefits of Intensive Treadmill Exercise Training on Cardiorespiratory Function and Quality of Life in Patients With Pulmonary Hypertension. <i>Chest</i> , 2013, 143, 333-343.	0.4	172
1410	Right Ventricular Outflow Tract Systolic Excursion: A Distinguishing Echocardiographic Finding in Acute Pulmonary Embolism. <i>Echocardiography</i> , 2013, 30, 649-657.	0.3	9
1411	Pulmonary Vascular Disease. , 2013, , 603-625.		1
1412	Role of Serial Quantitative Assessment of Right Ventricular Function by Strain in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2013, 111, 143-148.	0.7	137
1414	Survival after lung transplantation in systemic sclerosis. A systematic review. <i>Respiratory Medicine</i> , 2013, 107, 2081-2087.	1.3	64
1415	Transition from Prostacyclin Analogue Infusion to Oral Therapy in Patients with Pulmonary Arterial Hypertension: A 5-Year follow-up. <i>Pulmonary Circulation</i> , 2013, 3, 880-888.	0.8	4
1416	Right ventricular ejection fraction during exercise as a predictor of mortality in patients awaiting lung transplantation: a cohort study. <i>BMJ Open</i> , 2013, 3, e002108.	0.8	11
1417	Successful management of an acute subdural hematoma in a patient dependent on continuous treprostinil infusion therapy. <i>Journal of Neurosurgery</i> , 2013, 118, 753-756.	0.9	1
1418	Hemodynamic Predictors of Mortality in Adults with Sickle Cell Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 840-847.	2.5	114
1419	Cardiac magnetic resonance imaging in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2013, 22, 526-534.	3.0	69
1420	Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension. <i>Journal of Medical Economics</i> , 2013, 16, 298-306.	1.0	22
1421	The Role of Collagen Synthesis in Ventricular and Vascular Adaptation to Hypoxic Pulmonary Hypertension. <i>Journal of Biomechanical Engineering</i> , 2013, 135, 021018.	0.6	36
1422	Pulmonary Hypertension Complicating Connective Tissue Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 581-599.	0.8	7
1423	Anatomical Considerations for the Development of a New Transcatheter Aortopulmonary Shunt Device in Patients with Severe Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 639-646.	0.8	12
1424	Interdisciplinary Networks for the Treatment of Childhood Pulmonary Vascular Disease: What Pulmonary Hypertension Doctors Can Learn from Pediatric Oncologists. <i>Pulmonary Circulation</i> , 2013, 3, 792-801.	0.8	8
1425	Exhaled nitric oxide measurement to monitor pulmonary hypertension in a pneumonectomy-monocrotaline rat model. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2013, 305, L485-L490.	1.3	6
1426	Magnetic Resonance Imaging of the Right Ventricle in Pediatric Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 350-355.	0.8	15

#	ARTICLE	IF	CITATIONS
1427	Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Respiratory Research</i> , 2013, 14, 104.	1.4	83
1428	Shorter Survival in Familial versus Idiopathic Pulmonary Arterial Hypertension is Associated with Hemodynamic Markers of Impaired Right Ventricular Function. <i>Pulmonary Circulation</i> , 2013, 3, 589-598.	0.8	30
1429	Updating Clinical Endpoint Definitions. <i>Pulmonary Circulation</i> , 2013, 3, 206-216.	0.8	22
1430	From Short-term Benefits to Long-term Outcomes: The Evolution of Clinical Trials in Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 507-522.	0.8	8
1431	Provider Recognition and Response to Echocardiographic Findings Indicating Pulmonary Hypertension in the Veterans Affairs Medical Center Population. <i>Pulmonary Circulation</i> , 2013, 3, 389-395.	0.8	3
1432	Clinical Characterization and Survival of Patients with Borderline Elevation in Pulmonary Artery Pressure. <i>Pulmonary Circulation</i> , 2013, 3, 916-925.	0.8	49
1433	Current and Emerging Therapies for Pulmonary Arterial Hypertension. <i>Hospital Pharmacy</i> , 2013, 48, S7-S14.	0.4	0
1434	Short-term Improvement in Pulmonary Hemodynamics is Strongly Predictive of Long-term Survival in Patients with Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 523-532.	0.8	20
1435	Distinct loading conditions reveal various patterns of right ventricular adaptation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 305, H354-H364.	1.5	56
1436	Pulmonary Hypertension in Pregnancy. <i>Cardiology in Review</i> , 2013, 21, 167-173.	0.6	16
1437	Pulmonary arterial hypertension in pregnant women. <i>Therapeutic Advances in Respiratory Disease</i> , 2013, 7, 51-63.	1.0	22
1438	Endothelial-Like Progenitor Cells Engineered to Produce Prostacyclin Rescue Monocrotaline-Induced Pulmonary Arterial Hypertension and Provide Right Ventricle Benefits. <i>Circulation</i> , 2013, 128, 982-994.	1.6	33
1439	Magnetic Resonance and Computed Tomography Imaging of the Structural and Functional Changes of Pulmonary Arterial Hypertension. <i>Journal of Thoracic Imaging</i> , 2013, 28, 178-195.	0.8	24
1440	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 41, 96-103.	3.1	92
1441	Pulmonary Arterial Hypertension: Challenges in Translational Research and a Vision for Change. <i>Science Translational Medicine</i> , 2013, 5, 208sr5.	5.8	69
1442	Critical Role for the Advanced Glycation End-products Receptor in Pulmonary Arterial Hypertension Etiology. <i>Journal of the American Heart Association</i> , 2013, 2, e005157.	1.6	85
1443	Combination Pharmacotherapy in the Treatment of Pulmonary Arterial Hypertension. <i>Journal of Pharmacy Practice</i> , 2013, 26, 18-28.	0.5	2
1444	Treatment of Pulmonary Arterial Hypertension. , 2013, , 596-605.		0

#	ARTICLE	IF	CITATIONS
1445	Noninvasive cardiac output measurements in patients with pulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 42, 125-133.	3.1	59
1446	Outcome Prediction by Quantitative Right Ventricular Function Assessment in 575 Subjects Evaluated for Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 711-721.	1.3	349
1447	Pulmonary Hypertension in Portugal: First Data from a Nationwide Registry. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	40
1448	Pericardial Effusion in Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 467-477.	0.8	41
1449	Safety of Cardiac Catheterization at a Center Specializing in the Care of Patients with Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 831-839.	0.8	54
1451	A Practical Approach of Pulmonary Hypertension in the Elderly. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 654-664.	0.8	23
1452	Pulmonary hypertension: Another light in the dark tunnel. Learning the lesson from cancer. <i>Annals of Thoracic Medicine</i> , 2013, 8, 69.	0.7	9
1453	Pulmonary hypertension in Saudi Arabia: A single center experience. <i>Annals of Thoracic Medicine</i> , 2013, 8, 78.	0.7	18
1454	Left-to-Right Shunt with Congenital Heart Disease: Single Center Experience. <i>ISRN Cardiology</i> , 2013, 2013, 1-5.	1.6	2
1455	Pulmonary Dysfunction in COPD. <i>Pulmonary Medicine</i> , 2013, 2013, 1-2.	0.5	0
1456	Current Challenges in Pediatric Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 627-644.	0.8	19
1457	Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis. <i>Current Medical Research and Opinion</i> , 2013, 29, 889-899.	0.9	7
1458	Progressive right ventricular functional and structural changes in a mouse model of pulmonary arterial hypertension. <i>Physiological Reports</i> , 2013, 1, e00184.	0.7	48
1459	Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2013, 42, 414-424.	3.1	37
1460	Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. <i>European Journal of Heart Failure</i> , 2013, 15, 771-775.	2.9	108
1461	The prognostic significance of central hemodynamics in patients with cardiac amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 199-203.	1.4	17
1462	Building a pulmonary vascular service: the 12-year experience and outcomes of the Auckland pulmonary arterial hypertension clinic. <i>Internal Medicine Journal</i> , 2013, 43, 635-642.	0.5	4
1463	Assessment and Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary Hypertension. <i>Circulation</i> , 2013, 128, 2005-2015.	1.6	193

#	ARTICLE	IF	CITATIONS
1464	Right Ventricular Diastolic Impairment in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 2016-2025.	1.6	294
1465	Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?. <i>European Respiratory Review</i> , 2013, 22, 217-226.	3.0	68
1466	Oestrogen and the sexual dimorphism of pulmonary arterial hypertension: a translational challenge. <i>European Respiratory Journal</i> , 2013, 41, 1014-1016.	3.1	3
1467	Everolimus in Patients with Severe Pulmonary Hypertension: A Safety and Efficacy Pilot Trial. <i>Pulmonary Circulation</i> , 2013, 3, 632-638.	0.8	40
1468	Gene Transfer Therapy by Either Type 1 or Type 2 Adeno-Associated Virus Expressing Human Prostaglandin I ₂ Synthase Gene is Effective for Treatment of Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 54-59.	1.0	10
1469	Efficacy of Right Ventricular Free-Wall Longitudinal Speckle-Tracking Strain for Predicting Long-Term Outcome in Patients With Pulmonary Hypertension. <i>Circulation Journal</i> , 2013, 77, 756-763.	0.7	101
1470	Novel Oral Prostacyclin Analog With Thromboxane Synthase Inhibitory Activity for Management of Pulmonary Arterial Hypertension. <i>Circulation Journal</i> , 2013, 77, 1994-1995.	0.7	4
1471	Volumetric and Functional Assessment of Ventricles in Pulmonary Hypertension on 3-Dimensional Echocardiography. <i>Circulation Journal</i> , 2013, 77, 198-206.	0.7	17
1472	Pulmonary vascular remodeling and right heart failure in pulmonary hypertension: future role of positron emission tomography in decoding the enigma. <i>Translational Respiratory Medicine</i> , 2013, 1, 16.	3.8	1
1473	Rebuttal From Dr Rich. <i>Chest</i> , 2013, 143, 1540-1541.	0.4	3
1474	Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry. <i>Chest</i> , 2013, 144, 160-168.	0.4	87
1475	A paradigm shift in pulmonary arterial hypertension management. <i>European Respiratory Review</i> , 2013, 22, 423-426.	3.0	3
1476	Impact of differential right-to-left shunting on systemic perfusion in pulmonary arterial hypertension. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 888-895.	0.7	11
1477	Survival in Systemic Sclerosis With Pulmonary Arterial Hypertension Has Not Improved in the Modern Era. <i>Chest</i> , 2013, 144, 1282-1290.	0.4	65
1478	A pathophysiological approach towards right ventricular function and failure. <i>European Journal of Anaesthesiology</i> , 2013, 30, 386-394.	0.7	12
1479	The Right Ventricle: Biologic Insights and Response to Disease: Updated. <i>Current Cardiology Reviews</i> , 2013, 9, 73-81.	0.6	30
1480	Pharmacokinetics of Oral Treprostinil Sustained Release Tablets During Chronic Administration to Patients with Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 474-481.	0.8	30
1481	Pulmonary hypertension in POEMS syndrome. <i>Haematologica</i> , 2013, 98, 393-398.	1.7	55

#	ARTICLE	IF	CITATIONS
1483	A Case of Extrinsic Compression of the Left Main Coronary Artery Secondary to Pulmonary Artery Dilatation. <i>Journal of Korean Medical Science</i> , 2013, 28, 1543.	1.1	9
1484	Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes. <i>Patient Preference and Adherence</i> , 2013, 7, 401.	0.8	13
1485	Pulmonary arterial hypertension: diagnosis and treatment. <i>Studia Medyczne</i> , 2013, 3, 273-279.	0.0	0
1486	Pulmonary Artery Pressure, Gender, Menopause, and Pregnancy in Schistosomiasis-Associated Pulmonary Hypertension. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, 101, 154-9.	0.3	3
1487	Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension. <i>PLoS ONE</i> , 2013, 8, e73502.	1.1	15
1488	Directing Therapy in Pulmonary Arterial Hypertension Using a Target 6 Min Walk Distance. <i>Canadian Respiratory Journal</i> , 2013, 20, 111-115.	0.8	0
1489	Pulmonary Arterial Hypertension. , 2013, , 667-686.		4
1490	Pulmonary Arterial Hypertension: An Overview. , 0, , .		0
1491	Extraskelatal Manifestations in Rheumatoid Arthritis - Clinical Cases. , 0, , .		0
1492	Pathogenesis of Pulmonary Hypertension. , 2013, , .		0
1493	Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review. <i>Core Evidence</i> , 2014, 9, 71.	4.7	9
1494	Recent Strategies in Treatment of Pulmonary Arterial Hypertension, A Review. <i>Global Journal of Health Science</i> , 2014, 7, 307-22.	0.1	21
1495	Pulmonary Hypertension/Pulmonary Arterial Hypertension. , 2014, , 2625-2635.		0
1496	Functional Class and Targeted Therapy Are Related to the Survival in Patients with Pulmonary Arterial Hypertension. <i>Yonsei Medical Journal</i> , 2014, 55, 1526.	0.9	13
1497	The Significance of Pulmonary Artery Size in Pulmonary Hypertension. <i>Diseases (Basel, Switzerland)</i> , 2014, 2, 243-259.	1.0	25
1498	Macitentan for the treatment of pulmonary arterial hypertension. <i>Vascular Health and Risk Management</i> , 2014, 10, 665.	1.0	17
1499	Right Ventricular Geometry and Function in Pulmonary Hypertension: Non-Invasive Evaluation. <i>Diseases (Basel, Switzerland)</i> , 2014, 2, 274-295.	1.0	7
1500	Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 825.	0.9	23

#	ARTICLE	IF	CITATIONS
1501	Pulmonary Arterial Hypertension and Insulin Resistance. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2014, 02, .	0.1	7
1502	Investigating Cardiac MRI Based Right Ventricular Contractility as a Novel Non-Invasive Metric of Pulmonary Arterial Pressure. Clinical Medicine Insights: Cardiology, 2014, 8s1, CMC.S15711.	0.6	4
1503	Traffic-related Air Pollution and the Right Ventricle. The Multi-ethnic Study of Atherosclerosis. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1093-1100.	2.5	54
1504	Impact of increased hematocrit on right ventricular afterload in response to chronic hypoxia. Journal of Applied Physiology, 2014, 117, 833-839.	1.2	16
1506	Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre. Heart, 2014, 100, 224-230.	1.2	34
1507	Predicting prognosis of children with pulmonary arterial hypertension: the importance of multimodal expert assessment. Heart, 2014, 100, 1305-1307.	1.2	6
1508	Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness. Critical Care, 2014, 18, 523.	2.5	10
1509	Novel serum biomarkers in pulmonary arterial hypertension. Biomarkers in Medicine, 2014, 8, 1001-1011.	0.6	6
1510	Information Experiences and Needs in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension. Nursing Research and Practice, 2014, 2014, 1-8.	0.4	13
1511	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Perioperative management in patients with pulmonary hypertension. Annals of Thoracic Medicine, 2014, 9, 98.	0.7	14
1512	State of the Art: Advanced Imaging of the Right Ventricle and Pulmonary Circulation in Humans (2013 Grover Conference) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	24
1513	Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement. Indian Journal of Pharmacology, 2014, 46, 281.	0.4	13
1514	Vascular Stiffening in Pulmonary Hypertension: Cause or Consequence? (2013 Grover Conference) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	63
1515	Pulmonary Arterial Hypertension in Adults: Novel Drugs and Catheter Ablation Techniques Show Promise? Systematic Review on Pharmacotherapy and Interventional Strategies. BioMed Research International, 2014, 2014, 1-17.	0.9	12
1516	Pulmonary Hypertension and the Right Ventricleâ€”Thinking outside the Box (Third International Right) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	3
1517	Vascular Remodeling Process in Pulmonary Arterial Hypertension, with Focus on miRâ€204 and miRâ€126 (2013 Grover Conference Series). Pulmonary Circulation, 2014, 4, 175-184.	0.8	51
1518	Obstructive Sleep Apnea and Cardiovascular Comorbidities. Medicine (United States), 2014, 93, e45.	0.4	56
1519	Anticoagulation therapy versus placebo for pulmonary hypertension. The Cochrane Library, 2014, , CD010695.	1.5	9

#	ARTICLE	IF	CITATIONS
1520	Impact of Diabetes on Survival and Right Ventricular Compensation in Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2014, 4, 311-318.	0.8	50
1521	MicroRNA in Pulmonary Vascular Disease. <i>Progress in Molecular Biology and Translational Science</i> , 2014, 124, 43-63.	0.9	11
1522	Preoperative pulmonary hypertension and its impact on survival after heart transplantation. <i>Scandinavian Cardiovascular Journal</i> , 2014, 48, 47-58.	0.4	12
1523	Identification of treatment goals in paediatric pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2014, 44, 1616-1626.	3.1	80
1524	Submaximal exercise testing may be superior to the 6-min walk test in assessing pulmonary arterial hypertension disease severity. <i>Clinical Respiratory Journal</i> , 2014, 8, 404-409.	0.6	6
1525	Sex and haemodynamics in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2014, 43, 523-530.	3.1	89
1526	Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. <i>British Journal of Pharmacology</i> , 2014, 171, 567-579.	2.7	85
1527	Altered Right Ventricular Contractile Pattern after Cardiac Surgery: Monitoring of Septal Function Is Essential. <i>Echocardiography</i> , 2014, 31, 1159-1165.	0.3	31
1528	Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials. <i>International Journal of Clinical Practice</i> , 2014, 68, 568-577.	0.8	6
1529	LGE Patterns in Pulmonary Hypertension Do Not Impact Overall Mortality. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1209-1217.	2.3	82
1530	The role of the osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the pathogenesis of pulmonary arterial hypertension. <i>Vascular Pharmacology</i> , 2014, 63, 114-117.	1.0	6
1531	Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2014, 8, 202-216.	1.0	31
1532	Riociguat for pulmonary hypertension. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 259-270.	1.3	7
1533	Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H361-H369.	1.5	35
1534	“Real-life” information on pulmonary arterial hypertension: the iPHnet Project. <i>Current Medical Research and Opinion</i> , 2014, 30, 2409-2414.	0.9	7
1535	Carbon monoxide diffusing capacity and the complexity of diagnosis in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2014, 43, 963-965.	3.1	8
1536	Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. <i>BMC Pulmonary Medicine</i> , 2014, 14, 45.	0.8	56
1537	Reliability of Noninvasive Assessment of Systolic Pulmonary Artery Pressure by Doppler Echocardiography Compared to Right Heart Catheterization: Analysis in a Large Patient Population. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	147

#	ARTICLE	IF	CITATIONS
1538	Mechanism of the Susceptibility of Remodeled Pulmonary Vessels to Drug-Induced Cell Killing. <i>Journal of the American Heart Association</i> , 2014, 3, e000520.	1.6	32
1539	Existing Drugs and Agents Under Investigation for Pulmonary Arterial Hypertension. <i>Cardiology in Review</i> , 2014, 22, 297-305.	0.6	10
1540	Evidence for the Involvement of Type I Interferon in Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2014, 114, 677-688.	2.0	124
1541	Goal-oriented treatment of pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2014, 20, 409-413.	1.2	3
1542	Quantitative Magnetic Resonance Imaging of Pulmonary Hypertension. <i>Journal of Thoracic Imaging</i> , 2014, 29, 68-79.	0.8	68
1543	Percutaneous Transluminal Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension with Severe Right Heart Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1437-1439.	2.5	24
1544	The changing landscape of pulmonary arterial hypertension and implications for patient care. <i>European Respiratory Review</i> , 2014, 23, 450-457.	3.0	122
1545	Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension-Targeted Therapy. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 107-114.	1.3	139
1546	Effects of Dose and Age on Adverse Events Associated with Tadalafil in the Treatment of Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2014, 4, 45-52.	0.8	5
1547	<i>Cor Pulmonale.</i> , 2014, , 201-208.		0
1548	Reducing TRPC1 Expression through Liposome-Mediated siRNA Delivery Markedly Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension in a Murine Model. <i>Stem Cells International</i> , 2014, 2014, 1-19.	1.2	22
1549	Physician Attitudes toward Palliative Care for Patients with Pulmonary Arterial Hypertension: Results of a Cross-Sectional Survey. <i>Pulmonary Circulation</i> , 2014, 4, 504-510.	0.8	42
1550	Effects of Acute Intravenous Iloprost on Right Ventricular Hemodynamics in Rats with Chronic Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2014, 4, 612-618.	0.8	12
1551	Echocardiography-Derived Tricuspid Regurgitant Jet Velocity Is an Important Marker for the Progression of Sickle-Cell Disease. <i>Acta Haematologica</i> , 2014, 132, 152-158.	0.7	11
1552	Trends in Pulmonary Hypertension Mortality and Morbidity. <i>Pulmonary Medicine</i> , 2014, 2014, 1-5.	0.5	28
1553	Transthoracic Echocardiography and 6-Minute Walk Test in Kuwaiti Sickle Cell Disease Patients. <i>Medical Principles and Practice</i> , 2014, 23, 212-217.	1.1	12
1554	Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. <i>Annals of Thoracic Medicine</i> , 2014, 9, 1.	0.7	11
1555	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension. <i>Annals of Thoracic Medicine</i> , 2014, 9, 92.	0.7	30

#	ARTICLE	IF	CITATIONS
1556	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension in children. <i>Annals of Thoracic Medicine</i> , 2014, 9, 113.	0.7	3
1557	Pulmonary arterial hypertension in Saudi Arabia: Patients's clinical and physiological characteristics and hemodynamic parameters. A single center experience. <i>Annals of Thoracic Medicine</i> , 2014, 9, 209.	0.7	19
1558	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases. <i>Annals of Thoracic Medicine</i> , 2014, 9, 26.	0.7	3
1559	Non-invasive assessment of cardiac function and pulmonary vascular resistance in an canine model of acute thromboembolic pulmonary hypertension using 4D flow cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2014, 16, 23.	1.6	28
1560	Risk of Death and Need for Transplantation in Chronic Pulmonary Hypertension. <i>American Journal of the Medical Sciences</i> , 2014, 347, 106-111.	0.4	0
1561	Oral Anticoagulation for Pulmonary Arterial Hypertension: Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2014, 30, 879-887.	0.8	28
1562	Comprehensive Assessment of Right Ventricular Function in Patients with Pulmonary Hypertension with Global Longitudinal Peak Systolic Strain Derived from Multiple Right Ventricular Views. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 657-665.e3.	1.2	76
1563	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. <i>International Journal of Cardiology</i> , 2014, 172, 332-339.	0.8	47
1564	The genetic basis of pulmonary arterial hypertension. <i>Human Genetics</i> , 2014, 133, 471-479.	1.8	75
1565	Percutaneous Interventional Therapies for the Treatment of Patients With Severe Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2014, 63, 611-618.	1.2	34
1566	Pulmonary Hypertension and Thoracic Surgery: Diagnostics and Advances in Therapy and Intraoperative Management. <i>Current Anesthesiology Reports</i> , 2014, 4, 135-141.	0.9	7
1567	Impact of right ventricular dyssynchrony on left ventricular performance in patients with pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 713-720.	0.7	17
1568	Pressure-overload-induced right heart failure. <i>Pflugers Archiv European Journal of Physiology</i> , 2014, 466, 1055-63.	1.3	17
1569	Drug Treatment of Pulmonary Hypertension in Children. <i>Paediatric Drugs</i> , 2014, 16, 43-65.	1.3	51
1570	The synergistic therapeutic effect of hepatocyte growth factor and granulocyte colony-stimulating factor on pulmonary hypertension in rats. <i>Heart and Vessels</i> , 2014, 29, 520-531.	0.5	15
1571	STARTS-2. <i>Circulation</i> , 2014, 129, 1914-1923.	1.6	175
1572	Survival Differences in Pediatric Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2159-2169.	1.2	123
1573	Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure. <i>Acta Physiologica</i> , 2014, 211, 314-333.	1.8	15

#	ARTICLE	IF	CITATIONS
1574	Cystatin <scp>C</scp>: A potential biomarker for pulmonary arterial hypertension. <i>Respirology</i> , 2014, 19, 583-589.	1.3	21
1575	Endpoints in PAH clinical trials in the era of combination therapy: How do we decide whether something is working without going bankrupt?. <i>Drug Discovery Today</i> , 2014, 19, 1236-1240.	3.2	5
1576	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
1577	Clinical Diagnosis of Pulmonary Hypertension. <i>Circulation</i> , 2014, 130, 1820-1830.	1.6	100
1578	Right Ventricular Ejection Efficiency: A New Echocardiographic Measure of Mechanical Performance in Chronic Pulmonary Hypertension. <i>Echocardiography</i> , 2014, 31, 516-523.	0.3	30
1579	Oral targeted therapies in the treatment of pulmonary arterial hypertension: A meta-analysis of clinical trials. <i>Pulmonary Pharmacology and Therapeutics</i> , 2014, 29, 241-249.	1.1	16
1580	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. <i>Nature Medicine</i> , 2014, 20, 1289-1300.	15.2	233
1581	Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2014, 43, 569-573.	0.8	16
1582	Effects of Bisoprolol and Losartan Treatment in the Hypertrophic and Failing Right Heart. <i>Journal of Cardiac Failure</i> , 2014, 20, 864-873.	0.7	40
1583	Improved survival of Korean patients with idiopathic pulmonary arterial hypertension after the introduction of targeted therapies. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2014, 43, 561-568.	0.8	5
1584	Treatment of idiopathic/hereditary pulmonary arterial hypertension. <i>Journal of Cardiology</i> , 2014, 64, 243-249.	0.8	31
1585	Treatment for Pulmonary Arterial Hypertensionâ€™Associated Right Ventricular Dysfunction. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1101-1115.	1.5	30
1586	The Crossroads of Iron with Hypoxia and Cellular Metabolism. Implications in the Pathobiology of Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 51, 721-729.	1.4	33
1587	Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. <i>Hypertension Research</i> , 2014, 37, 507-512.	1.5	49
1588	Trial Occlusion to Assess the Risk of Persistent Pulmonary Arterial Hypertension After Closure of a Large Patent Ductus Arteriosus in Adolescents and Adults With Elevated Pulmonary Artery Pressure. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 473-481.	1.4	23
1589	Biomarkers in Pulmonary Arterial Hypertension. <i>Current Heart Failure Reports</i> , 2014, 11, 477-484.	1.3	13
1590	Current and advancing treatments for pulmonary arterial hypertension in childhood. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 615-628.	1.0	2
1591	Structural and Mechanical Adaptations of Right Ventricle Free Wall Myocardium to Pressure Overload. <i>Annals of Biomedical Engineering</i> , 2014, 42, 2451-2465.	1.3	89

#	ARTICLE	IF	CITATIONS
1592	Are Hemodynamics Surrogate End Points in Pulmonary Arterial Hypertension?. <i>Circulation</i> , 2014, 130, 768-775.	1.6	46
1593	Enhanced [¹⁸ F]fluorodeoxyglucose accumulation in the right ventricular free wall predicts long-term prognosis of patients with pulmonary hypertension: a preliminary observational study. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 666-672.	0.5	59
1594	Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation. <i>European Respiratory Journal</i> , 2014, 43, 156-165.	3.1	82
1595	β ₂ -Blocker Therapy Is Not Associated With Adverse Outcomes in Patients With Pulmonary Arterial Hypertension. <i>Circulation: Heart Failure</i> , 2014, 7, 903-910.	1.6	38
1596	Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents. <i>BMC Research Notes</i> , 2014, 7, 359.	0.6	3
1597	Pathogenesis of pulmonary hypertension: a case for caveolin-1 and cell membrane integrity. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 306, H15-H25.	1.5	47
1598	Potential Applications of Pharmacogenomics to Heart Failure Therapies. <i>Heart Failure Clinics</i> , 2014, 10, 599-606.	1.0	4
1600	Utility of combining assessment of right ventricular function and right atrial remodeling as a prognostic factor for patients with pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 1269-1277.	0.7	33
1601	Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass?. <i>European Respiratory Journal</i> , 2014, 43, 1556-1559.	3.1	5
1602	Echocardiographic screening for pulmonary arterial hypertension in HIV-positive patients. <i>Infection</i> , 2014, 42, 737-741.	2.3	17
1603	Current Clinical Management of Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2014, 115, 131-147.	2.0	55
1604	Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2014, 115, 115-130.	2.0	306
1605	Right Ventricular Diastolic Performance in Children With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 491-501.	1.3	47
1606	Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. <i>Life Sciences</i> , 2014, 118, 414-419.	2.0	59
1607	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 727-740.	2.5	197
1608	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry. <i>International Journal of Cardiology</i> , 2014, 172, 561-567.	0.8	28
1609	Performance of the REVEAL pulmonary arterial hypertension prediction model using non-invasive and routinely measured parameters. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 382-387.	0.3	35
1610	Analyses of Longitudinal and of Transverse Right Ventricular Function Provide Different Clinical Information in Patients with Pulmonary Hypertension. <i>Ultrasound in Medicine and Biology</i> , 2014, 40, 1096-1103.	0.7	9

#	ARTICLE	IF	CITATIONS
1611	Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1233-1240.	0.8	12
1612	The Metabolic Basis of Pulmonary Arterial Hypertension. <i>Cell Metabolism</i> , 2014, 19, 558-573.	7.2	194
1613	Isolated Right Ventricular Dysfunction in Patients With Human Immunodeficiency Virus. <i>Journal of Cardiac Failure</i> , 2014, 20, 414-421.	0.7	21
1614	Imaging in pulmonary hypertension: Focus on the role of echocardiography. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 261-271.	0.7	33
1615	Right Ventricular to Left Ventricular Diameter Ratio at End-Systole in Evaluating Outcomes in Children with Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 172-178.	1.2	84
1616	Prognostic factors in pulmonary arterial hypertension with Dana Point group 1. <i>Life Sciences</i> , 2014, 118, 404-409.	2.0	11
1617	Pulmonary arterial hypertension in pregnancy. <i>Seminars in Perinatology</i> , 2014, 38, 289-294.	1.1	29
1618	Orphan drugs and rare diseases: a scientometric review (2000 – 2014). <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 709-724.	0.5	172
1619	Four- and Seven-Year Outcomes of Patients With Congenital Heart Disease-Associated Pulmonary Arterial Hypertension (from the REVEAL Registry). <i>American Journal of Cardiology</i> , 2014, 113, 147-155.	0.7	95
1620	Long-term Survival of Japanese Patients with Pulmonary Arterial Hypertension Treated with Beraprost Sodium, an Oral Prostacyclin Analogue. <i>Internal Medicine</i> , 2014, 53, 1913-1920.	0.3	6
1621	Role of Endothelial Nitric Oxide Synthase and Collagen Metabolism in Right Ventricular Remodeling due to Pulmonary Hypertension. <i>Circulation Journal</i> , 2014, 78, 1465-1474.	0.7	25
1623	Is there a relationship between right-ventricular and right atrial mechanics and functional capacity in hypertensive patients?. <i>Journal of Hypertension</i> , 2014, 32, 929-937.	0.3	27
1624	MRI Catheterization in Cardiopulmonary Disease. <i>Chest</i> , 2014, 145, 30-36.	0.4	33
1625	Effect of Pulmonary Arterial Hypertension-Specific Therapies on Health-Related Quality of Life. <i>Chest</i> , 2014, 146, 686-708.	0.4	43
1626	Prognostic Relevance of Pulmonary Arterial Compliance in Patients With Chronic Heart Failure. <i>Chest</i> , 2014, 145, 1064-1070.	0.4	127
1627	CT-Base Pulmonary Artery Measurement in the Detection of Pulmonary Hypertension. <i>Medicine (United States)</i> , 2014, 93, 109-114.	1.0	78
1628	Imaging the heart in pulmonary hypertension: an update. <i>European Respiratory Review</i> , 2015, 24, 653-664.	3.0	40
1629	Pulmonary hypertension trials: how can we do better?. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 551-558.	1.0	1

#	ARTICLE	IF	CITATIONS
1630	Increased Cardiac Output and Preserved Gas Exchange Despite Decreased Alveolar Surface Area in Rats Exposed to Neonatal Hyperoxia and Adult Hypoxia. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 53, 902-906.	1.4	9
1631	Development of macitentan for the treatment of pulmonary arterial hypertension. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 68-81.	1.8	7
1632	Statement on Pregnancy in Pulmonary Hypertension from the Pulmonary Vascular Research Institute. <i>Pulmonary Circulation</i> , 2015, 5, 435-465.	0.8	230
1633	Gestational Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2015, 5, 730-733.	0.8	5
1634	The Adrenergic System in Pulmonary Arterial Hypertension: Bench to Bedside (2013 Grover Conference) Tj ETQq0 0.0 rgBT /Overlock 10	0.8	16
1635	Progress in the understanding and management of pulmonary arterial hypertension. <i>Global Cardiology Science & Practice</i> , 2015, 2015, 13.	0.3	3
1636	Pulmonary arterial compliance: How and why should we measure it?. <i>Global Cardiology Science & Practice</i> , 2015, 2015, 58.	0.3	42
1637	Deformation pattern and predictive value of right ventricular longitudinal strain in children with pulmonary arterial hypertension. <i>Cardiovascular Ultrasound</i> , 2015, 14, 27.	0.5	17
1639	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , 2015, 46, 1711-1720.	3.1	39
1640	Non-invasive determination by cardiovascular magnetic resonance of right ventricular-vascular coupling in children and adolescents with pulmonary hypertension. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2015, 17, 81.	1.6	31
1641	Detection of elevated right ventricular extracellular volume in pulmonary hypertension using Accelerated and Navigator-Gated Look-Locker Imaging for Cardiac T1 Estimation (ANGIE) cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2015, 17, 110.	1.6	56
1642	Diagnosing and treating the failing right heart. <i>Current Opinion in Cardiology</i> , 2015, 30, 292-300.	0.8	27
1643	Iloprost for children with pulmonary hypertension after surgery to correct congenital heart disease. <i>Pediatric Pulmonology</i> , 2015, 50, 588-595.	1.0	8
1644	Pulmonary Hypertension an Independent Risk Factor for Death in Intensive Care Unit: Correlation of Hemodynamic Factors with Mortality. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2015, 9, CCRPM.S22199.	0.5	19
1645	The changing paradigm in pulmonary hypertension trials. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 438-445.	1.2	5
1646	Significance of obstructive sleep apnea in the patient with pulmonary hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 569-578.	1.2	9
1647	The limits of oral therapy in pulmonary arterial hypertension management. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1731.	0.9	10
1648	Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension. <i>Journal of Korean Medical Science</i> , 2015, 30, 1429.	1.1	46

#	ARTICLE	IF	CITATIONS
1649	CASE REPORTS Pottsâ€™™ shunt in a child with idiopathic pulmonary arterial hypertension â€“one-and-a-half year observation. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2015, 2, 170-172.	0.1	2
1650	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. <i>Core Evidence</i> , 2015, 10, 99.	4.7	22
1651	Prostanoid therapies in the management of pulmonary arterial hypertension. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 535.	0.9	40
1652	Relationship between Right Ventricular Longitudinal Strain, Invasive Hemodynamics, and Functional Assessment in Pulmonary Arterial Hypertension. <i>Korean Circulation Journal</i> , 2015, 45, 398.	0.7	24
1653	Elevated Plasma CXCL12 \pm Is Associated with a Poorer Prognosis in Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2015, 10, e0123709.	1.1	27
1654	Impaired Global Right Ventricular Longitudinal Strain Predicts Long-Term Adverse Outcomes in Patients with Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Imaging</i> , 2015, 23, 91.	0.8	57
1655	Serum Caveolin-1 as a Novel Biomarker in Idiopathic Pulmonary Artery Hypertension. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	17
1656	The Therapeutic Effects of Human Mesenchymal Stem Cells Primed with Sphingosine-1 Phosphate on Pulmonary Artery Hypertension. <i>Stem Cells and Development</i> , 2015, 24, 1658-1671.	1.1	39
1657	The Right Ventricle in Scleroderma (2013 Grover Conference Series). <i>Pulmonary Circulation</i> , 2015, 5, 3-14.	0.8	22
1658	Five-Year Outcomes of Patients Enrolled in the REVEAL Registry. <i>Chest</i> , 2015, 148, 1043-1054.	0.4	368
1659	Pulmonary Hemodynamics and Right Heart Catheterization. <i>Respiratory Medicine</i> , 2015, , 225-264.	0.1	0
1660	Lung function in pulmonary hypertension. <i>Respiratory Medicine</i> , 2015, 109, 1244-1249.	1.3	41
1661	Characterization of Right Ventricular Remodeling in Pulmonary Hypertension Associated With Patient Outcomes by 3-Dimensional Wall Motion Tracking Echocardiography. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	1.3	66
1662	Pulmonary Hypertension in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002253.	1.4	4
1663	Novel Targets of Drug Treatment for Pulmonary Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 225-234.	1.0	31
1664	Exercise-Induced Right Heart Disease in Athletes. <i>Respiratory Medicine</i> , 2015, , 315-335.	0.1	1
1665	Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension. <i>Heart and Vessels</i> , 2015, 30, 798-804.	0.5	8
1666	Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 627-638.	2.3	44

#	ARTICLE	IF	CITATIONS
1667	Dobutamine stress for evaluation of right ventricular reserve in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015, 45, 700-708.	3.1	66
1668	Pulmonary Arterial Hypertension. , 2015, , 313-332.		1
1669	Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?. <i>Current Hypertension Reports</i> , 2015, 17, 56.	1.5	7
1670	Echocardiographic and Hemodynamic Predictors of Survival in Precapillary Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	1.3	47
1671	Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. <i>European Heart Journal</i> , 2015, 36, 623-632.	1.0	47
1672	Pediatric Pulmonary Hypertension. <i>Circulation</i> , 2015, 132, 2037-2099.	1.6	879
1673	Toward Precision Medicine in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1272-1274.	2.5	8
1674	Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2015, 132, 2152-2161.	1.6	10
1675	Right ventricular thickness as predictor of global myocardial performance in systemic sclerosis: A Doppler tissue imaging study. <i>Indian Heart Journal</i> , 2015, 67, 521-528.	0.2	8
1676	Echocardiographic Assessment of Estimated Right Atrial Pressure and Size Predicts Mortality in Pulmonary Arterial Hypertension. <i>Chest</i> , 2015, 147, 198-208.	0.4	78
1677	HIV Protease Inhibitors in Pulmonary Hypertension: Rationale and Design of a Pilot Trial in Idiopathic Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2015, 5, 538-546.	0.8	5
1678	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1366-1375.	0.3	103
1679	Treatment of pulmonary arterial hypertension. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 566-570.	0.1	1
1680	Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015, 45, 139-149.	3.1	53
1681	The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?. <i>Respiratory Medicine</i> , 2015, 109, 557-564.	1.3	37
1682	Reference Values for Right Ventricular Strain in Patients without Cardiopulmonary Disease: A Prospective Evaluation and Meta-analysis. <i>Echocardiography</i> , 2015, 32, 787-796.	0.3	79
1683	Treating pulmonary hypertension in pediatrics. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 711-726.	0.9	16
1684	Neonatal hyperoxic lung injury favorably alters adult right ventricular remodeling response to chronic hypoxia exposure. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 308, L797-L806.	1.3	32

#	ARTICLE	IF	CITATIONS
1685	Abnormal expression of vesicular transport proteins in pulmonary arterial hypertension in monocrotaline-treated rats. <i>Acta Biochimica Et Biophysica Sinica</i> , 2015, 47, 156-163.	0.9	0
1686	Long-Term Data from the Swiss Pulmonary Hypertension Registry. <i>Respiration</i> , 2015, 89, 127-140.	1.2	72
1687	Assessment of right ventricular adaptability to loading conditions can improve the timing of listing to transplantation in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 319-328.	0.3	45
1688	A Global Perspective on the Epidemiology of Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 375-381.	0.8	32
1689	Peripheral Blood Signature of Vasodilator-Responsive Pulmonary Arterial Hypertension. <i>Circulation</i> , 2015, 131, 401-409.	1.6	72
1690	Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 437-449.	1.5	24
1691	Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 75-85.	1.1	14
1692	Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 295-313.	0.8	16
1693	Tricuspid Valve Incompetence Following Implantation of Ventricular Leads. <i>Current Heart Failure Reports</i> , 2015, 12, 150-157.	1.3	9
1694	The Sexual Dimorphism Associated with Pulmonary Hypertension Corresponds to a Fibrotic Phenotype. <i>Pulmonary Circulation</i> , 2015, 5, 184-197.	0.8	34
1695	Pressure Overload Creates Right Ventricular Diastolic Dysfunction in a Mouse Model: Assessment by Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2015, 28, 828-843.	1.2	33
1696	Right Intraventricular Dyssynchrony in Idiopathic, Heritable, and Anorexigen-Induced Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 642-652.	2.3	83
1697	Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. <i>Reproductive Toxicology</i> , 2015, 56, 45-51.	1.3	27
1698	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 338-347.	0.3	10
1699	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 348-355.	0.3	13
1700	A Novel In Vivo Approach to Assess Radial and Axial Distensibility of Large and Intermediate Pulmonary Artery Branches. <i>Journal of Biomechanical Engineering</i> , 2015, 137, 044501.	0.6	5
1701	Prediction of Future Overt Pulmonary Hypertension by 6-Min Walk Stress Echocardiography in Patients With Connective Tissue Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 376-384.	1.2	65
1702	Epidemiology and Disease Classification of Pulmonary Hypertension. <i>Respiratory Medicine</i> , 2015, , 21-35.	0.1	1

#	ARTICLE	IF	CITATIONS
1703	Outcomes of β -blocker use in pulmonary arterial hypertension: a propensity-matched analysis. <i>European Respiratory Journal</i> , 2015, 46, 750-760.	3.1	43
1704	Survival in an Incident Cohort of Patients with Pulmonary Arterial Hypertension in Denmark. <i>Pulmonary Circulation</i> , 2015, 5, 364-369.	0.8	26
1705	Use of outcome measures in pulmonary hypertension clinical trials. <i>American Heart Journal</i> , 2015, 170, 419-429.e3.	1.2	17
1706	Biomarkers and Prognostic Indicators in Pulmonary Arterial Hypertension. <i>Current Hypertension Reports</i> , 2015, 17, 556.	1.5	8
1707	Exercise-Induced Pulmonary Artery Hypertension in a Patient with Compensated Cardiac Disease: Hemodynamic and Functional Response to Sildenafil Therapy. <i>Texas Heart Institute Journal</i> , 2015, 42, 50-54.	0.1	1
1708	Trends in Pediatric Pulmonary Hypertension-Related Hospitalizations in the United States from 2000-2009. <i>Pulmonary Circulation</i> , 2015, 5, 339-348.	0.8	40
1709	Fatty Acid Metabolism in Pulmonary Arterial Hypertension: Role in Right Ventricular Dysfunction and Hypertrophy. <i>Pulmonary Circulation</i> , 2015, 5, 269-278.	0.8	73
1710	The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 56-71.	1.0	69
1711	Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2015, 170, 96-103.e14.	1.2	15
1712	Prognostic value of acute vasodilator response in pulmonary arterial hypertension: Beyond the "classical" responders. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 312-318.	0.3	17
1713	Interventional and surgical therapeutic strategies for pulmonary arterial hypertension: Beyond palliative treatments. <i>Journal of Cardiology</i> , 2015, 66, 304-314.	0.8	22
1714	Right atrial volume and reservoir function are novel independent predictors of clinical worsening in patients with pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 414-423.	0.3	41
1715	Noninvasive identification of left-sided heart failure in a population suspected of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015, 46, 422-430.	3.1	37
1716	Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertension. <i>BMC Pulmonary Medicine</i> , 2015, 15, 11.	0.8	6
1717	Molecular and clinical analysis of TRPC6 and AGTR1 genes in patients with pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 1.	1.2	80
1718	Clinical relevance of right ventricular diastolic stiffness in pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 45, 1603-1612.	3.1	132
1719	Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan. <i>Clinical Pharmacokinetics</i> , 2015, 54, 457-471.	1.6	41
1720	Abnormal Right Ventricular Relaxation in Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2015, 5, 370-375.	0.8	38

#	ARTICLE	IF	CITATIONS
1721	Exploring Noninvasive Tricuspid dP/dt as a Marker of Right Ventricular Function. <i>Echocardiography</i> , 2015, 32, 1347-1351.	0.3	13
1722	Pulmonary Arterial Hypertension. <i>Cardiology in Review</i> , 2015, 23, 33-51.	0.6	13
1723	Using Cardiac Magnetic Resonance Imaging to Evaluate Cardiac Function and Predict Outcomes in Patients with Valvular Heart Disease. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2015, 10, 63-67.	0.4	1
1724	Heart Failure and Respiratory Hospitalizations Are Reduced in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease With the Use of an Implantable Pulmonary Artery Pressure Monitoring Device. <i>Journal of Cardiac Failure</i> , 2015, 21, 240-249.	0.7	50
1725	Patent ductus arteriosus stenting for palliation of severe pulmonary arterial hypertension in childhood. <i>Cardiology in the Young</i> , 2015, 25, 350-354.	0.4	7
1726	Pulmonary hypertension and congenital heart disease: An insight from the REHAP National Registry. <i>International Journal of Cardiology</i> , 2015, 184, 717-723.	0.8	80
1727	Management of Pulmonary Hypertension and Right Heart Failure in the Intensive Care Unit. <i>Current Hypertension Reports</i> , 2015, 17, 32.	1.5	8
1728	Right Ventricular Adaptation and Failure in Pulmonary Arterial Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 391-406.	0.8	140
1729	Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus maladaptive morphology. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 395-403.	0.3	66
1730	Building the Case for Novel Clinical Trials in Pulmonary Arterial Hypertension. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 114-123.	0.9	18
1731	Assessment of Right Ventricular Function in Pulmonary Hypertension. <i>Current Hypertension Reports</i> , 2015, 17, 35.	1.5	38
1732	Balloon atrial septostomy in pulmonary arterial hypertension: Effect on survival and associated outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 376-380.	0.3	72
1733	Validation of two predictive models for survival in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015, 46, 152-164.	3.1	82
1734	Chronic thromboembolic pulmonary hypertension: the evolving treatment landscape. <i>European Respiratory Review</i> , 2015, 24, 173-177.	3.0	9
1735	Right Atrial Function in Pulmonary Arterial Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, e003521; discussion e003521.	1.3	81
1737	Renal sympathetic denervation prevents the development of pulmonary arterial hypertension and cardiac dysfunction in dogs. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 405-412.	0.8	7
1738	Mechanical Support for the Failing Right Ventricle in Patients With Precapillary Pulmonary Hypertension. <i>Circulation</i> , 2015, 132, 526-536.	1.6	50
1739	New pharmacotherapy options for pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2113-2131.	0.9	20

#	ARTICLE	IF	CITATIONS
1740	Early Decline in Six-Minute Walk Distance from the Time of Diagnosis Predicts Clinical Worsening in Pulmonary Arterial Hypertension. <i>Respiration</i> , 2015, 89, 365-373.	1.2	9
1741	Survey of restless legs syndrome in a pulmonary hypertension population. <i>Clinical Respiratory Journal</i> , 2015, 9, 98-103.	0.6	7
1743	Prognostic value of neutrophil-to-lymphocyte ratio in pulmonary arterial hypertension. <i>Journal of International Medical Research</i> , 2015, 43, 661-671.	0.4	41
1744	Riociguat for pulmonary hypertension in congenital heart disease: opportunities and challenges. <i>Heart</i> , 2015, 101, 1771-1772.	1.2	1
1745	Systemic lupus erythematosus-associated pulmonary hypertension: clinical variables and survival outcome. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 149-160.	0.3	1
1746	Left Ventricular Myocardial Function in Children With Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	1.3	45
1747	Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1345-1354.	2.5	82
1748	Pulmonary vascular resistance and compliance relationship in pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 1178-1189.	3.1	73
1749	Riociguat for the treatment of pulmonary hypertension. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 679-695.	1.0	15
1750	Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. <i>Anaesthesia</i> , 2015, 70, 56-70.	1.8	107
1751	Current Treatment Approaches to Pulmonary Arterial Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 460-477.	0.8	24
1752	Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options. <i>Clinical Research in Cardiology</i> , 2015, 104, 197-207.	1.5	50
1753	Encapsulation of beraprost sodium in nanoparticles: Analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension. <i>Journal of Controlled Release</i> , 2015, 197, 97-104.	4.8	23
1754	The Interface Between Monitoring and Physiology at the Bedside. <i>Critical Care Clinics</i> , 2015, 31, 1-24.	1.0	16
1755	Diagnosis and treatment of pulmonary hypertension. <i>Heart</i> , 2015, 101, 311-319.	1.2	9
1756	Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitor. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 329-337.	0.3	56
1757	Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. <i>European Journal of Heart Failure</i> , 2015, 17, 63-73.	2.9	20
1759	The role of nuclear imaging in pulmonary hypertension. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 141-157.	1.4	21

#	ARTICLE	IF	CITATIONS
1760	The Cardiomyopathy of Sickle Cell Disease. , 0, , .		0
1761	Prosthesis-Patient Mismatch after Mitral Valve Replacement: Comparison of Different Methods of Effective Orifice Area Calculation. Yonsei Medical Journal, 2016, 57, 328.	0.9	17
1762	Usefulness of the second heart sound for predicting pulmonary hypertension in patients with interstitial lung disease. Sao Paulo Medical Journal, 2016, 134, 34-39.	0.4	1
1763	Recent advances in the management of pulmonary arterial hypertension. F1000Research, 2016, 5, 2755.	0.8	15
1764	Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: a retrospective study. Journal of Thoracic Disease, 2016, 8, 350-358.	0.6	20
1765	Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension. Journal of Thoracic Disease, 2016, 8, E298-E304.	0.6	4
1766	Review: Hemodynamic Characteristics and Outcomes of Sickle Cell Disease Associated Pulmonary Hypertension. Ethnicity and Disease, 2016, 26, 545.	1.0	4
1767	New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension. Journal of Managed Care & Specialty Pharmacy, 2016, 22, s3-s21.	0.5	13
1768	Assessment of Right Ventricle by Echocardiogram. , 0, , .		6
1769	The effects of pulmonary hypertension on early outcomes in patients undergoing coronary artery bypass surgery. Turkish Journal of Medical Sciences, 2016, 46, 1162-1167.	0.4	2
1770	Pulmonary Hypertension and Indicators of Right Ventricular Function. Frontiers in Medicine, 2016, 3, 23.	1.2	14
1771	Lung-specific RNA interference of coupling factor 6, a novel peptide, attenuates pulmonary arterial hypertension in rats. Respiratory Research, 2016, 17, 99.	1.4	4
1772	Automated 3D Volumetry of the Pulmonary Arteries based on Magnetic Resonance Angiography Has Potential for Predicting Pulmonary Hypertension. PLoS ONE, 2016, 11, e0162516.	1.1	15
1773	Update on pharmacotherapy for pulmonary hypertension. Medical Journal of Australia, 2016, 205, 271-276.	0.8	11
1774	Belastungstests bei pulmonal-arterieller Hypertonie. Karger Kompass Pneumologie, 2016, 4, 64-76.	0.0	0
1775	Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension. Medicine (United States), 2016, 95, e2575.	0.4	12
1776	Management of heart failure in the new era. Journal of Cardiovascular Medicine, 2016, 17, 569-580.	0.6	9
1777	Echocardiographic assessment of the right ventricle: Impact of the distinctly load dependency of its size, geometry and performance. International Journal of Cardiology, 2016, 221, 1132-1142.	0.8	49

#	ARTICLE	IF	CITATIONS
1778	Right Ventricular Imaging in 25 Seconds. Investigative Radiology, 2016, 51, 379-386.	3.5	15
1779	Right Heart Hemodynamics in Pulmonary Hypertension—An Echocardiography and Catheterization Study. Circulation Journal, 2016, 80, 2019-2025.	0.7	26
1780	Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart, 2016, 102, ii67-ii85.	1.2	55
1781	Risk assessment in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 390-398.	3.0	39
1782	Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study. Journal of Neonatal-Perinatal Medicine, 2016, 9, 251-259.	0.4	20
1783	Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart, 2016, 102, ii86-ii100.	1.2	89
1784	Cause of death in Chinese Takayasu arteritis patients. Medicine (United States), 2016, 95, e4069.	0.4	41
1785	A Correlative Study of Spirometric Parameters and Markers of Right Ventricular Dysfunction in Pediatric Patients with Pulmonary Arterial Hypertension. Journal of Interdisciplinary Medicine, 2016, 1, 153-158.	0.1	1
1786	Oxidative Stress Influence in the Development of Pulmonary Arterial Hypertension. , 2016, , 213-226.		0
1787	Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, 2016, 47, 1727-1736.	3.1	124
1788	Parenteral Prostanoid Use at a Tertiary Referral Center. Chest, 2016, 149, 660-666.	0.4	10
1789	Imaging right ventricular function to predict outcome in pulmonary arterial hypertension. International Journal of Cardiology, 2016, 218, 206-211.	0.8	94
1790	Update on pulmonary arterial hypertension pharmacotherapy. Postgraduate Medicine, 2016, 128, 460-473.	0.9	21
1791	Regional contribution to ventricular stroke volume is affected on the left side, but not on the right in patients with pulmonary hypertension. International Journal of Cardiovascular Imaging, 2016, 32, 1243-1253.	0.7	20
1792	Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. , 2016, 164, 195-203.		37
1793	Echocardiographic findings associated with mortality or transplant in patients with pulmonary arterial hypertension: A systematic review and meta-analysis. Netherlands Heart Journal, 2016, 24, 374-389.	0.3	13
1794	Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 1321-1329.	0.3	28
1795	Right sided heart failure and pulmonary hypertension: New insights into disease mechanisms and treatment modalities. Progress in Pediatric Cardiology, 2016, 43, 71-80.	0.2	2

#	ARTICLE	IF	CITATIONS
1796	Prognostic value of right ventricular free wall strain in pulmonary hypertension patients with pseudo-normalized tricuspid annular plane systolic excursion values. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 905-912.	0.7	47
1797	Pulmonary hypertension in the elderly: a different disease?. <i>Breathe</i> , 2016, 12, 43-49.	0.6	29
1798	Pulmonary hypertension associated with lung diseases and hypoxemia. <i>Heart Failure Reviews</i> , 2016, 21, 299-308.	1.7	12
1799	Characteristics and survival of adult Swedish PAH and CTEPH patients 2000â€“2014. <i>Scandinavian Cardiovascular Journal</i> , 2016, 50, 243-250.	0.4	104
1800	Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study. <i>Clinical Pharmacokinetics</i> , 2016, 55, 615-624.	1.6	13
1801	Glycoprotein 130 Inhibitor Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1356.e1-1356.e10.	0.8	17
1802	Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. <i>Blood</i> , 2016, 127, 820-828.	0.6	109
1803	Prognostic Factors in Patients With Pulmonary Hypertensionâ€”A Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	32
1804	miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?. <i>Epigenomics</i> , 2016, 8, 1311-1313.	1.0	4
1805	Diastolic pulmonary gradient predicts outcomes in group 1 pulmonary hypertension (analysis of the) Tj ETQq1 1 0.784314 rgBT /Over 1.3 15		
1806	Intermittent intravenous administration of Iloprost in patients with idiopathic pulmonary arterial hypertension. <i>International Journal of the Cardiovascular Academy</i> , 2016, 2, 114-118.	0.1	2
1807	Right ventricular end-diastolic stiffness heralds right ventricular failure in monocrotaline-induced pulmonary hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H1004-H1013.	1.5	17
1808	TAPSE: An old but useful tool in different diseases. <i>International Journal of Cardiology</i> , 2016, 225, 177-183.	0.8	54
1809	Sildenafil citrate therapy for secondary pulmonary arterial hypertension due to chronic obstructive lung disease. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2016, 65, 805-809.	0.1	4
1810	Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 110.	1.0	8
1811	Contemporary diagnosis and management of pulmonary hypertension. <i>Heart</i> , 2016, 102, 1680-1691.	1.2	3
1812	Special Situations in Pulmonary Hypertension. <i>Cardiology Clinics</i> , 2016, 34, 473-487.	0.9	13
1813	A Contemporary Approach to Pulmonary Arterial Hypertension. <i>Current Atherosclerosis Reports</i> , 2016, 18, 58.	2.0	1

#	ARTICLE	IF	CITATIONS
1814	Deletion of LR11 Attenuates Hypoxia-Induced Pulmonary Arterial Smooth Muscle Cell Proliferation With Medial Thickening in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1972-1979.	1.1	8
1815	Non-invasive evaluation of pulmonary arterial blood flow and wall shear stress in pulmonary arterial hypertension with 3D phase contrast magnetic resonance imaging. <i>SpringerPlus</i> , 2016, 5, 1071.	1.2	31
1816	Group III Pulmonary Hypertension. <i>Cardiology Clinics</i> , 2016, 34, 413-433.	0.9	70
1817	Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil+Bosentan and Sildenafil+Ambrisentan Combination Therapies for Pulmonary Hypertension. <i>Clinical and Translational Science</i> , 2016, 9, 29-35.	1.5	7
1818	Correlation between Pulmonary Artery Pressure Measured by Echocardiography and Right Heart Catheterization in Patients with Rheumatic Mitral Valve Stenosis (A Prospective Study). <i>Echocardiography</i> , 2016, 33, 7-13.	0.3	19
1819	World Health Organization Group I Pulmonary Hypertension. <i>Cardiology Clinics</i> , 2016, 34, 363-374.	0.9	111
1820	Impact of Pulmonary Hemodynamics and Ventricular Interdependence on Left Ventricular Diastolic Function in Children With Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	62
1821	Left Ventricular Diastolic Dysfunction in Pediatric Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	9
1822	Echocardiography Combined With Cardiopulmonary Exercise Testing for the Prediction of Outcome in Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 150, 1313-1322.	0.4	51
1824	Prognostic Factors for Survival in Pulmonary Hypertension Due to Left Heart Disease. <i>Circulation Journal</i> , 2016, 80, 243-249.	0.7	18
1825	Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension. <i>Circulation Journal</i> , 2016, 80, 1478-1483.	0.7	8
1826	Impaired Left Ventricular Longitudinal Function in Idiopathic Pulmonary Arterial Hypertension Children. <i>Journal of Interdisciplinary Medicine</i> , 2016, 1, 146-152.	0.1	1
1827	Assessment of the Effects of Renal Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521). <i>Pulmonary Circulation</i> , 2016, 6, S15-S26.	0.8	20
1828	Effects of Age and Sex on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521). <i>Pulmonary Circulation</i> , 2016, 6, S58-S65.	0.8	10
1829	The Serotonin Transporter Promotes a Pathological Estrogen Metabolic Pathway in Pulmonary Hypertension via Cytochrome P450 1B1. <i>Pulmonary Circulation</i> , 2016, 6, 82-92.	0.8	33
1830	Socioeconomic Status Affects Pulmonary Hypertension Disease Severity at Time of First Evaluation. <i>Pulmonary Circulation</i> , 2016, 6, 191-195.	0.8	27
1831	Assessment of the Physiologic Contribution of Right Atrial Function to Total Right Heart Function in Patients with and without Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2016, 6, 322-328.	0.8	32
1832	Methods for Evaluating Right Ventricular Function and Ventricular-Arterial Coupling. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 42-51.	1.6	42

#	ARTICLE	IF	CITATIONS
1833	Preventive aerobic training exerts a cardioprotective effect on rats treated with monocrotaline. <i>International Journal of Experimental Pathology</i> , 2016, 97, 238-247.	0.6	18
1834	Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63â€2521). <i>Pulmonary Circulation</i> , 2016, 6, S5-S14.	0.8	22
1835	Pulmonary Hypertension in Children. <i>Cardiology Clinics</i> , 2016, 34, 451-472.	0.9	43
1836	Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era. <i>JAMA Cardiology</i> , 2016, 1, 1056.	3.0	99
1837	Suppression of the expression of hypoxia-inducible factor-1 β by RNA interference alleviates hypoxia-induced pulmonary hypertension in adult rats. <i>International Journal of Molecular Medicine</i> , 2016, 38, 1786-1794.	1.8	17
1838	Pulmonary Arterial Hypertension and the Sex Hormone Paradox. <i>Current Hypertension Reports</i> , 2016, 18, 84.	1.5	47
1839	Gender-related differences in pulmonary arterial hypertension targeted drugs administration. <i>Pharmacological Research</i> , 2016, 114, 103-109.	3.1	33
1840	Time to consider death in clinical trials for PAH. <i>Lancet Respiratory Medicine</i> , 2016, 4, 849-850.	5.2	1
1841	New echocardiographic indexes for evaluating cardiac function in idiopathic pulmonary arterial hypertension using three-dimensional echocardiography. <i>Acta Cardiologica</i> , 2016, 71, 359-366.	0.3	0
1842	Right heart imaging in patients with heart failure. <i>Current Opinion in Cardiology</i> , 2016, 31, 469-482.	0.8	39
1844	Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy. <i>Open Heart</i> , 2016, 3, e000408.	0.9	36
1845	Does exercise pulmonary hypertension exist?. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 400-407.	1.2	5
1846	Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosisâ€Related Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2016, 68, 740-748.	2.9	19
1847	Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 1121-1130.	0.7	18
1848	Global research trends in the medical therapy of pulmonary arterial hypertension 2000â€2014. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 39, 21-27.	1.1	2
1849	Transforming growth factor beta 1 induced endothelin-1 release is peroxisome proliferator-activated receptor gamma dependent in A549 cells. <i>Journal of Inflammation</i> , 2016, 13, 19.	1.5	1
1850	Comprehensive Functional Assessment of Rightâ€Sided Heart Using Speckle Tracking Strain for Patients with Pulmonary Hypertension. <i>Echocardiography</i> , 2016, 33, 1001-1008.	0.3	27
1852	Hemodynamic Thresholds for Precapillary Pulmonary Hypertension. <i>Chest</i> , 2016, 149, 1061-1073.	0.4	33

#	ARTICLE	IF	CITATIONS
1853	Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study. <i>Pharmacoeconomics</i> , 2016, 34, 509-520.	1.7	25
1854	Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1168-1175.	2.5	104
1855	An Update on the Management of Pulmonary Arterial Hypertension and the Pharmacist's Role. <i>Journal of Pharmacy Practice</i> , 2016, 29, 67-76.	0.5	11
1856	Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. <i>European Respiratory Journal</i> , 2016, 47, 553-563.	3.1	54
1857	Curcumin nanoparticles attenuate cardiac remodeling due to pulmonary arterial hypertension. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 1909-1916.	1.9	23
1858	The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2016, 13, 842-849.	1.5	30
1859	Screening of Mechanical Complications of Dilated Pulmonary Artery Related to the Risk for Sudden Cardiac Death in Patients with Pulmonary Arterial Hypertension by Transthoracic Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 561-566.	1.2	11
1860	Priming with ceramide-1 phosphate promotes the therapeutic effect of mesenchymal stem/stromal cells on pulmonary artery hypertension. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 35-41.	1.0	17
1861	Definition of pulmonary hypertension challenged?. <i>Nature Reviews Cardiology</i> , 2016, 13, 250-251.	6.1	9
1862	Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and meta-analysis. <i>European Radiology</i> , 2016, 26, 3771-3780.	2.3	101
1863	Levosimendan Prevents Pressure-Overload-induced Right Ventricular Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 275-282.	0.8	10
1864	Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 243-252.	2.3	97
1865	Sex Hormones, Sex, Gender, and Pulmonary Hypertension. <i>Respiratory Medicine</i> , 2016, , 105-117.	0.1	0
1866	Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways. <i>Lancet Respiratory Medicine</i> , 2016, 4, 225-236.	5.2	60
1867	Speckle-tracking imaging in patients with Eisenmenger syndrome. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 104-112.	0.7	12
1868	The right ventricle and pulmonary hypertension. <i>Heart Failure Reviews</i> , 2016, 21, 259-271.	1.7	64
1869	Treatment of pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2016, 4, 323-336.	5.2	97
1870	A global view of pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2016, 4, 306-322.	5.2	523

#	ARTICLE	IF	CITATIONS
1871	Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 760-767.	0.3	22
1872	Novel approaches to pulmonary arterial hypertension drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 407-414.	2.5	6
1873	Carfilzomib reverses pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2016, 110, 188-199.	1.8	47
1874	Patients's™, relatives's™, and practitioners's™ views of pulmonary arterial hypertension: A qualitative study. <i>Presse Medicale</i> , 2016, 45, e11-e27.	0.8	18
1875	Right heart catheterisation: indications and interpretation. <i>Heart</i> , 2016, 102, 147-157.	1.2	49
1876	Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2016, 13, 31-39.	1.5	65
1877	FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosentan in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2016, 202, 52-58.	0.8	37
1878	Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure. <i>Heart Failure Reviews</i> , 2016, 21, 323-346.	1.7	24
1879	Pulmonary hypertension due to left heart disease: The prognostic implications of diastolic pulmonary vascular pressure gradient. <i>Journal of Cardiology</i> , 2016, 67, 555-559.	0.8	30
1880	Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. <i>Heart and Vessels</i> , 2016, 31, 939-946.	0.5	51
1882	Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 86-94.	0.5	61
1883	Moderate-to-severe obstructive sleep apnea is associated with subclinical myocardial injury and impaired hemodynamics in pulmonary hypertension patients. <i>Sleep Medicine</i> , 2017, 30, 121-127.	0.8	11
1884	Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 399-406.	0.3	13
1885	Translational Advances in the Field of Pulmonary Hypertension. From Population Genetics to Precision Medicine and Gene Editing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 23-31.	2.5	32
1886	Clinical characteristics and survival of patients with pulmonary hypertension: a 40-month mean follow-up. <i>Clinical Respiratory Journal</i> , 2017, 11, 103-112.	0.6	4
1887	Exercise-based rehabilitation programmes for pulmonary hypertension. <i>The Cochrane Library</i> , 2017, CD011285.	1.5	54
1888	Molecular targets of the Warburg effect and inflammatory cytokines in the pathogenesis of pulmonary artery hypertension. <i>Clinica Chimica Acta</i> , 2017, 466, 98-104.	0.5	20
1889	COUNTERPOINT: Should Wireless Pulmonary Artery Hemodynamic Monitoring Be Used to Monitor Patients With Pulmonary Hypertension? <i>No. Chest</i> , 2017, 152, 16-18.	0.4	2

#	ARTICLE	IF	CITATIONS
1890	POINT: Should Wireless Pulmonary Artery Hemodynamic Monitoring Be Used to Monitor Patients With Pulmonary Hypertension? Yes. <i>Chest</i> , 2017, 152, 13-15.	0.4	1
1891	Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 509-519.	0.3	22
1892	Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2017, 230, 53-58.	0.8	32
1893	Endocardial Device Leads in Patients with Patent Foramen Ovale: Echocardiographic Correlates of Stroke/TIA and Mortality. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 310-322.	0.5	2
1894	Targeting the NO-sGC-cGMP Pathway in Pulmonary Arterial Hypertension. , 2017, , 139-151.		2
1895	Obesity paradox in group 1 pulmonary hypertension: analysis of the NIH-Pulmonary Hypertension registry. <i>International Journal of Obesity</i> , 2017, 41, 1164-1168.	1.6	27
1896	Mechanism and prognostic role of qR in V 1 in patients with pulmonary arterial hypertension. <i>Journal of Electrocardiology</i> , 2017, 50, 476-483.	0.4	27
1897	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 957-967.	0.3	221
1898	Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2017, 119, 1479-1484.	0.7	56
1899	Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. <i>Arthritis Research and Therapy</i> , 2017, 19, 42.	1.6	67
1900	Epoprostenol and pulmonary arterial hypertension: 20+ years of clinical experience. <i>European Respiratory Review</i> , 2017, 26, 160055.	3.0	70
1901	The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 491-503.	1.0	55
1902	Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: observations from the PHAROS cohort. <i>Respirology</i> , 2017, 22, 1386-1392.	1.3	7
1903	Pulmonary Hypertension in Infants, Children, and Young Adults. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2551-2569.	1.2	128
1904	A reappraisal of the mechanisms underlying the cardiac complications of sickle cell anemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26607.	0.8	8
1905	Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). <i>Respiratory Medicine</i> , 2017, 126, 84-92.	1.3	15
1906	Direct bilirubin: A new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2017, 228, 895-899.	0.8	28
1907	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 717-726.	5.2	99

#	ARTICLE	IF	CITATIONS
1908	Pulmonary Hypertension and Precision Medicine through the "Omics" Looking Glass. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1558-1560.	2.5	5
1909	Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension. Lung, 2017, 195, 489-496.	1.4	24
1910	Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension. Scientific Reports, 2017, 7, 1923.	1.6	16
1911	Identifying "super responders" in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 300-311.	0.8	19
1912	The continuing challenge of evaluating diastolic function by echocardiography in children. Current Opinion in Cardiology, 2017, 32, 93-100.	0.8	30
1913	Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 448-454.	0.8	8
1914	Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension. Pulmonary Circulation, 2017, 7, 572-587.	0.8	15
1915	Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension. Pulmonary Circulation, 2017, 7, 20-37.	0.8	33
1916	Pulmonary Hypertension in Women: What Does the Cardiologist Need to Know?. Current Cardiovascular Risk Reports, 2017, 11, 1.	0.8	1
1917	Epidemiology and treatment of pulmonary arterial hypertension. Nature Reviews Cardiology, 2017, 14, 603-614.	6.1	310
1918	Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	72
1919	Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina. Journal of the American College of Cardiology, 2017, 69, 2808-2817.	1.2	91
1920	Pulmonary Hypertension in Pregnancy. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 148-159.	0.8	14
1921	<i>In vivo</i> Endocrine Secretion of Prostacyclin Following Expression of a Cyclooxygenase-1/Prostacyclin Fusion Protein in the Salivary Glands of Rats Via Nonviral Gene Therapy. Human Gene Therapy, 2017, 28, 681-689.	1.4	3
1922	Echocardiographic Predictors for Worsening of Six-Minute Walk Distances in Patients With Systemic Sclerosis (Scleroderma). American Journal of Cardiology, 2017, 120, 315-321.	0.7	6
1923	A systematic review of transition studies of pulmonary arterial hypertension specific medications. Pulmonary Circulation, 2017, 7, 326-338.	0.8	22
1924	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulmonary Circulation, 2017, 7, 312-325.	0.8	37
1925	Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival. Pulmonary Circulation, 2017, 7, 465-475.	0.8	4

#	ARTICLE	IF	CITATIONS
1926	Learning a Comorbidity-Driven Taxonomy of Pediatric Pulmonary Hypertension. <i>Circulation Research</i> , 2017, 121, 341-353.	2.0	21
1927	Follow-up tricuspid annular plane systolic excursion predicts survival in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 361-371.	0.8	52
1928	From the Cover: Mechanistic Insights in Cytotoxic and Cholestatic Potential of the Endothelial Receptor Antagonists Using HepaRG Cells. <i>Toxicological Sciences</i> , 2017, 157, 451-464.	1.4	15
1929	Critical care management of pulmonary hypertension. <i>BJA Education</i> , 2017, 17, 228-234.	0.6	16
1930	What are the side effects? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2017, 240, 386-391.	0.8	6
1932	Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 228-239.	2.5	122
1933	Right ventricular free wall longitudinal speckle tracking strain in patients with pulmonary arterial hypertension under specific treatment. <i>Echocardiography</i> , 2017, 34, 530-536.	0.3	12
1934	Maximal systolic excursion of the tricuspid annulus is independent of right atrial size and function in chronic pulmonary hypertension. <i>Echocardiography</i> , 2017, 34, 810-816.	0.3	2
1935	Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. <i>Heart and Vessels</i> , 2017, 32, 969-976.	0.5	10
1936	Real-world, long-term survival of incident patients with pulmonary arterial hypertension. <i>Revista Portuguesa De Pneumologia</i> , 2017, 23, 124-131.	0.7	9
1937	Effects of reduction of pressure overload on right ventricular function in patients with Eisenmenger syndrome. <i>Journal of Cardiology</i> , 2017, 69, 739-740.	0.8	0
1938	Midterm Effect of Balloon Pulmonary Angioplasty on Hemodynamics and Subclinical Myocardial Damage in Chronic Thromboembolic Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2017, 33, 463-470.	0.8	22
1939	Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Use in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 467-473.	0.4	4
1940	A simple hemodynamic parameter to predict clinical worsening in pulmonary arterial hypertension. <i>Journal of Critical Care</i> , 2017, 38, 324-327.	1.0	2
1941	Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension. <i>Internal and Emergency Medicine</i> , 2017, 12, 319-326.	1.0	11
1942	Pulmonary Hypertension and Thrombembolism: Long-Term Management and Chronic Oral Anticoagulation. <i>Physician Assistant Clinics</i> , 2017, 2, 727-741.	0.1	0
1944	Differences in right ventricular morphology, not function, indicate the nature of increased afterload in pulmonary hypertensive subjects with normal left ventricular function. <i>Echocardiography</i> , 2017, 34, 1584-1592.	0.3	16
1945	The Nitric Oxide Pathway: A Potential Target for Precision Medicine in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2017, 120, S69-S70.	0.7	3

#	ARTICLE	IF	CITATIONS
1946	Lung Transplantation for Pulmonary Hypertension and Strategies to Bridge to Transplant. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 701-710.	0.8	5
1947	Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 606-618.	0.8	5
1948	Pulmonary Hypertension Due to Left Heart Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 662-676.	0.8	1
1949	Medical Treatment of Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 686-700.	0.8	9
1950	Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, e32-e47.	2.5	36
1952	Treatment strategies for the right heart in pulmonary hypertension. <i>Cardiovascular Research</i> , 2017, 113, 1465-1473.	1.8	55
1953	Right atrial function and prognosis in idiopathic pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2017, 248, 320-325.	0.8	35
1954	Biomechanical and Hemodynamic Measures of Right Ventricular Diastolic Function: Translating Tissue Biomechanics to Clinical Relevance. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	38
1957	Decreased pulmonary arterial proportional pulse pressure is associated with increased mortality in group 1 pulmonary hypertension. <i>Clinical Cardiology</i> , 2017, 40, 988-992.	0.7	5
1958	Echocardiographic Pulmonary Hypertension Predicts Post-transplantation Renal Allograft Failure. <i>Transplantation Proceedings</i> , 2017, 49, 1256-1261.	0.3	12
1959	Incremental value of right atrial strain for early diagnosis of hemodynamic deterioration in pulmonary hypertension. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 866-874.	0.6	4
1960	Docetaxel Reverses Pulmonary Vascular Remodeling by Decreasing Autophagy and Resolves Right Ventricular Fibrosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 20-34.	1.3	15
1961	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1700889.	3.1	527
1962	Multi-view approach for the diagnosis of pulmonary hypertension using transthoracic echocardiography. <i>International Journal of Cardiovascular Imaging</i> , 2017, 34, 695-700.	0.7	13
1963	Right Atrial Deformation in Predicting Outcomes in Pediatric Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	41
1964	Access and Barriers to Utilization of Palliative Care in Pediatric Pulmonary Hypertension. <i>Journal of Hospice and Palliative Nursing</i> , 2017, 19, 474-479.	0.5	2
1965	Cyp2c44-mediated decrease of 15-HETE exacerbates pulmonary hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 313, H251-H255.	1.5	1
1966	Potts shunt in children with pulmonary arterial hypertension: institutional experience. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 25, 595-599.	0.5	11

#	ARTICLE	IF	CITATIONS
1967	Idiopathic Pulmonary Arterial Hypertension in Children: A Review. <i>Pulmonary Therapy</i> , 2017, 3, 67-92.	1.1	2
1968	The protective role of oestradiol against silent myocardial ischemia and hypertension risk in South African men: The SABPA study. <i>International Journal of Cardiology</i> , 2017, 244, 43-48.	0.8	5
1969	Role of P2X7R in the development and progression of pulmonary hypertension. <i>Respiratory Research</i> , 2017, 18, 127.	1.4	31
1970	Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2017, 19, 122.	1.6	53
1971	TSP1â€“CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction. <i>Cardiovascular Research</i> , 2017, 113, 15-29.	1.8	58
1972	Speckle-Tracking Echocardiographic Measures of Right Ventricular Diastolic Function Correlate with Reference Standard Measures Before and After Preload Alteration in Children. <i>Pediatric Cardiology</i> , 2017, 38, 27-35.	0.6	8
1973	Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. <i>Respirology</i> , 2017, 22, 372-377.	1.3	12
1974	Diagnostics in Children and Adolescents with Suspected or Confirmed Pulmonary Hypertension. <i>Paediatric Respiratory Reviews</i> , 2017, 23, 3-15.	1.2	8
1975	The Swan-Ganz Catheter Remains a Critically Important Component of Monitoring in Cardiovascular Critical Care. <i>Canadian Journal of Cardiology</i> , 2017, 33, 142-147.	0.8	11
1976	Acute effect of iloprost inhalation on right atrial function and ventricular dyssynchrony in patients with pulmonary artery hypertension. <i>Echocardiography</i> , 2017, 34, 53-60.	0.3	13
1977	Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome. <i>Journal of Cardiology</i> , 2017, 69, 741-746.	0.8	23
1978	Diagnostic and prognostic value of right ventricular strain in patients with pulmonary arterial hypertension and relatively preserved functional capacity studied with echocardiography and magnetic resonance. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 39-46.	0.7	33
1979	Native T1 mapping and extracellular volume fraction measurement for assessment of right ventricular insertion point and septal fibrosis in chronic thromboembolic pulmonary hypertension. <i>European Radiology</i> , 2017, 27, 1980-1991.	2.3	47
1980	Assessment of right ventricular metabolism: An emerging tool for monitoring pulmonary artery hypertension. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 1990-1993.	1.4	2
1981	Unravelling cardiovascular disease using four dimensional flow cardiovascular magnetic resonance. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1069-1081.	0.7	26
1982	Right ventricular recovery after bilateral lung transplantation for pulmonary arterial hypertensionâ€. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 24, 890-897.	0.5	42
1983	Advanced pulmonary arterial hypertension: mechanical support and lung transplantation. <i>European Respiratory Review</i> , 2017, 26, 170089.	3.0	23
1984	Palliative care in pulmonary arterial hypertension. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 7-11.	0.5	12

#	ARTICLE	IF	CITATIONS
1985	Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension. <i>Circulation Journal</i> , 2017, 81, 1360-1367.	0.7	19
1986	Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, S3-S4.	0.5	1
1987	Emerging Metabolic Therapies in Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2017, 6, 43.	1.0	40
1988	Gender, Estrogen, and Obliterative Lesions in the Lung. <i>International Journal of Endocrinology</i> , 2017, 2017, 1-13.	0.6	11
1989	Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 1195-1207.	2.0	25
1990	Natural reversal of pulmonary vascular remodeling and right ventricular remodeling in SU5416/hypoxia-treated Sprague-Dawley rats. <i>PLoS ONE</i> , 2017, 12, e0182551.	1.1	14
1991	Accuracy of echocardiographic indices for serial monitoring of right ventricular systolic function in patients with precapillary pulmonary hypertension. <i>PLoS ONE</i> , 2017, 12, e0187806.	1.1	7
1992	Lung and heart-lung transplantation in pulmonary arterial hypertension. <i>PLoS ONE</i> , 2017, 12, e0187811.	1.1	11
1993	Prevalence and etiologies of pulmonary hypertension in Africa: a systematic review and meta-analysis. <i>BMC Pulmonary Medicine</i> , 2017, 17, 183.	0.8	25
1994	Atrial volume and function during exercise in health and disease. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 19, 104.	1.6	25
1995	Right ventricular functional analysis utilizing first pass radionuclide angiography for pre-operative ventricular assist device planning: a multi-modality comparison. <i>Journal of Cardiothoracic Surgery</i> , 2017, 12, 89.	0.4	5
1996	Changing face of pulmonary arterial hypertension in Canada. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2017, 1, 242-252.	0.2	5
1998	Intravascular hemolysis and the pathophysiology of sickle cell disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 750-760.	3.9	435
1999	Nitric oxide and pulmonary arterial hypertension. <i>Global Cardiology Science & Practice</i> , 2017, 2017, 14.	0.3	30
2000	A genome-wide association analysis identifies PDE1A DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population. <i>Oncotarget</i> , 2017, 8, 74917-74926.	0.8	15
2001	Pulmonary hypertension: diagnosis, imaging techniques, and novel therapies. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 405-417.	0.7	19
2002	Presence of Kidney Disease as an Outcome Predictor in Patients with Pulmonary Arterial Hypertension. <i>American Journal of Nephrology</i> , 2018, 47, 134-143.	1.4	21
2003	The success of pulmonary hypertension treatment: improved cardiac function by reducing the arterial load. <i>Pulmonary Circulation</i> , 2018, 8, 1-2.	0.8	0

#	ARTICLE	IF	CITATIONS
2004	Evaluation of the right ventricle by echocardiography: particularities and major challenges. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 259-275.	0.6	27
2005	Pulmonary hypertension in chronic hemolytic anemias: Pathophysiology and treatment. <i>Respiratory Medicine</i> , 2018, 137, 191-200.	1.3	16
2006	Pulmonary hypertension: Real-world data from a Portuguese expert referral centre. <i>Pulmonology</i> , 2018, 24, 231-240.	1.0	8
2007	Analysis of Right Ventricular Myocardial Stiffness and Relaxation Components in Children and Adolescents With Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	7
2008	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. <i>European Respiratory Review</i> , 2018, 27, 180004.	3.0	21
2009	Depression and Anxiety in Patients With Pulmonary Hypertension: The Role of Life Satisfaction and Optimism. <i>Psychosomatics</i> , 2018, 59, 575-583.	2.5	21
2010	Strengths and weaknesses of echocardiography for the diagnosis of pulmonary hypertension. <i>International Journal of Cardiology</i> , 2018, 263, 177-183.	0.8	25
2011	Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 51, 1702310.	3.1	79
2012	Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001887.	1.6	104
2013	Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 137, e578-e622.	1.6	503
2014	Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study. <i>European Journal of Cardiovascular Nursing</i> , 2018, 17, 612-618.	0.4	4
2015	Sex differences in hemodynamic responses and long-term survival to optimal medical therapy in patients with pulmonary arterial hypertension. <i>Heart and Vessels</i> , 2018, 33, 939-947.	0.5	18
2016	Percutaneous Mechanical Circulation Support Combined with Extracorporeal Membrane Oxygenation (oxyRVAD) in Secondary Right Heart Failure. <i>ASAIO Journal</i> , 2018, 64, e64-e67.	0.9	9
2017	Right atrial function in patients with pulmonary hypertension: A study with two-dimensional speckle-tracking echocardiography. <i>International Journal of Cardiology</i> , 2018, 255, 200-205.	0.8	19
2018	Comparison of thermodilution and indirect Fick cardiac outputs in pulmonary hypertension. <i>International Journal of Cardiology</i> , 2018, 258, 228-231.	0.8	12
2019	Surrogate Endpoints for Pulmonary Hypertension Management and Trial Design. <i>Journal of the American College of Cardiology</i> , 2018, 71, 764-765.	1.2	1
2020	Defining the molecular signatures of human right heart failure. <i>Life Sciences</i> , 2018, 196, 118-126.	2.0	23
2021	Assessing Prognosis of Pulmonary Arterial Hypertension in the Therapeutic Era. <i>Circulation</i> , 2018, 137, 705-706.	1.6	5

#	ARTICLE	IF	CITATIONS
2022	Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy. <i>Pulmonary Circulation</i> , 2018, 8, 1-8.	0.8	5
2023	Multiparametric Magnetic Resonance Imaging in the Assessment of Pulmonary Hypertension: Initial Experience of a One-Stop Study. <i>Lung</i> , 2018, 196, 165-171.	1.4	3
2024	Mechanisms of right heart disease in pulmonary hypertension (2017 Grover Conference Series). <i>Pulmonary Circulation</i> , 2018, 8, 1-6.	0.8	11
2025	Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim) <i>Tj ETQq1 1 0.784314rgBT /Overlock 1</i>		
2026	Marked edema of colonic stoma after colectomy and severe pulmonary hypertension: Report of two cases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, e1-e4.	0.7	1
2027	The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 860-868.	2.5	45
2028	Current and emerging imaging techniques in the diagnosis and assessment of pulmonary hypertension. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 145-160.	1.0	7
2029	Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 12-17.	0.6	16
2030	Selective improvement of pulmonary arterial hypertension with a dual ET_A/ET_B receptors antagonist in the apolipoprotein E^{âˆ’/âˆ’} model of PAH and atherosclerosis. <i>Pulmonary Circulation</i> , 2018, 8, 1-11.	0.8	8
2031	Prognostic Value of Right Ventricular Strain Using Speckle-Tracking Echocardiography in Pulmonary Hypertension: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1069-1078.	0.8	54
2032	Quantitation of Perfused Lung Volume Using Hybrid SPECT/CT Allows Refining the Assessment of Lung Perfusion and Estimating Disease Extent in Chronic Thromboembolic Pulmonary Hypertension. <i>Clinical Nuclear Medicine</i> , 2018, 43, e170-e177.	0.7	24
2033	Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-8.	0.8	23
2034	Selection of Candidates for Lung Transplantation and Controversial Issues. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 117-125.	0.8	8
2035	Effect of 6-min Walk Test on pro-BNP Levels in Patients with Pulmonary Arterial Hypertension. <i>Lung</i> , 2018, 196, 315-319.	1.4	5
2036	Fluid challenge predicts clinical worsening in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2018, 261, 167-171.	0.8	18
2037	Rapid Inpatient Titration of Intravenous Treprostinil for Pulmonary Arterial Hypertension: Safe and Tolerable. <i>American Journal of Therapeutics</i> , 2018, 25, e213-e217.	0.5	8
2038	Impact of Pulmonary Capillary Wedge Pressure on Long-Term Mortality in Patients With Pulmonary Arterial Hypertension Treated With Parenteral Treprostinil. <i>Heart Lung and Circulation</i> , 2018, 27, 183-189.	0.2	2
2039	Pharmacologic stress myocardial perfusion imaging in patients with pulmonary hypertension: What do we know, and what remains to be learned?. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 828-832.	1.4	0

#	ARTICLE	IF	CITATIONS
2040	Validation of impedance cardiography in pulmonary arterial hypertension. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 254-260.	0.5	12
2041	Discriminatory ability of right atrial volumes with two- and three-dimensional echocardiography to detect elevated right atrial pressure in pulmonary hypertension. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 192-199.	0.5	4
2042	A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 4175-4181.	1.0	389
2043	The Association of Functional Capacity With Right Atrial Deformation in Patients With Pulmonary Arterial Hypertension: A Study With Two-Dimensional Speckle Tracking. <i>Heart Lung and Circulation</i> , 2018, 27, 350-358.	0.2	16
2044	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 137, 693-704.	1.6	155
2045	Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS study. <i>Pulmonary Circulation</i> , 2018, 8, 1-13.	0.8	10
2046	Y Not? Sex Chromosomes May Modify Sexual Dimorphism in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 858-859.	2.5	2
2047	Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. <i>Heart Lung and Circulation</i> , 2018, 27, 1368-1375.	0.2	26
2048	Ethnicity in Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 153, 310-320.	0.4	24
2049	Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 509-516.	2.5	145
2050	Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies. <i>Pulmonary Circulation</i> , 2018, 8, 1-9.	0.8	21
2051	Left ventricular end-diastolic dimension and septal $e\text{a}^2$ are predictors of cardiac index at rest, while tricuspid annular plane systolic excursion is a predictor of peak oxygen uptake in patients with pulmonary hypertension. <i>Heart and Vessels</i> , 2018, 33, 521-528.	0.5	8
2052	Pulmonary Hypertension in Patients for Transcatheter and Surgical Aortic Valve Replacement: A Focus on Outcomes and Perioperative Management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 2005-2018.	0.6	4
2053	Novel imaging techniques in pulmonary hypertension. <i>Current Opinion in Cardiology</i> , 2018, 33, 587-593.	0.8	5
2054	Key topics in pulmonary vascular diseases (assembly 13) from the European Respiratory Society 2018 Parisian Congress. <i>Journal of Thoracic Disease</i> , 2018, 10, S3029-S3033.	0.6	1
2055	Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1079-1088.	0.8	9
2056	Hemodynamics of the Right Heart in Health and Disease. , 2018, , 497-507.		1
2057	OBSOLETE: Hemodynamics of the Right Heart in Health and Disease. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
2058	OBSOLETE: Pulmonary Hypertension. , 2018, , .		0
2059	Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review. Canadian Respiratory Journal, 2018, 2018, 1-12.	0.8	7
2060	Clinical Utility and Prognostic Value of Right Atrial Function in Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2018, 11, e006984.	1.3	59
2061	A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. Drug Delivery, 2018, 25, 1898-1909.	2.5	15
2062	Safety, Tolerability, and Pharmacokinetics of NK-104-NP. International Heart Journal, 2018, 59, 1015-1025.	0.5	18
2063	Right heart size and function significantly correlate in patients with pulmonary arterial hypertension â€” a cross-sectional study. Respiratory Research, 2018, 19, 216.	1.4	11
2064	Rare Cardiac Emergencies: Aortic Dissection, Pulmonary Hypertensive Crisis, and Pulmonary Embolism. Clinical Pediatric Emergency Medicine, 2018, 19, 373-380.	0.4	1
2065	Potts Shunt Improves Right Ventricular Function and Coupling With Pulmonary Circulation in Children With Suprasystemic Pulmonary Arterial Hypertension. Circulation: Cardiovascular Imaging, 2018, 11, e007964.	1.3	40
2066	Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: A nationwide study based on the health insurance review and assessment service database. PLoS ONE, 2018, 13, e0209148.	1.1	22
2067	Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 78.	1.6	34
2068	Vascular Diseases. , 2018, , 98-126.e1.		1
2069	Anxiety and depression in patients with pulmonary hypertension: impact and management challenges. Vascular Health and Risk Management, 2018, Volume 14, 349-360.	1.0	48
2070	Classification and pathophysiology of pulmonary hypertension. Continuing Cardiology Education, 2018, 4, 2-12.	0.4	29
2071	Reversal of pulmonary arterial hypertension in POEMS syndrome with thalidomide: a case report. European Heart Journal - Case Reports, 2018, 2, yty051.	0.3	0
2072	An update on the diagnosis and management of bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension. Seminars in Perinatology, 2018, 42, 432-443.	1.1	52
2074	Safe and effective exercise training for patients with pulmonary arterial hypertension: putting current evidence into clinical practice. Expert Review of Respiratory Medicine, 2018, 12, 965-977.	1.0	5
2075	Lessons from pulmonary hypertension registries. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 759-761.	0.2	0
2076	Lung Transplantation in Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD). Current Pulmonology Reports, 2018, 7, 160-168.	0.5	2

#	ARTICLE	IF	CITATIONS
2077	Effects of Bcl-2/Bcl-xL Inhibitors on Pulmonary Artery Smooth Muscle Cells. <i>Antioxidants</i> , 2018, 7, 150.	2.2	10
2078	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 52, 1800678.	3.1	60
2079	Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricularâ€Pulmonary Arterial Coupling. <i>Lung</i> , 2018, 196, 745-753.	1.4	21
2080	When REVEAL meets AMBITION, does it reveal more?. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1397-1398.	0.3	0
2081	How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders. <i>Blood</i> , 2018, 132, 1770-1780.	0.6	16
2082	The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension. <i>Frontiers in Physiology</i> , 2018, 9, 1167.	1.3	28
2083	Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1410-1417.	0.3	15
2084	Lessons from pulmonary hypertension registries. <i>Revista Portuguesa De Cardiologia</i> , 2018, 37, 759-761.	0.2	1
2085	Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-9.	0.8	5
2086	Noninvasive Prediction of Pulmonary Hypertension Based on Finite Element Analysis and Machine Learning. , 2018, , .		0
2087	Clinical Use of Pediatric Bosentan in Japanese Children with Pulmonary Arterial Hypertension: Investigation of Efficacy, Pharmacokinetics, Safety, and Tolerability. <i>Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery</i> , 2018, 34, 22-29.	0.0	0
2088	Dart to the target: an alternative bullâ€™s eye parametric display for European Society of Cardiology / European Respiratory Society goalâ€™orientated risk reduction strategy in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-7.	0.8	3
2089	Right ventricle performances with echocardiography and ^{99m} Tc myocardial perfusion imaging in pulmonary arterial hypertension patients. <i>Experimental Biology and Medicine</i> , 2018, 243, 754-761.	1.1	5
2090	A disease looking for innovative drugs: The case of pulmonary arterial hypertension. <i>European Journal of Internal Medicine</i> , 2018, 55, 47-51.	1.0	3
2091	Basic Aspects of Cardiac Remodelling. , 2018, , 91-144.		1
2092	Atrial arrhythmias are associated with increased mortality in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-9.	0.8	32
2093	Pulmonary Arterial Hypertension. <i>Heart Failure Clinics</i> , 2018, 14, 255-269.	1.0	56
2094	Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	26

#	ARTICLE	IF	CITATIONS
2095	Behavior of right atrial strain in high systolic pulmonary artery pressure. <i>Echocardiography</i> , 2018, 35, 1557-1563.	0.3	4
2096	Multiscale structure-function relationships in right ventricular failure due to pressure overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H699-H708.	1.5	15
2097	Analysis of the microRNA signature driving adaptive right ventricular hypertrophy in an ovine model of congenital heart disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H847-H854.	1.5	15
2099	Process Research for (+)-Ambrisentan, an Endothelin-A Receptor Antagonist. <i>Organic Process Research and Development</i> , 2018, 22, 1200-1207.	1.3	3
2100	Increased Drp1-Mediated Mitochondrial Fission Promotes Proliferation and Collagen Production by Right Ventricular Fibroblasts in Experimental Pulmonary Arterial Hypertension. <i>Frontiers in Physiology</i> , 2018, 9, 828.	1.3	59
2101	Pulmonary Arterial Stiffness: An Early and Pervasive Driver of Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2018, 5, 204.	1.2	34
2102	A pilot randomised controlled trial investigating a mindfulness-based stress reduction (MBSR) intervention in individuals with pulmonary arterial hypertension (PAH): the PATHWAYS study. <i>Pilot and Feasibility Studies</i> , 2018, 4, 78.	0.5	14
2103	Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children. <i>Children</i> , 2018, 5, 44.	0.6	15
2104	CSI position statement on management of heart failure in India. <i>Indian Heart Journal</i> , 2018, 70, S1-S72.	0.2	18
2105	Left ventricular torsion rate and the relation to right ventricular function in pediatric pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-10.	0.8	10
2106	Platelet activation markers in children with congenital heart disease associated with pulmonary arterial hypertension. <i>Congenital Heart Disease</i> , 2018, 13, 506-511.	0.0	16
2107	Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-9.	0.8	17
2108	The importance of right ventricular function in patients with pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 809-815.	1.0	4
2109	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 790-794.	1.0	5
2110	Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e15-e43.	2.5	220
2111	Risk stratification in pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 407-415.	1.2	18
2112	Hepatic safety of ambrisentan alone and in combination with tadalafil: a post hoc analysis of the AMBITION trial. <i>Pulmonary Circulation</i> , 2018, 8, 1-8.	0.8	4
2113	Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials. <i>Pulmonary Circulation</i> , 2018, 8, 1-11.	0.8	6

#	ARTICLE	IF	CITATIONS
2114	Acute biventricular hemodynamic effects of cardiac resynchronization therapy in right bundle branch block. <i>Heart Rhythm</i> , 2018, 15, 1525-1532.	0.3	10
2115	Primary and Secondary Pulmonary Hypertension. , 2018, , 285-314.		0
2116	Inhaled Vasodilators in Right Heart Failure. , 2018, , 657-677.		0
2117	Hypertrophy and Dilatation, Markers of Dysfunction. , 2018, , 179-201.		0
2118	Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2018, 266, 229-235.	0.8	154
2119	Prognostic relevance of elevated pulmonary arterial pressure assessed non-invasively: Analysis in a large patient cohort with invasive measurements in near temporal proximity. <i>PLoS ONE</i> , 2018, 13, e0191206.	1.1	3
2120	Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. <i>PLoS ONE</i> , 2018, 13, e0191869.	1.1	17
2121	Inhalation of repurposed drugs to treat pulmonary hypertension. <i>Advanced Drug Delivery Reviews</i> , 2018, 133, 34-44.	6.6	14
2122	Analysis of Outcomes in Lung Transplantation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2019, 33, 1455-1466.	0.6	16
2123	Childhood Pulmonary Arterial Hypertension. , 2019, , 556-579.e4.		0
2124	Increased Pulmonary-Systemic Pulse Pressure Ratio Is Associated With Increased Mortality in Group 1 Pulmonary Hypertension. <i>Heart Lung and Circulation</i> , 2019, 28, 1059-1066.	0.2	3
2125	Downregulation of miRâ€™98 contributes to hypoxic pulmonary hypertension by targeting ALK1. <i>Molecular Medicine Reports</i> , 2019, 20, 2167-2176.	1.1	7
2126	Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients. <i>PLoS ONE</i> , 2019, 14, e0220490.	1.1	17
2127	Screening for pulmonary arterial hypertension in systemic sclerosis. <i>European Respiratory Review</i> , 2019, 28, 190023.	3.0	59
2128	Vena cava backflow and right ventricular stiffness in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019, 54, 1900625.	3.1	25
2129	Add-on parenteral therapy in pulmonary arterial hypertension: The good, the bad, and the ugly. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1003-1005.	0.3	1
2130	Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice. <i>Advances in Therapy</i> , 2019, 36, 2351-2363.	1.3	14
2131	Heart Rhythm Complexity Impairment in Patients with Pulmonary Hypertension. <i>Scientific Reports</i> , 2019, 9, 10710.	1.6	15

#	ARTICLE	IF	CITATIONS
2132	Right Ventricular Involution: Big Changes in Small Hearts. <i>Journal of Surgical Research</i> , 2019, 243, 255-264.	0.8	1
2133	Heart rate variability in pulmonary hypertension with and without sleep apnea. <i>Heliyon</i> , 2019, 5, e02034.	1.4	2
2134	Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling. <i>European Respiratory Journal</i> , 2019, 54, 1802400.	3.1	25
2135	Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil. <i>IJC Heart and Vasculature</i> , 2019, 25, 100373.	0.6	4
2136	Impact of right ventricular dyssynchrony on prognosis of patients with idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-9.	0.8	8
2137	The feasibility of contrast echocardiography in the assessment of right ventricular size and function. <i>Echocardiography</i> , 2019, 36, 1979-1988.	0.3	2
2138	Selexipag in the management of pulmonary arterial hypertension: an update. <i>Drug, Healthcare and Patient Safety</i> , 2019, Volume 11, 55-64.	1.0	8
2139	Is there a role for prostanoid-mediated inhibition of IL-6 signalling in the management of pulmonary arterial hypertension?. <i>Biochemical Society Transactions</i> , 2019, 47, 1143-1156.	1.6	8
2140	15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation. <i>Clinical Hypertension</i> , 2019, 25, 22.	0.7	7
2141	Safety and Efficacy of Ambrisentan Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice. <i>Circulation Reports</i> , 2019, 1, 268-275.	0.4	2
2142	Malignant cough syncope palliation- on a shoe string budget. <i>IJH Cardiovascular Case Reports (CVCR)</i> , 2019, 3, 62-64.	0.0	0
2143	Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 99-105.	1.0	10
2144	Palliative Care Issues in Pulmonary Arterial Hypertension #367. <i>Journal of Palliative Medicine</i> , 2019, 22, 220-222.	0.6	5
2145	MiR-449a-5p mediates mitochondrial dysfunction and phenotypic transition by targeting Myc in pulmonary arterial smooth muscle cells. <i>Journal of Molecular Medicine</i> , 2019, 97, 409-422.	1.7	29
2146	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005095.	0.9	8
2147	The role of extracorporeal life support in the management with severe idiopathic pulmonary artery hypertension undergoing lung transplantation: are those patients referred too late?. <i>Journal of Thoracic Disease</i> , 2019, 11, S929-S937.	0.6	6
2148	Dynamic right ventricular pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-10.	0.8	36
2149	Galectin-3 Mediates Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension. , 2019, 10, 731.		18

#	ARTICLE	IF	CITATIONS
2151	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. <i>Pulmonary Circulation</i> , 2019, 9, 204589401985169.	0.8	7
2152	Right ventricular-vascular coupling ratio in pediatric pulmonary arterial hypertension: A comparison between cardiac magnetic resonance and right heart catheterization measurements. <i>International Journal of Cardiology</i> , 2019, 293, 211-217.	0.8	16
2153	Mesenchymal stem/stromal cell therapy for pulmonary arterial hypertension: Comprehensive review of preclinical studies. <i>Journal of Cardiology</i> , 2019, 74, 304-312.	0.8	24
2154	Active and Passive Vaccination for Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2581-2583.	1.2	2
2156	Exercise-Induced Changes in Pulmonary Artery Stiffness in Pulmonary Hypertension. <i>Frontiers in Physiology</i> , 2019, 10, 269.	1.3	9
2157	Analysis of pulmonary hypertension patient survival after treatment in referral center (data of first) Tj ETQq1 1 0.784314 rgBT ₉ /Overlook	0.8	9
2158	Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension. <i>Chest</i> , 2019, 156, 53-63.	0.4	42
2159	The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 511-524.	1.5	19
2160	Two-dimensional speckle tracking echocardiography assessed right ventricular function and exercise capacity in pre-capillary pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1499-1508.	0.7	8
2161	Echocardiographic assessment of pulmonary arterial stiffness in human immunodeficiency virus-infected patients. <i>Echocardiography</i> , 2019, 36, 1123-1131.	0.3	14
2162	Non-invasive Multimodality Cardiovascular Imaging of the Right Heart and Pulmonary Circulation in Pulmonary Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 24.	1.1	23
2163	The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. <i>Current Hypertension Reports</i> , 2019, 21, 45.	1.5	20
2164	Highlights from the ERS International Congress 2018: Assembly 13 "Pulmonary Vascular Diseases. <i>ERJ Open Research</i> , 2019, 5, 00202-2018.	1.1	0
2165	Pulmonary Hypertension in an Oncologic Intensive Care Unit. , 2019, , 1-23.		0
2166	The Creation of an Interatrial Right-To-Left Shunt in Patients with Severe, Irreversible Pulmonary Hypertension: Rationale, Devices, Outcomes. <i>Current Cardiology Reports</i> , 2019, 21, 31.	1.3	15
2167	Management of Pulmonary Arterial Hypertension in the ICU. <i>Journal of Pharmacy Practice</i> , 2019, 32, 303-313.	0.5	8
2168	Predicting Survival in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2019, 156, 323-337.	0.4	408
2169	Endothelins in cardiovascular biology and therapeutics. <i>Nature Reviews Cardiology</i> , 2019, 16, 491-502.	6.1	154

#	ARTICLE	IF	CITATIONS
2170	Combined automated 3D volumetry by pulmonary CT angiography and echocardiography for detection of pulmonary hypertension. <i>European Radiology</i> , 2019, 29, 6059-6068.	2.3	20
2171	Notch3 signaling activation in smooth muscle cells promotes extrauterine growth restriction-induced pulmonary hypertension. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 639-651.	1.1	17
2172	Impact of pulmonary hypertension in patients undergoing atrial fibrillation ablation: A nationwide study. <i>IJC Heart and Vasculature</i> , 2019, 23, 100348.	0.6	4
2173	Risk Analysis of Perioperative Death in Lung Transplant Patients With Severe Idiopathic Pulmonary Hypertension. <i>Transplantation Proceedings</i> , 2019, 51, 875-879.	0.3	4
2174	Hypoxia-inducible factor-1 β deletion in myeloid lineage attenuates hypoxia-induced pulmonary hypertension. <i>Physiological Reports</i> , 2019, 7, e14025.	0.7	23
2175	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). <i>Circulation Journal</i> , 2019, 83, 842-945.	0.7	132
2176	Pulmonary Hypertension. <i>Medical Clinics of North America</i> , 2019, 103, 413-423.	1.1	43
2177	Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies. <i>Stem Cell Research and Therapy</i> , 2019, 10, 55.	2.4	11
2178	Ultrastructural Changes of the Right Ventricular Myocytes in Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2019, 8, e011227.	1.6	26
2179	Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-15.	0.8	24
2180	Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2019, 25, 14.	0.3	0
2181	Central airway compression by massively dilated pulmonary artery in a patient with pulmonary arterial hypertension: a rare entity. <i>BMJ Case Reports</i> , 2019, 12, e232468.	0.2	2
2182	Feasibility of oxygen sensitive cardiac magnetic resonance of the right ventricle in pulmonary artery hypertension. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 502-512.	0.7	4
2183	Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. <i>European Respiratory Review</i> , 2019, 28, 190050.	3.0	39
2184	Implications of immune-inflammatory responses in smooth muscle dysfunction and disease. <i>Journal of Smooth Muscle Research</i> , 2019, 55, 81-107.	0.7	1
2185	High stakes anesthesia: Anesthetic considerations and implications for complete dental extraction in a patient with complex comorbidities. <i>Journal of Dental Anesthesia and Pain Medicine</i> , 2019, 19, 167.	0.4	0
2186	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. <i>Blood Advances</i> , 2019, 3, 4002-4020.	2.5	21
2187	<p>Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH)</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1427-1442.	0.9	10

#	ARTICLE	IF	CITATIONS
2188	Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. , 2019, 10, 125-170.		92
2189	Beyond the World Symposium on Pulmonary Hypertension: practical management of pulmonary arterial hypertension and evolving concepts. European Heart Journal Supplements, 2019, 21, K1-K3.	0.0	1
2190	Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. Current Cardiology Reports, 2019, 21, 141.	1.3	51
2191	Senescence Marker Protein 30 Deficiency Exacerbates Pulmonary Hypertension in Hypoxia-Exposed Mice. International Heart Journal, 2019, 60, 1430-1434.	0.5	10
2192	The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia. BMC Pulmonary Medicine, 2019, 19, 226.	0.8	5
2193	POINT: Should Initial Combination Therapy Be the Standard of Care in Pulmonary Arterial Hypertension? Yes. Chest, 2019, 156, 1039-1042.	0.4	6
2194	Aortic valve replacement with pulmonary hypertension: Meta-analysis of 70676 patients. Journal of Cardiac Surgery, 2019, 34, 1617-1625.	0.3	4
2195	Left Ventricular Function Before and After Aerobic Exercise Training in Women With Pulmonary Arterial Hypertension. Journal of Cardiopulmonary Rehabilitation and Prevention, 2019, 39, 118-126.	1.2	7
2196	Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-8.	0.8	18
2197	Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-9.	0.8	35
2198	Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease. Journal of Cardiovascular Pharmacology, 2019, 73, 383-393.	0.8	10
2199	Advanced imaging in pulmonary hypertension: emerging techniques and applications. International Journal of Cardiovascular Imaging, 2019, 35, 1407-1420.	0.7	23
2200	Prognostic value of right ventricular longitudinal strain in patients with pulmonary hypertension: a systematic review and meta-analysis. European Heart Journal Cardiovascular Imaging, 2019, 20, 475-484.	0.5	49
2201	Red blood cell distribution width as a potential predictor of survival of pulmonary arterial hypertension associated with primary Sjogren's syndrome: a retrospective cohort study. Clinical Rheumatology, 2019, 38, 477-485.	1.0	10
2202	Emergency transcatheter coronary intervention for left main compression secondary to pulmonary hypertension in a 4-year-old child. Catheterization and Cardiovascular Interventions, 2019, 93, 105-107.	0.7	5
2203	The Keys to Making a Confident Diagnosis of IPF. Respiratory Medicine, 2019, , 299-323.	0.1	0
2204	TGF β 2 and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. Drug Discovery Today, 2019, 24, 703-716.	3.2	64
2205	Characterization of Right Ventricular Deformation in Pulmonary Arterial Hypertension Using Three-Dimensional Principal Strain Analysis. Journal of the American Society of Echocardiography, 2019, 32, 385-393.	1.2	21

#	ARTICLE	IF	CITATIONS
2206	Redox Biology of Peroxisome Proliferator-Activated Receptor- β in Pulmonary Hypertension. Antioxidants and Redox Signaling, 2019, 31, 874-897.	2.5	20
2207	Isolation, identification, characterization, synthesis and quality control strategy of new process-related impurities in ambrisentan. Journal of Pharmaceutical and Biomedical Analysis, 2019, 165, 325-337.	1.4	7
2208	The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach. American Heart Journal, 2019, 208, 91-99.	1.2	24
2210	An update on current and emerging treatments for pulmonary arterial hypertension in childhood and adolescence. Expert Review of Respiratory Medicine, 2019, 13, 205-215.	1.0	3
2211	Assessment of quality of life in pediatric patients with pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-6.	0.8	11
2212	Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. European Respiratory Journal, 2019, 53, 1800081.	3.1	49
2213	Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. European Heart Journal, 2019, 40, 476-484.	1.0	212
2214	Fischer rats exhibit maladaptive structural and molecular right ventricular remodelling in severe pulmonary hypertension: a genetically prone model for right heart failure. Cardiovascular Research, 2019, 115, 788-799.	1.8	35
2215	Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. Heart Lung and Circulation, 2019, 28, 1655-1663.	0.2	9
2216	Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801889.	3.1	614
2217	Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. European Respiratory Journal, 2019, 53, 1801900.	3.1	315
2218	Intra-tracheal gene delivery of aerosolized SERCA2a to the lung suppresses ventricular arrhythmias in a model of pulmonary arterial hypertension. Journal of Molecular and Cellular Cardiology, 2019, 127, 20-30.	0.9	23
2219	Pulmonary Hypertension in Central Australia: A Community-Based Cohort Study. Heart Lung and Circulation, 2019, 28, 598-604.	0.2	5
2220	Haemodynamically Derived Pulmonary Artery Pulsatility Index Predicts Mortality in Pulmonary Arterial Hypertension. Heart Lung and Circulation, 2019, 28, 752-760.	0.2	24
2221	Duration of interventricular septal shift toward the left ventricle is associated with poor clinical outcome in precapillary pulmonary hypertension: A cardiac magnetic resonance study. Hellenic Journal of Cardiology, 2020, 61, 112-117.	0.4	9
2223	Heritable and Idiopathic Forms of Pulmonary Arterial Hypertension. , 2020, , 439-462.		2
2224	Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 458-468.	2.5	99
2225	Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort. Chest, 2020, 157, 162-172.	0.4	23

#	ARTICLE	IF	CITATIONS
2226	Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. <i>International Journal of Cardiology</i> , 2020, 300, 228-235.	0.8	27
2227	Programmed death-ligand 1 triggers PASMCs pyroptosis and pulmonary vascular fibrosis in pulmonary hypertension. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 138, 23-33.	0.9	48
2228	Patients with pulmonary hypertension presenting to the emergency department. <i>American Journal of Emergency Medicine</i> , 2020, 38, 2313-2317.	0.7	3
2229	Graded balloon atrial septostomy for palliation of congenital pulmonary hypertension in a dog: A case report. <i>Journal of Veterinary Internal Medicine</i> , 2020, 34, 283-288.	0.6	4
2230	Pulmonary Arterial Hypertension: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 932-943.	0.6	10
2231	Characteristics of Japanese elderly patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-13.	0.8	6
2232	Nocturnal hypoxia in patients with idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-7.	0.8	5
2233	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. , 2020, 11, 1623.		29
2234	Pharmacologic therapy for pulmonary artery hypertension. <i>Current Opinion in Cardiology</i> , 2020, 35, 643-656.	0.8	6
2235	Safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension: a meta-analysis on the randomised controlled trials. <i>Cardiology in the Young</i> , 2020, 30, 1882-1889.	0.4	6
2236	Right atrial strain is a surrogate of coupling in the right heart. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 863-864.	0.5	6
2237	Endothelial to mesenchymal transition (EndMT) and vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 1027-1043.	1.0	47
2238	Age-associated changes in 4D flow CMR derived Tricuspid Valvular Flow and Right Ventricular Blood Flow Kinetic Energy. <i>Scientific Reports</i> , 2020, 10, 9908.	1.6	13
2239	Prognostic importance of Kidney, Heart and Interstitial lung diseases (KHI triad) in PH: A machine learning study. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 630-641.	0.7	3
2240	Right ventricular dysfunction and long-term risk of death. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1646-1658.	0.7	12
2241	Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1675-1685.	0.7	14
2242	SCUBE1 Controls BMP2-Relevant Pulmonary Endothelial Function. <i>JACC Basic To Translational Science</i> , 2020, 5, 1073-1092.	1.9	8
2243	The six-transmembrane protein Stamp2 ameliorates pulmonary vascular remodeling and pulmonary hypertension in mice. <i>Basic Research in Cardiology</i> , 2020, 115, 68.	2.5	7

#	ARTICLE	IF	CITATIONS
2244	Critical care of patients with pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 414-421.	1.2	10
2245	Noninvasive Prediction of Elevated Wedge Pressure in Pulmonary Hypertension Patients Without Clear Signs of Left-Sided Heart Disease: External Validation of the OPTICS Risk Score. <i>Journal of the American Heart Association</i> , 2020, 9, e015992.	1.6	14
2246	Hemodynamic trajectories and outcomes in patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 204589402094134.	0.8	4
2247	Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2020, 142, 1464-1484.	1.6	96
2248	Role of Hypoxia-Inducible Factors in Regulating Right Ventricular Function and Remodeling during Chronic Hypoxia-induced Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 63, 652-664.	1.4	30
2249	Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries. <i>Pulmonary Circulation</i> , 2020, 10, 1-10.	0.8	5
2250	Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal. <i>BMC Pulmonary Medicine</i> , 2020, 20, 202.	0.8	4
2251	Beyond the genome: challenges and potential for epigenetics-driven therapeutic approaches in pulmonary arterial hypertension. <i>Biochemistry and Cell Biology</i> , 2020, 98, 631-646.	0.9	1
2252	How low should we go? Potential benefits and ramifications of the pulmonary hypertension hemodynamic definitions proposed by the 6th World Symposium. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 384-390.	1.2	7
2253	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 214-225.	0.2	3
2254	Controversies and advances in connective tissue disease-related pulmonary arterial hypertension. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1269-1275.	0.9	0
2255	Pediatric Pulmonary Arterial Hypertension. <i>Pediatric Clinics of North America</i> , 2020, 67, 903-921.	0.9	9
2256	Outcomes of Atriaseptostomy with Stenting in Patients with Pulmonary Arterial Hypertension from a Large Single-Institution Cohort. <i>Diagnostics</i> , 2020, 10, 725.	1.3	10
2257	Automatic Diagnosis of Chronic Thromboembolic Pulmonary Hypertension Based on Volumetric Data from SPECT Ventilation and Perfusion Images. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 5360.	1.3	2
2258	Right Atrial Pressure During Exercise Predicts Survival in Patients With Pulmonary Hypertension. <i>Journal of the American Heart Association</i> , 2020, 9, e018123.	1.6	8
2259	Timing it right: the challenge of recipient selection for lung transplantation. <i>Annals of Translational Medicine</i> , 2020, 8, 408-408.	0.7	4
2260	Risk stratification in pulmonary arterial hypertension using Bayesian analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000008.	3.1	38
2261	Relationship Between Left Ventricular Geometry and Invasive Hemodynamics in Pediatric Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009825.	1.3	39

#	ARTICLE	IF	CITATIONS
2262	Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 55, 2000041.	3.1	48
2263	Early Intervention of Tongxinluo (é€šâ;fç»œ) on Right Ventricular Function Assessed by Echocardiography in Rats with Pulmonary Arterial Hypertension Induced by Monocrotaline. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 913-920.	0.7	5
2264	A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 56, 2000513.	3.1	42
2265	Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 316-324.	0.7	19
2266	Bioequivalence of macitentan and tadalafil given as fixedâ€dose combination or singleâ€component tablets in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2424-2434.	1.1	6
2268	Performance of pulmonary artery dimensions measured on high-resolution computed tomography scan for identifying pulmonary hypertension. <i>ERJ Open Research</i> , 2020, 6, 00232-2019.	1.1	8
2269	Biventricular diastolic dysfunction, thrombocytopenia, and red blood cell macrocytosis in experimental pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-12.	0.8	7
2270	Combination of Dichloroacetate and Atorvastatin Regulates Excessive Proliferation and Oxidative Stress in Pulmonary Arterial Hypertension Development via p38 Signaling. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-15.	1.9	9
2271	Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension. <i>Diseases (Basel, Switzerland)</i> , 2020, 8, 22.	1.0	19
2272	Children and Adolescents with Pulmonary Arterial Hypertension: Baseline and Follow-Up Data from the Polish Registry of Pulmonary Hypertension (BNP-PL). <i>Journal of Clinical Medicine</i> , 2020, 9, 1717.	1.0	14
2273	Recognizing genetic disease: A key aspect of pediatric pulmonary care. <i>Pediatric Pulmonology</i> , 2020, 55, 1794-1809.	1.0	2
2274	Comprehensive identification of signaling pathways for idiopathic pulmonary arterial hypertension. <i>American Journal of Physiology - Cell Physiology</i> , 2020, 318, C913-C930.	2.1	7
2275	Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2020, 126, 1723-1745.	2.0	83
2276	Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD. <i>Chest</i> , 2020, 158, 722-734.	0.4	24
2277	Metacognitive Therapy for Adjustment Disorder in a Patient With Newly Diagnosed Pulmonary Arterial Hypertension: A Case Report. <i>Frontiers in Psychology</i> , 2020, 11, 143.	1.1	11
2278	MicroRNA-17 as a potential diagnostic biomarker in pulmonary arterial hypertension. <i>Journal of International Medical Research</i> , 2020, 48, 030006052092043.	0.4	8
2279	Changes in heart morphometric parameters over the course of a monocrotaline-induced pulmonary arterial hypertension rat model. <i>Journal of Translational Medicine</i> , 2020, 18, 262.	1.8	9
2280	Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-mediated Regulation of PDGFRÎ². <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1445-1457.	2.5	45

#	ARTICLE	IF	CITATIONS
2281	Pulmonary arterial hypertension associated with primary Sjögren's syndrome: a multicentre cohort study from China. <i>European Respiratory Journal</i> , 2020, 56, 1902157.	3.1	27
2282	Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension. <i>Chest</i> , 2020, 158, 2546-2555.	0.4	11
2283	Systemic hypoxia led to little retinal neuronal loss and dramatic optic nerve glial response. <i>Experimental Eye Research</i> , 2020, 193, 107957.	1.2	17
2284	Myocardial perfusion abnormalities in Eisenmenger syndrome. <i>Nuclear Medicine Communications</i> , 2020, 41, 206-211.	0.5	1
2285	Pulmonary arterial capacitance predicts outcomes in patients with pulmonary hypertension independent of race/ethnicity, sex, and etiology. <i>Respiratory Medicine</i> , 2020, 163, 105891.	1.3	1
2286	Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. <i>European Respiratory Review</i> , 2020, 29, 190089.	3.0	40
2287	Pediatric Pulmonary Arterial Hypertension: Evaluation and Treatment. <i>Current Treatment Options in Pediatrics</i> , 2020, 6, 12-28.	0.2	1
2288	Long-Term Outcomes in Ventriculoatrial Shunt Surgery in Patients with Pediatric Hydrocephalus: Retrospective Single-Center Study. <i>World Neurosurgery</i> , 2020, 138, e112-e118.	0.7	15
2289	Sex differences of hemodynamics during acute vasoreactivity testing to predict the outcomes of chronic thromboembolic pulmonary hypertension. <i>Clinical Respiratory Journal</i> , 2020, 14, 611-621.	0.6	5
2290	Pulmonary Hypertension and Right Ventricular Failure. <i>Cardiology Clinics</i> , 2020, 38, 269-281.	0.9	4
2291	Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center. <i>Chest</i> , 2020, 158, 330-340.	0.4	18
2292	Identification of a pulmonary arterial hypertension (PAH) patient cohort and study of its burden of illness in Programme de Médicalisation des Systèmes d'information (PMSI). <i>International Journal of Cardiology</i> , 2020, 306, 175-180.	0.8	6
2293	Cardiac Magnetic Resonance Imaging in Pulmonary Hypertension. <i>Chest</i> , 2020, 157, 470.	0.4	0
2294	Aetiology and outcomes of severe right ventricular dysfunction. <i>European Heart Journal</i> , 2020, 41, 1273-1282.	1.0	42
2295	FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction. <i>Basic Research in Cardiology</i> , 2020, 115, 17.	2.5	17
2296	Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL). <i>Journal of Clinical Medicine</i> , 2020, 9, 173.	1.0	38
2297	Pulmonary Hypertension Remodels the Genomic Fabrics of Major Functional Pathways. <i>Genes</i> , 2020, 11, 126.	1.0	9
2298	Drug Treatment of Pulmonary Hypertension in Children. <i>Paediatric Drugs</i> , 2020, 22, 123-147.	1.3	21

#	ARTICLE	IF	CITATIONS
2299	Should Patients Choose Lung Transplantation or Optimal Drug Therapy?â€• The Clinical Situation in the Treatment of Pulmonary Arterial Hypertension in Japan â€•. <i>Circulation Journal</i> , 2020, 84, 158-160.	0.7	2
2300	Supraâ€•coronary aortic banding improves right ventricular function in experimental pulmonary arterial hypertension in rats by increasing systolic right coronary artery perfusion. <i>Acta Physiologica</i> , 2020, 229, e13483.	1.8	12
2301	Angiotensin converting enzyme 2 and angiotensin (1â€•7) axis in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 56, 1902416.	3.1	29
2302	Identification of Cardiac MRI and Bio-Marker Thresholds for One-Year Survival in Pre-Capillary Pulmonary Hypertension: Prospective Study. <i>Medicina (Lithuania)</i> , 2020, 56, 167.	0.8	3
2303	Assessment of electrocardiographic markers of acute and longâ€•term hemodynamic improvement in patients with pulmonary hypertension. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12758.	0.5	11
2304	Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients. <i>Current Medical Research and Opinion</i> , 2020, 36, 921-928.	0.9	4
2305	The relationship between Tâ€•wave peakâ€•toâ€•end interval and hemodynamic parameters in patients with pulmonary arterial hypertension. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12764.	0.5	4
2306	Pulmonary hypertension in Saudi Arabia: First data from the <scp>SAUDIPH</scp> registry with a focus on pulmonary arterial hypertension. <i>Respirology</i> , 2021, 26, 92-101.	1.3	5
2307	Identification of Differentially Expressed Genes Associated with Idiopathic Pulmonary Arterial Hypertension by Integrated Bioinformatics Approaches. <i>Journal of Computational Biology</i> , 2021, 28, 79-88.	0.8	16
2308	Anticoagulation in Pulmonary Arterial Hypertension: Do We Know the Answer?. <i>Current Problems in Cardiology</i> , 2021, 46, 100738.	1.1	8
2309	Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children. <i>Pediatric Pulmonology</i> , 2021, 56, 593-613.	1.0	5
2310	Prognostic Value of Change in Cardiac Index After Prostacyclin Initiation in Pediatric Pulmonary Hypertension. <i>Pediatric Cardiology</i> , 2021, 42, 116-122.	0.6	2
2311	Left main coronary artery compression in pulmonary hypertension. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E956-E966.	0.7	10
2312	The Value of Hemodynamic Measurements or Cardiac MRI in the Follow-up of Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2021, 159, 1575-1585.	0.4	18
2313	Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	84
2314	Commentary: To transplant or not to transplant: Potts shunt as an alternative to pediatric lung transplantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1149-1150.	0.4	0
2315	Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2001120.	3.1	22
2316	An evaluation of selexipag for the treatment of pulmonary hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 29-36.	0.9	5

#	ARTICLE	IF	CITATIONS
2317	A case series of transcatheter Potts Shunt creation in a pediatric population affected with refractory pulmonary artery hypertension: focus on the role of ECMO. <i>Perfusion (United Kingdom)</i> , 2021, 36, 415-420.	0.5	4
2318	Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings. <i>Heart Failure Reviews</i> , 2021, 26, 263-275.	1.7	11
2319	United States Pulmonary Hypertension Scientific Registry. <i>Chest</i> , 2021, 159, 311-327.	0.4	25
2320	Cor Pulmonale. , 2021, , 163-170.		0
2321	Cardiopulmonary Monitoring of Patients with Pulmonary Hypertension and Right Ventricular Failure. , 2021, , 871-903.		0
2322	Study of the effect of Occlutech Atrial Flow Regulator on symptoms, hemodynamics, and echocardiographic parameters in advanced pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	0.8	12
2323	Extrinsic compression of coronary and pulmonary vasculature. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1125-1139.	0.7	3
2324	Diastolic Function in Children and in Children With Congenital Heart Disease. , 2021, , 349-374.		0
2325	Risk assessment in precapillary pulmonary hypertension: a comparative analysis. <i>Respiratory Research</i> , 2021, 22, 28.	1.4	6
2326	A Case of Hypopituitarism Complicated by Non-Alcoholic Steatohepatitis and Severe Pulmonary Hypertension. <i>American Journal of Case Reports</i> , 2021, 22, e928004.	0.3	2
2327	Atrial Septostomy. , 2021, , 349-363.		0
2328	Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR). <i>BMC Pulmonary Medicine</i> , 2021, 21, 28.	0.8	2
2330	Screening of key biomarkers and immune infiltration in Pulmonary Arterial Hypertension via integrated bioinformatics analysis. <i>Bioengineered</i> , 2021, 12, 2576-2591.	1.4	11
2331	GOLPH3 Contributes to Endothelial Cells Pyroptosis by Promoting Golgi Dispersal in Pulmonary Arterial Hypertension. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2332	SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 36.	2.1	41
2333	Factors related to instrumental activities of daily living in persons with chronic thromboembolic pulmonary hypertension. <i>Chronic Respiratory Disease</i> , 2021, 18, 147997312110466.	1.0	4
2334	The many challenges to the field of pediatric pulmonology posed by pediatric pulmonary hypertension and the path forward. <i>Pediatric Pulmonology</i> , 2021, 56, 583-586.	1.0	0
2335	Natural course of tricuspid regurgitation and prognostic implications. <i>Open Heart</i> , 2021, 8, e001529.	0.9	21

#	ARTICLE	IF	CITATIONS
2336	The Growing Role of Echocardiography in Pulmonary Arterial Hypertension Risk Stratification: The Missing Piece. <i>Journal of Clinical Medicine</i> , 2021, 10, 619.	1.0	13
2337	Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 66, 101985.	1.1	0
2338	COVID-19 patients may become predisposed to pulmonary arterial hypertension. <i>Medical Hypotheses</i> , 2021, 147, 110483.	0.8	37
2339	Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 493-504.	1.0	2
2340	Subtle right ventricular dysfunction in asymptomatic chronic heavy cigarette smokers: a speckle tracking case-control study. <i>Egyptian Heart Journal</i> , 2021, 73, 25.	0.4	0
2341	Outcomes of idiopathic pulmonary arterial hypertension in Japanese children: a retrospective cohort study. <i>Heart and Vessels</i> , 2021, 36, 1392-1399.	0.5	3
2342	Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension. <i>Cells</i> , 2021, 10, 638.	1.8	11
2343	Long-term Outcomes in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. <i>Arthritis and Rheumatology</i> , 2021, 73, 837-847.	2.9	26
2344	Cost-effectiveness of Combination Therapy for Patients With Systemic Sclerosis-related Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2021, 10, e015816.	1.6	7
2345	Influence of demographic characteristics on the clinical course and results of therapy in patients with precapillary pulmonary hypertension. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 283-289.	0.2	1
2346	Hypoxia-induced inflammation: Profiling the first 24-hour posthypoxic plasma and central nervous system changes. <i>PLoS ONE</i> , 2021, 16, e0246681.	1.1	6
2347	Prognostic Significance of Systemic Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Idiopathic Pulmonary Hypertension. <i>Vascular Health and Risk Management</i> , 2021, Volume 17, 77-93.	1.0	7
2348	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 209-221.	2.5	88
2349	Prediction Models and Scores in Pulmonary Hypertension: A Review. <i>Current Pharmaceutical Design</i> , 2021, 27, 1266-1276.	0.9	2
2350	Anesthetic management in lung transplantation: Our single-center experience. <i>Turkish Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 29, 191-200.	0.2	1
2351	Off-label use of PAH-targeted medications approved for adults and their financial coverage by health insurances are vital for children with pulmonary hypertension. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13571.	1.7	1
2352	Left Main Coronary Artery Compression in Pulmonary Arterial Hypertension: Percutaneous Treatment to Improve Symptoms. <i>CJC Open</i> , 2021, 3, 690-692.	0.7	0
2353	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. <i>Genome Medicine</i> , 2021, 13, 80.	3.6	43

#	ARTICLE	IF	CITATIONS
2354	Serial T1 mapping of right ventricle in pulmonary hypertension: comparison with histology in an animal study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 64.	1.6	5
2355	Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 360-370.	1.9	42
2356	PTBP1 Targets ILK to Regulate the Hypoxia-Induced Phenotypic Transformation of Pulmonary Artery Smooth Muscle Cells. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2025-2033.	2.0	8
2357	Primary and revision shoulder arthroplasty in patients with pulmonary hypertension: an underlying condition associated with high perioperative mortality and complications. <i>Seminars in Arthroplasty</i> , 2021, 31, 772-782.	0.3	3
2359	Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2021, 26, 512-516.	0.3	3
2360	The role of imaging in pulmonary hypertension. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 859-880.	0.7	5
2361	Epoprostenol for the treatment of pulmonary arterial hypertension. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1005-1013.	1.3	6
2362	Survival in severe pulmonary hypertension due to chronic lung disease: influence of in-hospital platelet distribution width. <i>Pulmonary Circulation</i> , 2021, 11, 1-7.	0.8	2
2363	Pulmonary arterial banding in mice may be a suitable model for studies on ventricular mechanics in pediatric pulmonary arterial hypertension. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 66.	1.6	3
2364	Pulmonary Artery Hypertension as A Risk Factor for Long-Term Survival after Heart Transplantation. <i>Heart Surgery Forum</i> , 2021, 24, E544-E549.	0.2	4
2365	Better Outcomes in Pulmonary Arterial Hypertension After Repair of Congenital Heart Disease, Compared With Idiopathic Pulmonary Arterial Hypertension. <i>CJC Open</i> , 2021, 3, 872-879.	0.7	4
2366	Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study. <i>ERJ Open Research</i> , 2021, 7, 00082-2021.	1.1	3
2367	Changes in the Pulmonary Artery Wave Reflection in Dogs with Experimentally-Induced Acute Pulmonary Embolism and the Effect of Vasodilator. <i>Animals</i> , 2021, 11, 1977.	1.0	12
2368	Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension?. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 614-622.	0.3	4
2369	Shifting gears: the search for group 3 pulmonary hypertension treatment. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 296-302.	1.2	2
2370	Evaluation of echocardiographic derived parameters for right ventricular size and function using cardiac magnetic resonance imaging. <i>Echocardiography</i> , 2021, 38, 1336-1344.	0.3	2
2371	Non-invasive Assessment of Pulmonary Artery Wave Reflection in Dogs With Suspected Pulmonary Hypertension. <i>Frontiers in Veterinary Science</i> , 2021, 8, 659194.	0.9	6
2372	Acute Hemodynamic Effect of Acetazolamide in Patients With Pulmonary Hypertension Whilst Breathing Normoxic and Hypoxic Gas: A Randomized Cross-Over Trial. <i>Frontiers in Medicine</i> , 2021, 8, 681473.	1.2	4

#	ARTICLE	IF	CITATIONS
2373	Use of Handheld Ultrasound to Estimate Right Atrial Pressure in a Pulmonary Hypertension Clinic. <i>Annals of the American Thoracic Society</i> , 2022, 19, 179-185.	1.5	5
2374	What's new in pulmonary hypertension clinical research: lessons from the best abstracts at the 2020 American Thoracic Society International Conference. <i>Pulmonary Circulation</i> , 2021, 11, 1-27.	0.8	4
2375	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. <i>Chest</i> , 2021, 160, 277-286.	0.4	21
2376	The Evolution of Risk Assessment in Pulmonary Arterial Hypertension. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 134.	0.5	0
2377	TIFA protein expression is associated with pulmonary arterial hypertension. <i>Scientific Reports</i> , 2021, 11, 14140.	1.6	1
2378	Critical Care Management of Decompensated Right Heart Failure in Pulmonary Arterial Hypertension Patients – An Ongoing Approach. <i>The Journal of Critical Care Medicine</i> , 2021, 7, 170-183.	0.3	3
2379	Systemic Sclerosis: Highlighting Respiratory Complications and Significance of Early Screening. <i>Cureus</i> , 2021, 13, e17291.	0.2	0
2380	Serious illness conversations in pulmonary hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-6.	0.8	3
2381	The Prognostic Value of Right Atrial Strain Imaging in Patients with Precapillary Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 851-861.e1.	1.2	25
2382	Novel Echocardiographic Algorithm for Right Ventricular Mass Quantification: Cardiovascular Magnetic Resonance and Clinical Prognosis Validation. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 839-850.e1.	1.2	2
2383	Palliative Care in Pediatric Pulmonology. <i>Children</i> , 2021, 8, 802.	0.6	0
2384	Critical Role of Caveolin-1 Loss/Dysfunction in Pulmonary Hypertension. <i>Medical Sciences (Basel)</i> , 2021, 9, 1074. <small>Tj ETQq1 1 0.784314 rgBT /Overlo</small>	1.3	0
2385	Right ventricular function as assessed by cardiac magnetic resonance imaging-derived strain parameters compared to high-fidelity micromanometer catheter measurements. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	0.8	4
2386	Assessment of right ventricle in pulmonary arterial hypertension with three-dimensional echocardiography and cardiovascular magnetic resonance. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, 929-936.	0.6	3
2387	Hyperuricemia in patients with pulmonary hypertension: A study in a tertiary care center. <i>IP Indian Journal of Immunology and Respiratory Medicine</i> , 2021, 6, 173-177.	0.1	0
2388	Pulmonary Artery Proportional Pulse Pressure (PAPP) Index Identifies Patients With Improved Survival From the CardioMEMS Implantable Pulmonary Artery Pressure Monitor. <i>Heart Lung and Circulation</i> , 2021, 30, 1389-1396.	0.2	4
2389	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1172-1180.	0.3	9
2390	Novel molecular insights and public omics data in pulmonary hypertension. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166200.	1.8	6

#	ARTICLE	IF	CITATIONS
2392	Cardiac - Pulmonary Hypertension, Gastro-Intestinal (GOR, Hepatopulmonary Syndrome), Hematology/Oncology (Infections, Approach to Diagnosis), Neuromuscular (Bulbar, Diaphragm,) Tj ETQq0 0 0 rgBT /Overlock10 Tf 50 7		
2393	Lung Transplantation: Recipient Selection. , 2022, , 606-622.		0
2394	Lung Transplantation for Pulmonary Hypertension. , 2022, , 650-660.		0
2395	Palliative Care in Pulmonary Arterial Hypertension. Respiratory Medicine, 2021, , 255-279.	0.1	0
2396	Health Disparities in Pulmonary Arterial Hypertension and the Impact of the COVID-19 Pandemic. Advances in Pulmonary Hypertension, 2021, 20, 6-15.	0.1	5
2397	[11C]meta-hydroxyephedrine PET evaluation in experimental pulmonary arterial hypertension: Effects of carvedilol of right ventricular sympathetic function. Journal of Nuclear Cardiology, 2021, 28, 407-422.	1.4	1
2398	Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension. ESC Heart Failure, 2021, 8, 1230-1243.	1.4	6
2400	Prostacyclin for pulmonary arterial hypertension. The Cochrane Library, 2019, 2019, CD012785.	1.5	32
2401	Phosphodiesterase-5 Inhibitors in Pulmonary Arterial Hypertension. , 0, , 105-125.		1
2402	Pulmonary Vascular Disease. , 2008, , 1032-1087.		7
2403	Nursing Care of Patients with Pulmonary Arterial Hypertension. , 2011, , 1531-1558.		3
2404	Epidemiology of Pediatric Pulmonary Hypertension. , 2014, , 2123-2137.		2
2405	Correlation of Acute Prostacyclin Response in Primary (Unexplained) Pulmonary Hypertension with Efficacy of Treatment with Calcium Channel Blockers and Survival. , 1993, , 317-330.		11
2406	Lung Transplantation for Connective Tissue Disease-Associated Lung Disease. , 2014, , 179-191.		1
2407	Atrial Septostomy. Respiratory Medicine, 2015, , 419-437.	0.1	9
2408	The Right Ventricle in Pulmonary Hypertension. , 2008, , 93-125.		2
2409	The Keys to Making a Confident Diagnosis of IPF. , 2014, , 77-101.		3
2410	Disease Progression in Systemic Sclerosis Associated Pulmonary Arterial Hypertension. , 2009, , 289-303.		2

#	ARTICLE	IF	CITATIONS
2411	Inhaled Nitric Oxide as a Therapy for Diseases of the Pulmonary Vasculature. , 2000, , 201-208.		1
2412	Historical Perspective on the Classification and Nomenclature of Pulmonary Hypertension. , 2016, , 3-15.		1
2413	Targeting of Platelet-Derived Growth Factor Signaling in Pulmonary Arterial Hypertension. Handbook of Experimental Pharmacology, 2013, 218, 381-408.	0.9	12
2414	Pulmonary Hypertension: Current Management and Future Directions. Handbook of Experimental Pharmacology, 2013, 218, 551-555.	0.9	1
2415	Pulmonary Hypertension: Biomarkers. Handbook of Experimental Pharmacology, 2013, 218, 77-103.	0.9	5
2416	Calciumantagonisten bei pulmonaler Hypertonie. , 1996, , 325-335.		1
2417	Plötzlicher Tod im Erwachsenenalter. , 2004, , 965-1069.		17
2418	Pulmonary Hypertension: Old Targets Revisited (Statins, PPARs, Beta-Blockers). Handbook of Experimental Pharmacology, 2013, , 531-548.	0.9	8
2419	Pulmonary Hypertension: Current Management and Future Directions. Handbook of Experimental Pharmacology, 2013, , 551-555.	0.9	1
2420	Pulmonary Hypertension: Biomarkers. Handbook of Experimental Pharmacology, 2013, , 77-103.	0.9	7
2421	Role of Proteases in Lung Disease: A Brief Overview. , 2017, , 333-374.		15
2422	Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension. , 2020, , 31-61.		4
2423	Coexistence of nodular regenerative hyperplasia of the liver and pulmonary arterial hypertension in patients with connective tissue diseases: report of three cases and review of the literature. Modern Rheumatology, 2006, 16, 389-394.	0.9	1
2425	Pulmonary Complications in Patients with Liver Disease. , 2006, , 477-488.		1
2426	Pulmonary Arterial Hypertension. , 2008, , 936-963.		3
2429	Detection of mechanical complications related to the potential risk of sudden cardiac death in patients with pulmonary arterial hypertension by computed tomography. International Journal of Cardiology, 2017, 243, 460-465.	0.8	11
2430	Pulmonary arterial hypertension specific therapy: The old and the new. , 2020, 214, 107576.		38
2431	PLEUROPULMONARY MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America, 1994, 20, 159-193.	0.8	151

#	ARTICLE	IF	CITATIONS
2432	Echocardiographic Evaluation of Right Ventricular Function. , 0, .		24
2433	Medical and Surgical Treatment Options for Pulmonary Hypertension. American Journal of the Medical Sciences, 1998, 315, 179-184.	0.4	19
2434	High Prevalence of Hypothyroidism in Patients with Primary Pulmonary Hypertension. American Journal of the Medical Sciences, 1999, 318, 289.	0.4	79
2435	OUTCOME OF CHILDREN WITH PULMONARY HYPERTENSION REFERRED FOR LUNG OR HEART AND LUNG TRANSPLANTATION1. Transplantation, 1996, 62, 1824-1828.	0.5	9
2436	RISK FACTORS FOR EARLY DEATH IN PATIENTS AWAITING HEART-LUNG OR LUNG TRANSPLANTATION. Transplantation, 1998, 66, 123-127.	0.5	18
2437	INTERNATIONAL GUIDELINES FOR THE SELECTION OF LUNG TRANSPLANT CANDIDATES. Transplantation, 1998, 66, 951-956.	0.5	221
2438	Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry. Respirology, 2020, 25, 863-871.	1.3	46
2439	Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease. British Heart Journal, 2003, 89, 1221-1226.	2.2	15
2440	Do Patients With Primary Pulmonary Hypertension Develop Extensive Central Thrombi?. Circulation, 1995, 91, 741-745.	1.6	90
2441	Blade Balloon Atrial Septostomy in Patients With Severe Primary Pulmonary Hypertension. Circulation, 1995, 91, 2028-2035.	1.6	220
2442	Single Lung Transplantation for Pulmonary Hypertension. Circulation, 1995, 92, 2252-2258.	1.6	150
2443	Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary Hypertension. Circulation, 1996, 93, 484-488.	1.6	96
2444	Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension. Circulation, 1997, 95, 1479-1486.	1.6	271
2445	Induced Septal Infarction. Circulation, 1997, 95, 1981-1982.	1.6	34
2446	PVDOMICS. Circulation Research, 2017, 121, 1136-1139.	2.0	113
2448	Simvastatin as a Treatment for Pulmonary Hypertension Trial. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1106-1113.	2.5	112
2449	Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity. JCI Insight, 2017, 2, e91415.	2.3	41
2450	Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats.. Journal of Clinical Investigation, 1996, 97, 2491-2498.	3.9	117

#	ARTICLE	IF	CITATIONS
2451	Abnormal Pulmonary Function in Adults with Sickle Cell Disease: Association of Decreased DLCO with Systemic Disease.. <i>Blood</i> , 2005, 106, 316-316.	0.6	5
2452	Adaptation and validation of the quality of life assessment of the Cambridge pulmonary hypertension outcome review (CAMPHOR) for Brazil. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 43.	0.9	7
2453	Epidemiology of pulmonary hypertension in the elderly. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 11-16.	0.2	16
2454	An integrated approach to the diagnosis of pulmonary hypertension. , 2011, , 170-194.		1
2455	Pulmonary Artery Pressure as a Treatment Target to Improve the Prognosis of Idiopathic Pulmonary Arterial Hypertension—Insight From a Cohort From Two Japanese Pulmonary Hypertension Centers . <i>Circulation Reports</i> , 2020, 2, 249-254.	0.4	3
2456	Response to a Dolutegravir-based Regimen in an HIV-Infected Woman with Multiple Comorbidities and a Highly Resistant Strain. <i>American Journal of Medical Case Reports</i> , 2015, 3, 201-204.	0.1	2
2457	Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: State of the art. <i>World Journal of Clinical Cases</i> , 2020, 8, 2679-2702.	0.3	23
2458	The PPAR γ Agonist GW0742 Relaxes Pulmonary Vessels and Limits Right Heart Hypertrophy in Rats with Hypoxia-Induced Pulmonary Hypertension. <i>PLoS ONE</i> , 2010, 5, e9526.	1.1	43
2459	Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension. <i>PLoS ONE</i> , 2011, 6, e18883.	1.1	36
2460	Increased CD39 Nucleotidase Activity on Microparticles from Patients with Idiopathic Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2012, 7, e40829.	1.1	43
2461	Longitudinal In Vivo SPECT/CT Imaging Reveals Morphological Changes and Cardiopulmonary Apoptosis in a Rodent Model of Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2012, 7, e40910.	1.1	16
2462	Circulating miRNAs as Potential Marker for Pulmonary Hypertension. <i>PLoS ONE</i> , 2013, 8, e64396.	1.1	106
2463	Paracrine Effects of Bone Marrow-Derived Endothelial Progenitor Cells: Cyclooxygenase-2/Prostacyclin Pathway in Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2013, 8, e79215.	1.1	14
2464	Evaluation of Circulating Proteins and Hemodynamics Towards Predicting Mortality in Children with Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2013, 8, e80235.	1.1	13
2465	Positive Feedback-Loop of Telomerase Reverse Transcriptase and 15-Lipoxygenase-2 Promotes Pulmonary Hypertension. <i>PLoS ONE</i> , 2013, 8, e83132.	1.1	14
2466	Quality of Life, Safety and Efficacy Profile of Thermostable Flolan in Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2015, 10, e0120657.	1.1	9
2467	Exercise Physiology and Pulmonary Hemodynamic Abnormality in PH Patients with Exercise Induced Venous-To-Systemic Shunt. <i>PLoS ONE</i> , 2015, 10, e0121690.	1.1	16
2468	Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2015, 10, e0121894.	1.1	5

#	ARTICLE	IF	CITATIONS
2469	Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia. PLoS ONE, 2015, 10, e0137539.	1.1	5
2470	Association of Right Ventricular Pressure and Volume Overload with Non-Ischemic Septal Fibrosis on Cardiac Magnetic Resonance. PLoS ONE, 2016, 11, e0147349.	1.1	6
2471	Oxidative profiling of the failing right heart in rats with pulmonary hypertension. PLoS ONE, 2017, 12, e0176887.	1.1	24
2472	Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database. PLoS ONE, 2017, 12, e0187734.	1.1	21
2473	The selective PGI2 receptor agonist selexipag ameliorates Sugren 5416/hypoxia-induced pulmonary arterial hypertension in rats. PLoS ONE, 2020, 15, e0240692.	1.1	9
2474	Linkage Analysis in a Large Family With Primary Pulmonary Hypertension. Chest, 2002, 121, 54S-56S.	0.4	18
2475	Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: RegiSty on clinical outcome and survival in pulmonary hypertension Groups (SIMURG). Anatolian Journal of Cardiology, 2017, 18, 242-250.	0.5	13
2476	Drug Interactions in Pulmonary Arterial Hypertension and Their Implications. European Cardiology Review, 2009, 5, 46.	0.7	2
2477	Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator. European Cardiology Review, 2018, 13, 35.	0.7	12
2478	Demographic and clinical characteristics of pulmonary arterial hypertension caused by schistosomiasis are indistinguishable from other etiologies. Revista Da Sociedade Brasileira De Medicina Tropical, 2020, 53, e20190418.	0.4	5
2479	'Editors' Choice' Pulmonary Hypertension: Diagnosis, Management, and Treatment. Nagoya Journal of Medical Science, 2019, 81, 19-30.	0.6	15
2480	Sildenafil in the treatment of pulmonary hypertension. Vascular Health and Risk Management, 2006, 2, 411-422.	1.0	127
2481	Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension. Global Cardiology Science & Practice, 2018, 2018, 14.	0.3	4
2482	Cardiac Catheterization in Pulmonary Arterial Hypertension: A Guide to Proper Use. Advances in Pulmonary Hypertension, 2002, 1, 15-21.	0.1	1
2483	The Nuts and Bolts of Interpreting Hemodynamics in Pulmonary Hypertension Associated With Diastolic Heart Failure. Advances in Pulmonary Hypertension, 2011, 10, 33-40.	0.1	7
2484	An Update on Therapies for Pediatric Pulmonary Arterial Hypertension 2011. Advances in Pulmonary Hypertension, 2011, 10, 109-114.	0.1	1
2485	Pulmonary Arterial Hypertension: Epidemiology and Registries. Advances in Pulmonary Hypertension, 2014, 13, 21-26.	0.1	5
2486	Ask the Expert: Are Newer Management Approaches Increasing the Economic Burden of Treating Pulmonary Arterial Hypertension?. Advances in Pulmonary Hypertension, 2014, 13, 92-93.	0.1	1

#	ARTICLE	IF	CITATIONS
2487	Prognostication in Pulmonary Arterial Hypertension and Use of Current Risk Prediction Models. <i>Advances in Pulmonary Hypertension</i> , 2015, 14, 37-43.	0.1	1
2488	Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it. <i>Advances in Pulmonary Hypertension</i> , 2018, 16, 125-135.	0.1	12
2489	PH Professional Network: Team-Based Care for Professionals in Pulmonary Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2018, 16, 95-96.	0.1	1
2490	Evolution in PH Care: 3 Decades of Milestones. <i>Advances in Pulmonary Hypertension</i> , 2018, 16, 165-169.	0.1	2
2491	Update on the PHA Pulmonary Hypertension Care Center Network: Early Experience With the National Accreditation Program. <i>Advances in Pulmonary Hypertension</i> , 2018, 16, 179-184.	0.1	6
2492	Listing the Patient: Deciding When Transplantation Is the Only Viable Life-Sustaining Option. <i>Advances in Pulmonary Hypertension</i> , 2004, 3, 4-8.	0.1	1
2493	Cardiac Catheterization in Pulmonary Arterial Hypertension: An Updated Guide to Proper Use. <i>Advances in Pulmonary Hypertension</i> , 2005, 4, 15-25.	0.1	14
2494	Managing Right Ventricular Failure in PAH: An Algorithmic Approach. <i>Advances in Pulmonary Hypertension</i> , 2005, 4, 16-26.	0.1	8
2495	Pulmonary Arterial Hypertension In Adults With Congenital Heart Disease: General Overview of Disease Mechanisms. <i>Advances in Pulmonary Hypertension</i> , 2007, 6, 121-125.	0.1	2
2496	Getting More From Right Heart Catheterization: A Focus on the Right Ventricle. <i>Advances in Pulmonary Hypertension</i> , 2008, 7, 343-345.	0.1	2
2497	The Role of Echocardiography in the Diagnosis and Assessment of Pulmonary Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2008, 7, 379-385.	0.1	2
2498	Cardiopulmonary Hemodynamics in Pulmonary Hypertension: Pressure Tracings, Waveforms, and More. <i>Advances in Pulmonary Hypertension</i> , 2008, 7, 386-393.	0.1	10
2499	Role of Cardiac MRI in Pulmonary Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2008, 7, 396-402.	0.1	1
2500	Pulmonary Hypertension and Lung Transplantation, 2010. <i>Advances in Pulmonary Hypertension</i> , 2010, 9, 22-30.	0.1	1
2501	Balloon Dilation Atrial Septostomy and Potts Anastomosis for Severe Pulmonary Arterial Hypertension: Why, When, and How. <i>Advances in Pulmonary Hypertension</i> , 2016, 15, 19-25.	0.1	1
2502	The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets. <i>Current Medicinal Chemistry</i> , 2020, 27, 7168-7188.	1.2	27
2503	Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension. <i>Current Vascular Pharmacology</i> , 2009, 7, 225-233.	0.8	44
2504	Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension. <i>Current Vascular Pharmacology</i> , 2015, 13, 331-340.	0.8	27

#	ARTICLE	IF	CITATIONS
2505	New Concepts in the Invasive and Non Invasive Evaluation of Remodelling of the Right Ventricle and Pulmonary Vasculature in Pulmonary Arterial Hypertension. <i>Open Respiratory Medicine Journal</i> , 2009, 3, 31-37.	1.3	9
2507	Current and emerging therapeutic approaches to pulmonary hypertension. <i>Reviews in Cardiovascular Medicine</i> , 2020, 21, 163.	0.5	51
2508	L-Arginine in Combination With Sildenafil Potentiates the Attenuation of Hypoxic Pulmonary Hypertension in Rats. <i>Physiological Research</i> , 2013, 62, 589-595.	0.4	4
2509	Right Heart Size and Right Ventricular Reserve in Pulmonary Hypertension: Impact on Management and Prognosis. <i>Diagnostics</i> , 2020, 10, 1110.	1.3	6
2510	Echocardiography for the Assessment of Pulmonary Hypertension and Congenital Heart Disease in the Young. <i>Diagnostics</i> , 2021, 11, 49.	1.3	7
2511	SARS-CoV-2 Spike Protein and Lung Vascular Cells. <i>Journal of Respiration</i> , 2021, 1, 40-48.	0.4	6
2512	Metformin prevents the development of monocrotaline-induced pulmonary hypertension by decreasing serum levels of big endothelin-1. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 149.	0.8	15
2513	Survival and Prognostic Factors in Patients with Primary Pulmonary Hypertension. <i>Korean Journal of Internal Medicine</i> , 2001, 16, 75-79.	0.7	9
2514	Survival benefits of warfarin in Korean patients with idiopathic pulmonary arterial hypertension. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 837-845.	0.7	5
2515	Diagnosis and evaluation of pulmonary hypertension.. <i>Cleveland Clinic Journal of Medicine</i> , 2003, 70, S9-S9.	0.6	28
2516	Diagnostic strategies for suspected pulmonary arterial hypertension: a primer for the internist.. <i>Cleveland Clinic Journal of Medicine</i> , 2007, 74, 737-747.	0.6	9
2517	Treating pulmonary arterial hypertension: cautious hope in a deadly disease.. <i>Cleveland Clinic Journal of Medicine</i> , 2007, 74, 789-793.	0.6	6
2518	Imaging the right ventricle in pulmonary hypertension. <i>Pulmonary Vascular Research Institute (PVRI) Review</i> , 2009, 1, 180.	0.1	5
2519	Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin. <i>Annals of Thoracic Medicine</i> , 2015, 10, 204.	0.7	9
2520	A review of imaging modalities in pulmonary hypertension. <i>Annals of Thoracic Medicine</i> , 2017, 12, 61.	0.7	51
2521	Evidence of apoptosis in right ventricular dysfunction in rheumatic mitral valve stenosis. <i>Indian Journal of Medical Research</i> , 2016, 144, 718.	0.4	4
2522	Current and Emerging Therapies in Pulmonary Arterial Hypertension: Focus on Treprostinil. <i>Clinical Medicine Reviews in Vascular Health</i> , 0, 3, 39-52.	3.0	2
2523	The long-term response to treatment with calcium channel blockers in a patient with idiopathic pulmonary arterial hypertension.. <i>Bratislava Medical Journal</i> , 2013, 114, 283-286.	0.4	5

#	ARTICLE	IF	CITATIONS
2524	Efficacy of Isovolumic Acceleration in Assessing Right Ventricular Function in Pulmonary Hypertension. <i>International Journal of Clinical Medicine</i> , 2014, 05, 674-680.	0.1	1
2525	Short-Term Drug-Drug Interaction between Sildenafil and Bosentan under Long-Term Use in Patients with Pulmonary Arterial Hypertension. <i>Pharmacology & Pharmacy</i> , 2013, 04, 542-548.	0.2	1
2526	Long term combination treatment for severe idiopathic pulmonary arterial hypertension. <i>World Journal of Cardiology</i> , 2010, 2, 68.	0.5	3
2527	Early Recognition and Management of Pulmonary Arterial Hypertension: A Case for Profiling. <i>Oman Medical Journal</i> , 2012, 27, 1-2.	0.3	4
2528	Role of High-flow Nasal Oxygen Therapy in Cases with Pulmonary Hypertension in an Intensive Care Unit Setting. <i>Indian Journal of Critical Care Medicine</i> , 2019, 23, 458-461.	0.3	5
2529	Right Heart Failure during Veno-Venous Extracorporeal Membrane Oxygenation for H1N1 Induced Acute Respiratory Distress Syndrome: Case Report and Literature Review. <i>Korean Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 48, 289-293.	0.6	12
2530	Echocardiographic evaluation of right ventricular systolic function: The traditional and innovative approach. <i>Cardiology Journal</i> , 2017, 24, 563-572.	0.5	57
2531	The Right Ventricle: A Comprehensive Review From Anatomy, Physiology, and Mechanics to Hemodynamic, Functional, and Imaging Evaluation. <i>Archives of Cardiovascular Imaging</i> , 2015, 3, .	0.2	14
2532	Efficacy and safety of prostacyclins therapy in pulmonary arterial hypertension: A meta-analysis. <i>African Journal of Pharmacy and Pharmacology</i> , 2011, 5, .	0.2	1
2533	Early Assessment of Right Ventricular Function in Systemic Lupus Erythematosus Patients using Strain and Strain Rate Imaging. <i>Arquivos Brasileiros De Cardiologia</i> , 2018, 111, 75-81.	0.3	9
2534	Noninvasive prediction of pulmonary hemodynamics in chronic thromboembolic pulmonary hypertension by electrocardiogram-gated computed tomography. <i>European Journal of Radiology Open</i> , 2021, 8, 100384.	0.7	3
2535	Pulmonary arterial hypertension: achievements and realities of modern treatment, a look into the future. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1009-1017.	0.2	3
2536	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2022, 59, 2102024.	3.1	57
2537	Clinical efficacy, safety, tolerability, and survival outcome of long-term inhaled iloprost treatment in the management of pulmonary arterial hypertension: Data from prospective multicenter observational OPTION study. , 2021, 25, 721-732.		2
2538	Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00846.	1.1	2
2539	AtualizaÃ§Ã£o no Tratamento da HipertensÃ£o Arterial Pulmonar. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 750-764.	0.3	6
2540	Murine models of sickle cell disease and beta-thalassemia demonstrate pulmonary hypertension with distinctive features. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	11
2541	Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era. <i>European Respiratory Journal</i> , 2022, 59, 2101552.	3.1	27

#	ARTICLE	IF	CITATIONS
2542	Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association, 2021, 10, e021095.	1.6	5
2543	Acute right ventricular failure associated with pulmonary hypertension in pediatrics: understanding the hemodynamic profiles. Journal of Perinatology, 2022, 42, 139-142.	0.9	2
2544	Chronisches Cor pulmonale. , 2000, , 889-904.		0
2545	Pulmonale Hypertonie. , 2000, , 113-128.		0
2546	Respiratory Disorders. , 2000, , 513-556.		0
2547	Hipertensã pulmonar: relato de seis casos e atualizaã do tema. Jornal De Pneumologia, 2000, 26, 321-336.	0.1	5
2550	Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax, 2001, 56, 734-736.	2.7	2
2551	Hypertensive Pulmonary Vasculopathies: Diagnostic Evaluations. , 2002, , 1632-1640.		0
2552	Hypertensive Pulmonary Vasculopathies: Clinical Management. , 2002, , 1641-1649.		0
2553	Continuous Intravenous Epoprostenol for Pulmonary Arterial Hypertension: Highlighting Practical Issues, Special Considerations. Advances in Pulmonary Hypertension, 2002, 1, 4-8.	0.1	2
2554	Aktuelle Aspekte der systemischen Sklerodermie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2003, , 344-346.	0.0	0
2555	New Directions in Pulmonary Hypertension: Expanding the Spectrum of End Points to Enhance Clinical Evaluation. Advances in Pulmonary Hypertension, 2003, 2, 17-27.	0.1	0
2556	Pulmonale Hypertonie â Cor pulmonale. , 2004, , 1201-1216.		1
2557	Nitrate in der Behandlung der pulmonalvenãsen Hypertonie. , 2004, , 65-70.		0
2558	Tratamiento crãnico combinado con iloprost y sildenafil en un paciente con hipertensiãn pulmonar primaria. Revista Medica De Chile, 2004, 132, .	0.1	0
2559	Advances in Prostacyclin Therapy for Pulmonary Arterial Hypertension. Critical Care Nurse, 2004, 24, 42-54.	0.5	2
2561	Avaliaão hemodinãmica da hipertensão pulmonar. Jornal Brasileiro De Pneumologia, 2005, 31, S9-S12.	0.4	1
2562	PHA Achieves Educational Breakthrough With New Interactive CD-ROM. Advances in Pulmonary Hypertension, 2005, 4, 2-2.	0.1	0

#	ARTICLE	IF	CITATIONS
2564	Childhood Pulmonary Arterial Hypertension. , 2006, , 910-926.		0
2565	Pulmonary Hypertension in Children. , 2006, , 274-287.		0
2566	Respiratory Disorders. , 2006, , 559-609.		0
2567	Respiratory Disorders. , 2006, , 559-609.		0
2569	Practical Nursing Issues in the Outpatient Management of Pulmonary Vascular Disease. , 2006, , 314-329.		0
2570	The etiology and pathogenesis of pulmonary arterial hypertension. Cor Et Vasa, 2006, 48, 108-113.	0.1	2
2571	Management of Idiopathic PAH in Children: Reexamining the Evolving Treatment Algorithm. Advances in Pulmonary Hypertension, 2006, 5, 13-21.	0.1	1
2573	Advances in Prostanoid Therapy: New Studies, New Methods of Delivery. Advances in Pulmonary Hypertension, 2006, 5, 23-30.	0.1	1
2574	Pulmonary Arterial Hypertension. , 2007, , 2203-2246.		0
2576	Treatment of Severe Idiopathic Pulmonary Hypertension. , 2007, , 758-766.		0
2577	Left Main Stem Bronchus Compression Occurred in Primary Pulmonary Hypertension Patient - A case report -. Daehan Macwi'gwa Haghoeji, 2007, 53, 104.	0.2	1
2578	Pulmonale Hypertonie (PH)1 (S2). , 2007, , 17-23.		0
2579	Anesthetic Management in a Patient with Severe Primary Pulmonary Hypertension with Right Ventricular Dysfunction - A case report -. Daehan Macwi'gwa Haghoeji, 2008, 54, 473.	0.2	0
2581	Vascular Diseases. , 2008, , 99-129.		0
2582	Pharmacological Treatment of Pulmonary Hypertension. , 2008, , 226-247.		0
2583	Phase 2 and 3 Clinical Trials in Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2008, 7, 228-234.	0.1	1
2584	Pulmonary Arterial Hypertension. , 2008, , 393-398.		0
2585	48 Pulmonale hypertensie. , 2008, , 443-449.		0

#	ARTICLE	IF	CITATIONS
2586	Inhaled Prostanoids in the Therapy of Pulmonary Hypertension. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, .	1.2	0
2588	Diseases of the Pulmonary Vascular System. , 2009, , 1-18.		0
2589	Survival Patterns Without Cardiac Surgery or Interventional Catheterization: A Narrowing Base. , 2009, , 25-67.		4
2590	Pulmonary Arterial Hypertension. Tuberculosis and Respiratory Diseases, 2009, 67, 177.	0.7	0
2591	Chronic Pulmonary Hypertension. , 2009, , 483-505.		0
2592	Pulmonary Arterial Hypertension in Pregnancy. , 2009, , 285-312.		0
2594	Pulmonary Arterial Hypertension Complicating Connective Tissue Diseases. , 2009, , 183-197.		0
2595	Atrial Septostomy for the Treatment of Severe Pulmonary Hypertension. , 2009, , 442-454.		0
2596	Pulmonary arterial hypertension. Cor Et Vasa, 2009, 51, 455-461.	0.1	1
2597	Infectious complications of long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Cor Et Vasa, 2009, 51, 488-490.	0.1	0
2598	Diagnosis and Management of Pulmonary Hypertension Associated With Pulmonary Fibrosis. Advances in Pulmonary Hypertension, 2009, 8, 141-147.	0.1	0
2600	Idiopathic and Familial Pulmonary Arterial Hypertension. , 2010, , 39-84.		0
2603	Niveles aumentados de estr�s oxidativo se asocian a disfunci�n endotelial perif�rica y respuesta vascular pulmonar disminuida frente a vasodilatadores en pacientes con hipertensi�n pulmonar. Revista Chilena De Cardiolog�a, 2010, 29, 291-298.	0.0	0
2604	Pulmonary Arterial Hypertension. , 2010, , 195-211.		0
2605	Patient Evaluation and Selection. , 2010, , 311-313.		0
2606	Idiopathic Pulmonary Hypertension: New Challenges. , 2010, , 147-157.		0
2607	Ipertensione arteriosa polmonare: stima della casistica italiana e considerazioni sull�mpatto sul budget dell�introduzione di tadalafil. Farmeconomia E Percorsi Terapeutici, 2010, 11, 77-82.	0.2	0
2608	Pulmonary Hypertension and Cor Pulmonale. , 2011, , 353-371.		0

#	ARTICLE	IF	CITATIONS
2609	Update From the NHLBI on Lung Vascular and Pulmonary Hypertension Research. <i>Advances in Pulmonary Hypertension</i> , 2010, 9, 152-155.	0.1	0
2610	<i>Pediatric Pulmonary Hypertension: An Integrated View from Pediatric Subspecialists.</i> , 2011, , 1083-1108.		0
2611	<i>Atrial Septostomy.</i> , 2011, , 1561-1567.		0
2612	<i>Results of Lung Transplantation.</i> , 2011, , 1613-1626.		0
2613	<i>Pathobiology and Treatment of Pulmonary Hypertension in HIV Disease.</i> , 2011, , 1033-1041.		0
2614	<i>Pulmonary Arterial Hypertension Related to Scleroderma and Collagen Vascular Diseases.</i> , 2011, , 1011-1022.		0
2615	<i>Living-Donor Lobar Lung Transplantation for Pulmonary Arterial Hypertension.</i> , 2011, , 1603-1611.		0
2616	<i>Epidemiology of Pulmonary Arterial Hypertension.</i> , 2011, , 943-961.		0
2617	<i>Genetics of Familial and Idiopathic Pulmonary Arterial Hypertension.</i> , 2011, , 997-1009.		0
2618	<i>Late Limited Systemic Sclerosis Patient Who Develops Shortness of Breath on Exertion.</i> , 2011, , 127-137.		0
2619	<i>Pulmonale Hypertonie.</i> , 2011, , 309-334.		0
2620	<i>Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension.</i> , 2011, , 755-789.		1
2621	<i>Primary Pulmonary Hypertension.</i> , 2011, , 322-323.		0
2623	<i>Chronická plicní hypertenze. Doporučení diagnostické a léčebné postupy České kardiologické společnosti, 2010. Cor Et Vasa</i> , 2011, 53, 169-182.	0.1	3
2624	<i>Prostacyclins.</i> , 2011, , 313-325.		0
2625	<i>Atrial septostomy and other interventional procedures.</i> , 2011, , 391-404.		2
2627	<i>Successful Epoprostenol Withdrawal in Pulmonary Arterial Hypertension. Case Report and Literature Review.</i> <i>Respiratory Care</i> , 2012, 58, e1-5.	0.8	7
2628	<i>Primary Pulmonary Hypertension.</i> , 2012, , 196-211.		1

#	ARTICLE	IF	CITATIONS
2629	Future development of therapy with inhaled iloprost in pulmonary arterial hypertension. Pulmonologiya, 2012, , 95-102.	0.2	1
2630	Epigastric pain as the initial presentation of undiagnosed HIV and its associated pulmonary arterial hypertension. International Journal of Case Reports and Images, 2012, 3, 19.	0.0	0
2631	Mortality-Related Risk Factors in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. The Importance of Response to Treatment. Open Journal of Respiratory Diseases, 2012, 02, 17-24.	0.1	1
2633	Pulmonary Hypertension/Eisenmenger Syndrome. , 2012, , 2413-2423.		0
2635	Krankheiten des Herzens. , 2012, , 335-393.		0
2636	Screening for Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2012, 11, 78-83.	0.1	1
2638	Contemporary treatment of pulmonary arterial hypertension: the North-West Registry data analysis. Cardiovascular Therapy and Prevention (Russian Federation), 2012, 11, 79-84.	0.4	0
2639	Pulmonary arterial hypertension in patients with HIV infection. , 2012, , 82-93.		0
2640	Pulmonary Hypertension: A Review. Faridpur Medical College Journal, 2013, 7, 82-87.	0.0	0
2641	Erkrankungen des pulmonalen Gefäßsystems. , 2013, , 399-429.		0
2642	Pulmonary Arterial Hypertension: Use of Delayed Contrast-Enhanced Cardiovascular Magnetic Resonance in Risk Assessment. Arquivos Brasileiros De Cardiologia, 2013, 101, 336-43.	0.3	13
2643	ECHOCARDIOGRAPHY IN RIGHT VENTRICULAR MYOCARDIAL INFARCTION. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 58-62.	0.4	0
2647	Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group. , 2014, , 2139-2158.		0
2648	Heart Failure and Pulmonary Hypertension in Women. , 2014, , 155-173.		0
2649	Targeted Pulmonary Arterial Hypertension Therapies and a Combined Medical-Surgical Approach for Congenital Heart Disease Patients. Advances in Pulmonary Hypertension, 2013, 11, 183-188.	0.1	0
2650	Transitioning the Pediatric Pulmonary Hypertension Patient. Advances in Pulmonary Hypertension, 2013, 11, 162-164.	0.1	0
2651	Diagnosis and Treatment of Pulmonary Arterial Hypertension. , 2014, , 1-33.		0
2652	Pediatric Lung Transplantation. , 2014, , 401-409.		0

#	ARTICLE	IF	CITATIONS
2653	Ambulatory Hemodynamic Monitoring in the Management of Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2014, 13, 81-85.	0.1	4
2654	Atrial Septostomy. , 2014, , 305-316.		0
2655	Aging and Right Ventricular Failure from Pulmonary Hypertension: Effect of Right Ventricular and Pulmonary Artery Remodeling. , 2014, , 291-304.		0
2656	Dual Extracorporeal Membrane Oxygenation Support for Bridging Lung Transplantation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. <i>The Korean Journal of Critical Care Medicine</i> , 2014, 29, 207.	0.2	0
2657	Pulmonalkreislauf. , 2014, , 105-113.		0
2658	Nitric Oxide Therapeutics in Pulmonary Vascular Disease. <i>Advances in Pulmonary Hypertension</i> , 2014, 13, 134-137.	0.1	0
2659	Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database. <i>Journal of Health Economics and Outcomes Research</i> , 2013, 1, 254-265.	0.6	1
2660	CLINICAL ASPECTS OF LUNG TRANSPLANTATION. <i>Clinics in Chest Medicine</i> , 1993, 14, 335-357.	0.8	14
2661	When to refer a patient for lung transplantation. , 1995, , 267-275.		1
2662	Cor Pulmonale in Systemic Lupus Erythematosus: A Case Report and Review of the Literature. <i>Annals of Saudi Medicine</i> , 1995, 15, 282-283.	0.5	0
2663	Transplantation of the Heart and Both Lungs - Indications, Selection, and Evaluation. , 1996, , 605-608.		0
2664	Pulmonale Hypertonie. , 1997, , 1-14.		0
2665	Pulmonale Hypertonie. , 1998, , 425-442.		0
2666	Ethical Issues in Lung Transplantation. <i>American Journal of the Medical Sciences</i> , 1998, 315, 142-145.	0.4	3
2668	The Pathobiology of Chronic Right Ventricular Failure. <i>Respiratory Medicine</i> , 2015, , 283-301.	0.1	0
2669	A Retrospective Analysis of Patients with Pulmonary Hypertension to Assess the Role of Overnight Oximetry in the Diagnosis of Sleep Disordered Breathing. <i>International Journal of Respiratory and Pulmonary Medicine</i> , 2014, 1, .	0.1	0
2670	Pulmonic Valve: Pulmonary Arterial Hypertension. , 2015, , 191-203.		0
2671	Pharmacologic Treatment of the Failing Right Heart. , 2015, , 89-107.		0

#	ARTICLE	IF	CITATIONS
2673	Diagnosis and Treatment of Pulmonary Arterial Hypertension. , 2015, , 4105-4133.		0
2674	Pulmonary Hypertension in the Elderly: Impact of Age on Diagnosis and Therapy Options. , 2015, , 109-133.		0
2676	Using Cardiac Magnetic Resonance Imaging to Evaluate Cardiac Function and Predict Outcomes in Patients with Valvular Heart Disease. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2015, 10, 63-67.	0.4	0
2677	The importance of stress echocardiography. Choonpa Igaku, 2015, 42, 599-610.	0.0	0
2678	Adjunct Therapy and Calcium Channel Blockers. Respiratory Medicine, 2015, , 303-321.	0.1	0
2679	We Obtain A Hemodynamic Near Normalization? Clues from Three Long-Term Survivors on Epoprostenol Treatment. MOJ Clinical & Medical Case Reports, 2015, 2, .	0.0	0
2680	Clinical case: combination therapy with iloprost and sildenafil in the treatment of idiopathic pulmonary hypertension. Systemic Hypertension, 2015, 12, 66-70.	0.1	0
2681	Epidemiology of Pulmonary Hypertension: From Quaternary Referral Centre to the Community. , 2016, , 63-79.		0
2682	Genetics of Pulmonary Vascular Disease. , 2016, , 105-121.		0
2683	Surgery, Devices, Transplantation and Other Interventional Options for the Treatment of Advanced Pulmonary Hypertension. , 2016, , 283-306.		0
2684	Biomarkers and Other Methods for Assessing Patient Progress. , 2016, , 231-240.		0
2685	Patient Registries in Pulmonary Arterial Hypertension: the Role of Survival Equations and Risk Calculators. , 2016, , 307-325.		1
2687	Tuberculosis and pulmonary hypertension: Commentary. Lung India, 2016, 33, 232.	0.3	5
2688	Assessing Disease State in the Pulmonary Vasculature in Clinical Practice and Research. , 2016, , 219-229.		1
2689	The Cardiopulmonary Hemodynamic Evaluation of Pulmonary Hypertension. , 2016, , 173-198.		0
2690	Therapeutic Options for Childhood Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2016, 15, 82-86.	0.1	0
2692	RIGHT VENTRICULAR DYSFUNCTION IN CHRONIC KIDNEY DISEASE STAGES 3 AND 4. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 4959-4963.	0.0	0
2693	Hoarseness of voice as presenting complaint of idiopathic pulmonary arterial hypertension. Lung India, 2017, 34, 212.	0.3	1

#	ARTICLE	IF	CITATIONS
2694	Invasive Techniques for Diagnosis of PH. , 2017, , 29-44.		0
2695	Derivation and Validation of Formula relating Pulmonary Acceleration Time and Mean Pulmonary Artery Pressure in Indian Population. Journal of Perioperative Echocardiography, 2017, 5, 3-11.	0.2	1
2696	Assessment of Right Ventricular Function by Newer Imaging in Echocardiography in Idiopathic Pulmonary Arterial Hypertension. Cardiology Research, 2017, 8, 214-219.	0.5	3
2697	Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort. Advances in Pulmonary Hypertension, 2017, 16, 14-19.	0.1	0
2698	Pulmonary Arterial Hypertension. , 2017, , .		0
2699	Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs. Systemic Hypertension, 2017, 14, 58-64.	0.1	0
2700	The Road Toward Precision in PH: Personal Omics, Phenomics, and Wearablesâ€”Oh My!. Advances in Pulmonary Hypertension, 2018, 17, 141-147.	0.1	1
2701	Barriers and Solutions to Developing Future Therapies for Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2018, 17, 159-165.	0.1	0
2702	Single- and Bilateral Lung Transplantation: Indications, Contraindications, Evaluation, and Requirements for Patients to Be Considered Eligible. , 2018, , 17-40.		0
2703	CONTEMPORARY STRATEGY OF PULMONARY HYPERTENSION MANAGEMENT IN PEDIATRICS. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 101-124.	0.4	4
2704	The importance of the World Symposium on Pulmonary Hypertension. Jornal Brasileiro De Pneumologia, 2018, 44, 173-174.	0.4	3
2706	Organization of pharmacological support of patients with rare diseases in moscow as exemplified by pulmonary arterial hypertension. Meditsinskiy Sovet, 2018, , 24-31.	0.1	1
2707	THE COMPLEXITY OF DIAGNOSING IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2018, 63, 167-171.	0.1	0
2708	Chronic Lung Pathologies That Require Repair and Regeneration. , 2019, , 1-12.		1
2709	Pulmonary Vascular Disease. , 2019, , 153-161.		0
2713	Expert Council resolution on pulmonary arterial hypertension (PAH) "Changing the paradigm of treating patients with pulmonary arterial hypertension". Terapevticheskii Arkhiv, 2019, 91, 114-116.	0.2	2
2714	Clinical case of delayed systemic sclerosis and pulmonary arterial hypertension diagnostics. ZaporoÅ¼skij Medicinskij Å½urnal, 2019, .	0.0	0
2715	Chronic postembolic pulmonary embolism: the role of radionuclide imaging. Regional Blood Circulation and Microcirculation, 2019, 18, 17-23.	0.1	0

#	ARTICLE	IF	CITATIONS
2716	EVALUATION OF THE EFFECT OF SILDENAFIL IN HEMODIALYSIS PATIENTS WITH PULMONARY HYPERTENSION. <i>Ain Shams Medical Journal</i> , 2019, 70, 579-586.	0.0	0
2717	Goal-Oriented Sequential Combination Therapy Evaluated Using Cardiopulmonary Exercise Parameters for the Treatment of Newly Diagnosed Pulmonary Arterial Hypertension – Goal-Oriented Therapy Evaluated by Cardiopulmonary Exercise Testing for Pulmonary Arterial Hypertension (GOOD EYE) – <i>Circulation Reports</i> , 2019, 1, 303-311.	0.4	3
2718	Prognosis and its predictors for pulmonary hypertension associated with connective tissue diseases (data of the first Ukrainian register). <i>Hypertension</i> , 2019, .	0.2	0
2719	Genetic Pediatric Pulmonary Disease. , 2020, , 199-210.		0
2721	Clinical Outcomes and Treatment Options in Patients With Pulmonary Hypertension Who Received Pulmonary Hypertension-Specific Drugs – Single-Center Case Series – <i>Circulation Reports</i> , 2019, 1, 389-395.	0.4	1
2722	Brain Natriuretic Peptide Response to Six-minute Walk Test in Pulmonary Arterial Hypertension. <i>International Journal of Pulmonary & Respiratory Sciences</i> , 2019, 4, .	0.1	0
2723	Pulmonary Arterial Hypertension in Hispanics. <i>Cureus</i> , 2019, 11, e5834.	0.2	0
2724	Pulmonary Hypertension in an Oncologic Intensive Care Unit. , 2020, , 675-697.		0
2725	Cardiac magnetic resonance imaging and clinical prognosis in pulmonary arterial hypertension. <i>Radiologia Brasileira</i> , 2019, 52, V-VI.	0.3	2
2726	Relationship between right atrium area and right ventricular ejection fraction on magnetic resonance imaging: comparison with other prognostic markers in patients with pulmonary arterial hypertension. <i>Radiologia Brasileira</i> , 2019, 52, 351-355.	0.3	2
2727	Right ventricular myocardial stiffness and relaxation components by kinematic model-based analysis. <i>Journal of Medical Investigation</i> , 2020, 67, 11-20.	0.2	0
2728	Predictors of Long-term Outcomes in Patients With Connective Tissue Disease Associated With Pulmonary Arterial Hypertension. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e371-e377.	0.5	2
2729	Non-Invasive Risk Prediction Based on Right Ventricular Function in Patients with Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2021, 10, 5130.	1.0	1
2730	The prognostic significance of the alterations of pulmonary hemodynamics in patients with pulmonary arterial hypertension: a meta-regression analysis of randomized controlled trials. <i>Systematic Reviews</i> , 2021, 10, 284.	2.5	5
2731	Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models. <i>Frontiers in Pharmacology</i> , 2021, 12, 756226.	1.6	8
2732	Imaging of Pulmonary Hypertension in Congenital Heart Disease. , 2021, , 499-514.		0
2734	Strategies to Treat Pulmonary Hypertension Using Programmed Cell Death-Inducing Anti-Cancer Drugs without Damaging the Heart. , 0, , .		0
2736	Chronic Pulmonary Hypertension. , 2020, , 465-489.		0

#	ARTICLE	IF	CITATIONS
2737	Introduction to the Right Heart. <i>Clinical Cases in Cardiology</i> , 2020, , 1-19.	0.0	0
2738	Advanced Right Ventricular Assessment: Pulmonary Artery Compliance and RV-PA Coupling. <i>Respiratory Medicine</i> , 2020, , 29-50.	0.1	0
2739	Should oral combination therapy be the standard of care for pulmonary arterial hypertension?. Expert Review of <i>Respiratory Medicine</i> , 2020, 14, 341-343.	1.0	1
2740	Heart-Lung Transplantation. , 2020, , 645-654.		1
2742	Traditional and Novel Invasive Hemodynamic Indices in the Evaluation of Congestive Heart Failure in Cardiorenal Syndrome. , 2020, , 379-395.		0
2743	Evaluation of Right Ventricular Function on Cardiac Magnetic Resonance Imaging and Correlation With Hemodynamics in Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation Reports</i> , 2020, 2, 174-181.	0.4	2
2744	Gas exchange: the neglected piece in the PAH puzzle. <i>European Respiratory Journal</i> , 2021, 58, 2101407.	3.1	0
2745	Krankheiten des Herzens. , 2008, , 311-373.		0
2747	The Pulmonary Circulation in Health and Disease. , 2002, , 218-240.		2
2748	Indications, Selection and Pretransplant Management of the Potential Recipient. , 1996, , 433-441.		0
2749	Lung Transplantation in Infants and Children - Indications, Surgical Techniques, and Special Considerations. , 1996, , 573-580.		0
2750	Primary Pulmonary Hypertension. , 2005, , 413-435.		0
2751	Pulmonary Vascular Disease. , 2005, , 661-680.		0
2752	Lung Transplantation and Atrial Septostomy for Pulmonary Arterial Hypertension. , 2008, , 383-403.		2
2753	Classification of Pulmonary Hypertension. , 2008, , 15-31.		1
2754	Diagnostic Approach to Pulmonary Arterial Hypertension. , 2008, , 33-50.		0
2755	Pulmonary Hypertension Associated with HIV, Liver Disease, Sarcoidosis, and Sickle Cell Disease. , 2008, , 173-198.		0
2756	Bosentan for treatment of pulmonary arterial hypertension (I). <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 843-847.	0.2	0

#	ARTICLE	IF	CITATIONS
2757	Chronische pulmonale Hypertonie. , 2009, , 291-303.		0
2758	Pulmonary Hypertension: Old Targets Revisited (Statins, PPARs, Beta-Blockers). Handbook of Experimental Pharmacology, 2013, 218, 531-548.	0.9	5
2760	â€œPortraitâ€•of patients with idiopathic pulmonary hypertension and chronic thromboembolic pulmonary hypertension depending on comorbid status: current and prognosis features. Pulmonologiya, 2020, 30, 427-436.	0.2	5
2762	Evidence for the Role of Cell Reprogramming in Naturally Occurring Cardiac Repair. , 0, ,		0
2763	Multi-detector CT assessment in pulmonary hypertension: techniques, systematic approach to interpretation and key findings. Quantitative Imaging in Medicine and Surgery, 2015, 5, 423-32.	1.1	18
2765	Lung transplantation. Part I. Indications and operative management. Western Journal of Medicine, 1996, 165, 355-63.	0.3	4
2766	Recommendations on the management of pulmonary hypertension in clinical practice. Heart, 2001, 86 Suppl 1, I1-13.	1.2	31
2767	Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review. MedGenMed: Medscape General Medicine, 2006, 8, 29.	0.2	2
2768	A review of pulmonary arterial hypertension: role of ambrisentan. Vascular Health and Risk Management, 2007, 3, 11-22.	1.0	40
2769	Review of bosentan in the management of pulmonary arterial hypertension. Vascular Health and Risk Management, 2007, 3, 887-900.	1.0	34
2770	A review of pulmonary arterial hypertension: Part 1. Novel insights and classification. Netherlands Heart Journal, 2004, 12, 287-294.	0.3	1
2771	Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. Core Evidence, 2008, 2, 225-31.	4.7	2
2772	Endothelin-1 and endothelial nitric oxide polymorphisms in idiopathic pulmonary arterial hypertension. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 208-13.	0.4	22
2773	Pulmonary hypertension for primary care providers. Ochsner Journal, 2009, 9, 234-40.	0.5	0
2774	Effects of cardiac rehabilitation program on right ventricular function after coronary artery bypass graft surgery. Journal of Tehran University Heart Center, 2012, 7, 25-9.	0.2	0
2775	A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2010, 26, 206-218.	0.0	1
2776	Mechanics and mechanisms of pulmonary hypertension-Conference summary and translational perspectives. Pulmonary Circulation, 2013, 3, 128-36.	0.8	6
2777	Pulmonary hypertension: a woman's disease. Texas Heart Institute Journal, 2013, 40, 302-3.	0.1	2

#	ARTICLE	IF	CITATIONS
2778	Life span of patients with Eisenmenger syndrome is not superior to that of patients with other causes of pulmonary hypertension. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 341-9.	0.7	8
2779	Complete therapeutical approach in pulmonary arterial hypertension: from vasodilators to lung transplantation - case report. <i>MĂdica</i> , 2014, 9, 198-203.	0.4	0
2780	Complete resolution of chronic pericardial effusion with an intensive course of inhaled iloprost in an adult patient with unrepaired ventricular septal defect, and life-threatening severe pulmonary arterial hypertension. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2014, 35, 1257-9.	0.5	1
2781	Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. <i>Minerva Pediatrica</i> , 2015, 67, 169-85.	2.6	6
2782	Abnormal expression of NSF, Î±-SNAP and SNAP23 in pulmonary arterial hypertension in rats treated with monocrotaline. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 1834-43.	1.3	2
2783	Iranian Pulmonary Arterial Hypertension Registry. <i>Tanaffos</i> , 2015, 14, 115-20.	0.5	5
2784	Pulmonary arterial hypertension associated with rare cause of ANCA-associated vasculitis misdiagnosed as idiopathic one. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 16850-3.	1.3	2
2785	2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. <i>Acta Cardiologica Sinica</i> , 2014, 30, 401-44.	0.1	13
2786	Breaking Down the Barriers: Why the Delay in Referral for Pulmonary Arterial Hypertension?. <i>Ochsner Journal</i> , 2016, 16, 257-62.	0.5	2
2787	Effect of early administration of lower dose versus high dose of fresh mitochondria on reducing monocrotaline-induced pulmonary artery hypertension in rat. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 5151-5168.	0.0	9
2788	Role of Meticulous Observation: Successful Pregnancy in a 30-Year-Old Woman with Severe Pulmonary Hypertension. <i>Tanaffos</i> , 2016, 15, 187-190.	0.5	1
2789	Clinical and hemodynamic profiles of elderly patients with pulmonary arterial hypertension: a single center, prospective study. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 20-27.	0.2	5
2790	Which prognostic factors should be used in pulmonary arterial hypertension in elderly patients?. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 28-34.	0.2	3
2791	The Changing Landscape of Pulmonary Arterial Hypertension in 21 Century. <i>Acta Cardiologica Sinica</i> , 2017, 33, 510-513.	0.1	9
2792	Effects of Levosimendan on Right Ventricular Function in Patients with Acute Decompensated Heart Failure. <i>Acta Cardiologica Sinica</i> , 2019, 35, 585-591.	0.1	9
2793	Effects of oral sildenafil on exercise capacity in children with pulmonary arterial hypertension: a randomised trial. <i>Open Heart</i> , 2019, 6, e001149.	0.9	1
2794	Pulmonary Hypertension in Intensive Care Units: An Updated Review. <i>Tanaffos</i> , 2019, 18, 180-207.	0.5	7
2795	Pulmonary hypertension: From an orphan disease to a global epidemic. <i>Global Cardiology Science & Practice</i> , 2020, 2020, e202005.	0.3	3

#	ARTICLE	IF	CITATIONS
2796	The haemodynamic assessment of patients with pulmonary arterial hypertension. <i>Global Cardiology Science & Practice</i> , 2020, 2020, e202004.	0.3	0
2797	Chronic thromboembolic pulmonary hypertension - still evolving. <i>Global Cardiology Science & Practice</i> , 2020, 2020, e202011.	0.3	1
2798	Advanced Circulatory Support and Lung Transplantation in Pulmonary Hypertension. <i>Cardiology Clinics</i> , 2022, 40, 129-138.	0.9	3
2799	Pulmonary arterial hypertension in the elderly population. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 18-23.	0.6	3
2800	Successful epoprostenol withdrawal and termination with an aid of the exercise stress test in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2022, 346, 80-85.	0.8	3
2801	The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension. <i>Chest</i> , 2022, 161, 1347-1359.	0.4	9
2802	Pulmonary hypertension – general considerations. <i>Medic Ro</i> , 2021, 5, 30.	0.0	0
2803	Celastrol attenuates the remodeling of pulmonary vascular and right ventricular in monocrotaline-induced pulmonary arterial hypertension in rats. <i>Cardiovascular Diagnosis and Therapy</i> , 2022, 12, 88-102.	0.7	3
2804	Data of modern registries on clinical course and prognosis of patients with idiopathic pulmonary arterial hypertension. <i>Kardiologicheskii Vestnik</i> , 2021, 16, 23.	0.1	1
2805	CLINICAL AND HEMODYNAMIC PROFILE AND NEUROHORMONAL INDICATORS IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION, DEPENDING ON VASOREACTIVITY RESERVE OF PULMONARY ARTERIES. <i>Eurasian Heart Journal</i> , 2016, , 12-20.	0.2	1
2806	The haemodynamic assessment of patients with pulmonary arterial hypertension. <i>Global Cardiology Science & Practice</i> , 2020, 2020, e202004.	0.3	1
2807	Pulmonary hypertension: From an orphan disease to a global epidemic. <i>Global Cardiology Science & Practice</i> , 2020, 2020, e202005.	0.3	10
2808	Chronic thromboembolic pulmonary hypertension – still evolving. <i>Global Cardiology Science & Practice</i> , 2020, 2020, e202011.	0.3	4
2809	Prognostic Impact of the Pulmonary Artery Pulsatility Index in Patients with Chronic Heart Failure and Severe Mitral Regurgitation Undergoing Percutaneous Edge-to-Edge Repair. <i>Cardiology</i> , 2021, 146, 74-84.	0.6	2
2810	The role of intraoperative pulmonary arterial catheterization data in determining the need for extracorporeal membrane oxygenation in lung transplantation. <i>Turkish Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 29, 480-486.	0.2	1
2811	Recovery of right ventricular function after bilateral lung transplantation for pediatric pulmonary hypertension. <i>Pediatric Transplantation</i> , 2022, , e14236.	0.5	0
2812	Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension. <i>Biomedicines</i> , 2022, 10, 170.	1.4	7
2813	Circulating Blood-Based Biomarkers in Pulmonary Hypertension. <i>Journal of Clinical Medicine</i> , 2022, 11, 383.	1.0	6

#	ARTICLE	IF	CITATIONS
2814	A Review of Pulmonary Arterial Hypertension Treatment in Extracorporeal Membrane Oxygenation: A Case Series of Adult Patients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842110690.	1.0	5
2815	Comparing Diagnosis and Treatment of Pulmonary Hypertension Patients at a Pulmonary Hypertension Center versus Community Centers. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 5.	1.0	5
2816	Utility of Automated Cardiac Chamber Volumetry by Non-Gated CT Pulmonary Angiography for Detection of Pulmonary Hypertension Using the 2018 Updated Hemodynamic Definition. <i>American Journal of Roentgenology</i> , 2022, , .	1.0	0
2817	Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 322, L315-L332.	1.3	4
2818	Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study. <i>Pulmonary Circulation</i> , 2022, 12, e12020.	0.8	16
2819	Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension. <i>International Heart Journal</i> , 2022, 63, 99-105.	0.5	1
2820	Role of cardiopulmonary exercise test in the prediction of hemodynamic impairment in patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2022, 12, e12044.	0.8	6
2821	Inferior Vena Cava Edge Tracking Echocardiography: A Promising Tool with Applications in Multiple Clinical Settings. <i>Diagnostics</i> , 2022, 12, 427.	1.3	5
2822	Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2021, 385, 2361-2376.	13.9	241
2824	Sevoflurane prevents pulmonary vascular remodeling and right ventricular dysfunction in pulmonary arterial hypertension in rats. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 11302-11315.	0.0	1
2825	1,8-Cineole Ameliorates Right Ventricle Dysfunction Associated with Pulmonary Arterial Hypertension by Restoring Connexin 43 and Mitochondrial Homeostasis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2826	The prognostic ability of cardiac output determined by inert gas rebreathing technique in pulmonary hypertension. <i>Chronic Respiratory Disease</i> , 2022, 19, 147997312210784.	1.0	1
2827	Elective lower limb orthopedic arthroplasty surgery in patients with pulmonary hypertension. <i>Pulmonary Circulation</i> , 2022, 12, e12019.	0.8	2
2828	A Retrospective Population-Based Survival Study of Idiopathic Pulmonary Arterial Hypertension in Korea. <i>Journal of Korean Medical Science</i> , 2022, 37, e80.	1.1	1
2829	Identifying Potential Mitochondrial Proteome Signatures Associated with the Pathogenesis of Pulmonary Arterial Hypertension in the Rat Model. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-23.	1.9	3
2830	The spectrum and prevalence of arrhythmia in different clinical pulmonary hypertension groups in Chinese population. <i>Clinical Cardiology</i> , 2022, 45, 495-502.	0.7	5
2831	CMR Measures of Left Atrial Volume Index and Right Ventricular Function Have Prognostic Value in Chronic Thromboembolic Pulmonary Hypertension. <i>Frontiers in Medicine</i> , 2022, 9, 840196.	1.2	2
2832	Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension. <i>AsiaIntervention</i> , 2022, 8, 58-68.	0.1	5

#	ARTICLE	IF	CITATIONS
2833	Pulmonary arterial hypertension in hereditary hemorrhagic telangiectasia associated with ACVRL1 mutation: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, 99.	0.4	7
2834	Pulmonary arterial hypertension: challenges and achievements 2021. <i>Eurasian Heart Journal</i> , 2022, , 80-89.	0.2	2
2835	Renal Venous Stasis Index Reflects Renal Congestion and Predicts Adverse Outcomes in Patients With Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 772466.	1.1	10
2836	Echocardiography Nomogram for Predicting Survival among Chronic Lung Disease Patients with Severe Pulmonary Hypertension. <i>Journal of Clinical Medicine</i> , 2022, 11, 1603.	1.0	0
2837	1,8-Cineole ameliorates right ventricle dysfunction associated with pulmonary arterial hypertension by restoring connexin43 and mitochondrial homeostasis. <i>Pharmacological Research</i> , 2022, 180, 106151.	3.1	8
2839	Pulmonary Hypertension in Pregnancy: Challenges and Solutions. <i>Integrated Blood Pressure Control</i> , 2022, Volume 15, 33-41.	0.4	3
2840	TGF β 2 receptor mutations and clinical prognosis in Chinese Pediatric Patients with idiopathic/hereditary Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2022, 12, e12076.	0.8	2
2841	Training and clinical testing of artificial intelligence derived right atrial cardiovascular magnetic resonance measurements. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2022, 24, 25.	1.6	8
2842	The Glycobiology of Pulmonary Arterial Hypertension. <i>Metabolites</i> , 2022, 12, 316.	1.3	8
2843	An Acute Hyperoxia Test Predicts Survival in Children with Pulmonary Hypertension Living at High Altitude. <i>High Altitude Medicine and Biology</i> , 2021, 22, 395-405.	0.5	0
2844	Pulsatile hemodynamics and ventricular-arterial interactions in the pulmonary circulation: physiologic concepts. , 2022, , 883-897.		0
2845	Características clínicas, evolución y tratamiento de hipertensión arterial pulmonar en un hospital peruano de referencia. <i>Horizonte Médico</i> , 2022, 22, e1685.	0.1	0
2846	Diagnosis and Treatment of Pulmonary Arterial Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1379.	3.8	165
2847	Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4554.	1.8	4
2848	Polychlorinated Biphenyls and Pulmonary Hypertension. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4705.	1.2	0
2859	Speckle-tracking echocardiographic evaluation of the right ventricle in patients with ischemic left ventricular dysfunction. <i>Cardiology Journal</i> , 2022, , .	0.5	0
2860	Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression.. <i>Acta Cardiologica Sinica</i> , 2022, 38, 113-123.	0.1	1
2862	Riociguat in the Treatment of Pulmonary Arterial Hypertension in Mexico. <i>Archives of Medical Research</i> , 2022, , .	1.5	1

#	ARTICLE	IF	CITATIONS
2863	Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials?. <i>Respiratory Medicine and Research</i> , 2022, 81, 100893.	0.4	1
2864	Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024969.	1.6	50
2865	Y-Chromosome Gene, <i>Uty</i> , Protects Against Pulmonary Hypertension by Reducing Proinflammatory Chemokines. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 186-196.	2.5	24
2866	Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response. <i>Heart</i> , 2022, 108, 1392-1400.	1.2	15
2867	The Association of Body Mass Index With Mortality Among Pulmonary Hypertension Patients: A Systematic Review and Meta-Analysis of Cohort Studies. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	1
2868	Genetic factors in the development and course of pulmonary diseases. , 2014, 48, 17-23.		0
2872	Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan. <i>JACC Asia</i> , 2022, 2, 273-284.	0.5	10
2873	Right ventricular strain and volume analyses through deep learning-based fully automatic segmentation based on radial long-axis reconstruction of short-axis cine magnetic resonance images. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2022, 35, 911-921.	1.1	1
2874	Progress in Pulmonary Vein Stenosis: Lessons from Success in Treating Pulmonary Arterial Hypertension. <i>Children</i> , 2022, 9, 799.	0.6	0
2875	A potential model of systemic sclerosis with pulmonary hypertension induced by monocrotaline plus bleomycin. <i>Clinical and Experimental Hypertension</i> , 0, , 1-7.	0.5	0
2876	Various factors contribute to death in patients with different types of pulmonary hypertension: A retrospective pilot study from a single tertiary center. <i>Respiratory Investigation</i> , 2022, 60, 647-657.	0.9	3
2877	Mechanistic Insights into Tricuspid Regurgitation Secondary to Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2022, 175, 97-105.	0.7	2
2878	Severe Functional Tricuspid Valve Regurgitation: Predictors of Mortality After Initial Diagnosis. <i>Heart Lung and Circulation</i> , 2022, , .	0.2	1
2879	A Brief Review on Gender Differences in Mexican-Mestizo Patients with Pulmonary Arterial Hypertension (PAH) at a Tertiary-Level Hospital. <i>Current Problems in Cardiology</i> , 2022, 47, 101275.	1.1	2
2881	The Impact of Socioeconomic, Racial, and Ethnic Disparities on Pulmonary Hypertension Diagnosis and Treatment. <i>Advances in Pulmonary Hypertension</i> , 2022, 21, 30-34.	0.1	0
2882	A case series describing the multidisciplinary management of pulmonary arterial hypertension in pregnancy: Time for optimism. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 0, , .	0.4	1
2883	Gaps of evidence in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2022, , .	0.8	0
2884	Role of NO-cGMP-PKG axis in pulmonary arterial hypertension. <i>Folia Pharmacologica Japonica</i> , 2022, 157, 221-225.	0.1	1

#	ARTICLE	IF	CITATIONS
2885	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 937-948.	5.2	57
2886	The role of macrophages in right ventricular remodeling in experimental pulmonary hypertension. <i>Pulmonary Circulation</i> , 2022, 12, .	0.8	3
2887	Prostaglandin E1 reduces apoptosis and improves the homing of mesenchymal stem cells in pulmonary arterial hypertension by regulating hypoxia-inducible factor 1 alpha. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	5
2888	Pre-Existing Right Ventricular Dysfunction as an Independent Risk Factor for Post Intubation Cardiac Arrest and Hemodynamic Instability in Critically Ill Patients: A Retrospective Observational Study. <i>Journal of Intensive Care Medicine</i> , 2023, 38, 169-178.	1.3	3
2889	An echocardiographic analysis of the right ventricular morphological changes in pulmonary hypertension. <i>International Journal of Health Sciences</i> , 0, , 1-7.	0.0	0
2890	Validation of the New Pediatric Pulmonary Hypertension Risk Score by <scp>CMR</scp> and Speckle Tracking Echocardiography. <i>European Journal of Clinical Investigation</i> , 0, , .	1.7	1
2891	Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020. <i>Bioengineered</i> , 2022, 13, 14667-14680.	1.4	11
2892	Clinician's Corner: Counseling Patients with Pulmonary Vascular Disease Traveling to High Altitude. <i>High Altitude Medicine and Biology</i> , 0, , .	0.5	2
2893	AMBRISANTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM. <i>Eurasian Heart Journal</i> , 2014, , 95-108.	0.2	1
2894	CLINICAL CASE: COMBINATION THERAPY WITH BOSENTAN AND SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION. <i>Eurasian Heart Journal</i> , 2014, , 26-33.	0.2	0
2895	CLINICAL CASE: THERAPY WITH SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION. <i>Eurasian Heart Journal</i> , 2015, , 40-47.	0.2	0
2896	CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRISANTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION. <i>Eurasian Heart Journal</i> , 2015, , 48-55.	0.2	0
2897	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Respiratory Journal</i> , 2023, 61, 2200879.	3.1	445
2898	Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
2899	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Heart Journal</i> , 2022, 43, 3618-3731.	1.0	1,033
2900	Pregnancy Considerations in the Multidisciplinary Care of Patients with Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 260.	0.8	2
2901	Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia. <i>JACC Asia</i> , 2022, 2, 538-546.	0.5	14
2904	Lateral annular systolic excursion ratio: A novel measurement of right ventricular systolic function by two-dimensional echocardiography. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0

#	ARTICLE	IF	CITATIONS
2905	Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension: determinants and clinical impact. <i>Vascular Pharmacology</i> , 2022, 146, 107099.	1.0	4
2906	Hemodynamic indices in pulmonary hypertension: a narrative review. <i>Cardiovascular Diagnosis and Therapy</i> , 2022, 12, 693-707.	0.7	4
2907	Intra-Airway Gene Delivery for Pulmonary Hypertension in Rodent Models. <i>Methods in Molecular Biology</i> , 2022, , 263-278.	0.4	0
2908	Exercise MR-proANP unmasks latent right heart failure in CTEPH. <i>Journal of Heart and Lung Transplantation</i> , 2022, , .	0.3	2
2909	The evolution of survival of pulmonary arterial hypertension over 15 years. <i>Pulmonary Circulation</i> , 2022, 12, .	0.8	8
2910	Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
2911	Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1761-1772.	0.3	19
2912	Stem Cells in Hypertension. , 0, , .		0
2913	Safety of chronic high-dose calcium channel blockers exposure in children with pulmonary arterial hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
2914	EACVI survey on the multi-modality imaging assessment of the right heart. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1417-1422.	0.5	5
2915	Hospital outcomes for patients with pulmonary arterial hypertension in sepsis and septic shock. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	1
2916	Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211327.	1.0	0
2917	Smoking history and pulmonary arterial hypertension: Demographics, onset, and outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2023, 42, 377-389.	0.3	5
2918	NCAPG Promotes Pulmonary Artery Smooth Muscle Cell Proliferation as a Promising Therapeutic Target of Idiopathic Pulmonary Hypertension: Bioinformatics Analysis and Experiment Verification. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11762.	1.8	3
2919	Recent Advances in the Treatment of Pulmonary Arterial Hypertension. <i>Pharmaceuticals</i> , 2022, 15, 1277.	1.7	6
2920	Portopulmonary Hypertension in Nontransplanted Patients: Results of the Largest US Single-Institution Registry. <i>Mayo Clinic Proceedings</i> , 2022, 97, 2236-2247.	1.4	3
2921	Severe pulmonary hypertension: data from the swiss registry. <i>Swiss Medical Weekly</i> , 0, , .	0.8	11
2922	Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. <i>Swiss Medical Weekly</i> , 0, , .	0.8	4

#	ARTICLE	IF	CITATIONS
2925	The Swiss registry for pulmonary arterial hypertension: The paediatric experience. <i>Swiss Medical Weekly</i> , 0, , .	0.8	22
2926	Pulmonary hypertension in Switzerland: treatment and clinical course. <i>Swiss Medical Weekly</i> , 0, , .	0.8	16
2927	Epidemiology of pulmonary hypertension: new data from the Swiss registry. <i>Swiss Medical Weekly</i> , 0, , .	0.8	28
2928	Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension. <i>Pulmonary Circulation</i> , 2022, 12, .	0.8	2
2929	Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
2930	Clinical differences between children and adults with idiopathic and heritable pulmonary arterial hypertension. <i>Cardiology in the Young</i> , 0, , 1-4.	0.4	0
2931	Is combined use of radiofrequency ablation and balloon dilation the future of interatrial communications?. <i>Expert Review of Cardiovascular Therapy</i> , 0, , 1-9.	0.6	0
2932	Correlation Between Right Ventricular Echocardiography Measurements and Functional Capacity in Patients With Pulmonary Arterial Hypertension. <i>Texas Heart Institute Journal</i> , 2022, 49, .	0.1	1
2933	Pulmonary Arterial Hypertension: Emerging Principles of Precision Medicine across Basic Science to Clinical Practice. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 378.	0.5	2
2934	Lung transplantation for pulmonary sarcoidosis. <i>European Respiratory Journal</i> , 1998, 11, 738-744.	3.1	37
2935	The Cardiovascular System: Systemic and Pulmonary Arteries. , 2001, , .		0
2936	Pulmonary arterial hypertension incidence in Latvia in 2019. <i>Pulmonary Circulation</i> , 2022, 12, .	0.8	0
2937	Sex- and Gender-Related Aspects in Pulmonary Hypertension. <i>Heart Failure Clinics</i> , 2023, 19, 11-24.	1.0	1
2938	Risk stratification, prognosis, and survival in a pulmonary arterial hypertension cohort in Latin America. A multicenter study. <i>Respiratory Medicine and Research</i> , 2023, 83, 100945.	0.4	0
2939	Socioeconomically disadvantaged veterans experience treatment delays for pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2022, 12, .	0.8	3
2940	Long-term prognostic value of cardiac catheterization and acute vasodilator testing with inhaled iloprost in pediatric idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2022, 12, .	0.8	1
2941	Palliative Care Perspectives of Patients with Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 0, , .	1.5	1
2942	Left Heart Disease Phenotype in Elderly Patients with Pulmonary Arterial Hypertension: Insights from the Italian PATRIARCA Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 7136.	1.0	5

#	ARTICLE	IF	CITATIONS
2943	Right ventricular systolic strain in patients with pulmonary hypertension: clinical feasibility, reproducibility, and correlation with ejection fraction. <i>Journal of Echocardiography</i> , 2023, 21, 105-112.	0.4	2
2944	From acute SARS-CoV-2 infection to pulmonary hypertension. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	8
2945	Preventative practices and effects of the COVID-19 pandemic on caregivers of children with pediatric pulmonary hypertension. <i>BMC Public Health</i> , 2022, 22, .	1.2	1
2947	Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report. <i>Eurasian Heart Journal</i> , 2022, , 74-81.	0.2	0
2948	A World of Maximalist Medicine: Physician Perspectives on Palliative Care and End-of-life for Patients With Pulmonary Arterial Hypertension. <i>Journal of Pain and Symptom Management</i> , 2022, , .	0.6	1
2949	Apply pressure-strain loop to quantify myocardial work in pulmonary hypertension: A prospective cohort study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
2950	Diagnosis and management of pulmonary arterial hypertension. <i>Breathe</i> , 2022, 18, 220168.	0.6	1
2951	Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review. <i>Consilium Medicum</i> , 2022, 24, 688-695.	0.1	1
2952	Therapeutic potential of nitric oxide pathway management in pulmonary arterial hypertension: from nitric oxide to its synthetic analog " Oxacom. <i>Kardiologicheskii Vestnik</i> , 2022, 17, 24.	0.1	0
2953	Lungenerkrankungen. , 2022, , 289-378.		0
2954	Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials. <i>Cureus</i> , 2023, , .	0.2	0
2955	Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data. <i>Pulmonary Circulation</i> , 2023, 13, .	0.8	7
2956	Metabolomic Signatures Associated With Pulmonary Arterial Hypertension Outcomes. <i>Circulation Research</i> , 2023, 132, 254-266.	2.0	11
2957	Risk assessment validation in patients with pulmonary arterial hypertension: Data from a Southern Brazil Registry (RESPHIRAR Study). <i>Pulmonary Circulation</i> , 0, , .	0.8	0
2958	Prostacyclin receptor agonists induce DUSP1 to inhibit pulmonary artery smooth muscle cell proliferation. <i>Life Sciences</i> , 2023, 315, 121372.	2.0	2
2959	Multimodal Learning for Predicting Mortality in Patients with Pulmonary Arterial Hypertension. , 2022, , .		0
2960	Differences in right ventricular function and response to targeted therapy between patients with IPAH and PAH-CHD. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
2961	Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis. <i>Value in Health Regional Issues</i> , 2023, 36, 44-50.	0.5	1

#	ARTICLE	IF	CITATIONS
2962	Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies. <i>BMC Pediatrics</i> , 2023, 23, .	0.7	1
2963	Left Ventricular Filling Pressure in Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2023, 81, 653-664.	1.2	11
2964	Ambrisentan for in pediatric pulmonary arterial hypertension: A cost utility analysis. <i>Pediatric Pulmonology</i> , 2023, 58, 1562-1568.	1.0	1
2965	The First Pulmonary Hypertension Registry in the United Arab Emirates (UAEPH): Clinical Characteristics, Hemodynamic Parameters with Focus on Treatment and Outcomes for Patients with Group 1-PH. <i>Journal of Clinical Medicine</i> , 2023, 12, 1996.	1.0	4
2966	Prognosis in Hispanic patient population with pulmonary arterial hypertension: An application of common risk stratification models. <i>Pulmonary Circulation</i> , 2023, 13, .	0.8	1
2967	Comparative assessment of the effects of dobutamine and levosimendan on right ventricular ejection fraction in patients with biventricular heart failure. <i>Kardiologiya</i> , 2023, 63, 46-51.	0.3	0
2968	Potential Prognostic Value of Native T1 in Pulmonary Hypertension Patients. <i>Life</i> , 2023, 13, 775.	1.1	0
2969	Epidemiology of PAH in Korea: An Analysis of the National Health Insurance Data, 2002–2018. <i>Korean Circulation Journal</i> , 2023, 53, 313.	0.7	1
2970	Principles of healthcare management for patients with pulmonary hypertension: focus on continuity. <i>Russian Journal of Cardiology</i> , 2023, 28, 5335.	0.4	1
2971	Jagged/Notch proteins promote endothelial-mesenchymal transition-mediated pulmonary arterial hypertension via upregulation of the expression of <i>GATAs</i> . <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 1110-1130.	1.6	3
2972	FUT8-Mediated Core Fucosylation Promotes the Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. , 2023, 14, 1927.		1
2974	Single Nucleotide Polymorphism rs9277336 Controls the Nuclear Alpha Actinin 4 Human Leukocyte Antigen-DPA1 Axis and Pulmonary Endothelial Pathophenotypes in Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	1
2975	Prognostic Value of Respiratory Variation in Right Atrial Pressure in Patients With Precapillary Pulmonary Hypertension. <i>Chest</i> , 2023, 164, 481-489.	0.4	3
2976	Pathophysiology and new advances in pulmonary hypertension. , 2023, 2, e000137.		13
2977	Advances in the discovery of drugs that treat pulmonary arterial hypertension. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 445-466.	2.5	0
2978	Current Trends and Movements in Managing Pulmonary Arterial Hypertension in Korea. <i>Korean Circulation Journal</i> , 0, 53, .	0.7	0
2979	Residual risk identified in routine noninvasive follow-up assessments in pulmonary arterial hypertension. <i>ERJ Open Research</i> , 2023, 9, 00072-2023.	1.1	1
2980	Cardiac Magnetic Resonance Derived Left Ventricular Eccentricity Index and Right Ventricular Mass Measurements Predict Outcome in Children with Pulmonary Arterial Hypertension. <i>Children</i> , 2023, 10, 756.	0.6	0

#	ARTICLE	IF	CITATIONS
2988	Pulmonary arterial hypertension. , 2023, , 180-191.		0
2997	Pulmonale Hypertonie. Springer Reference Medizin, 2023, , 1-30.	0.0	0
3012	Pediatric Pulmonary Hypertension. , 2023, , 1-34.		0
3020	Recent developments in dry powder inhalation (DPI) formulations for lung-targeted drug delivery. Journal of Pharmaceutical Investigation, 0, , .	2.7	1
3028	Pulmonale Hypertonie. Springer Reference Medizin, 2023, , 459-488.	0.0	0